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Abstract 
This thesis investigates the adverse outcomes amongst survivors of childhood 
cancer using the British Childhood Cancer Survivor Study (BCCSS) and the Pancare 
Childhood and Adolescent Cancer Survivor Care and Follow-up studies (PCSF).  
 
The specific aims were to investigate (1) adverse outcomes up to 50 years of follow-
up in survivors of Wilms’ tumour; (2) risks of hospitalisations due to renal morbidities 
in childhood cancer survivors; (3) risk of subsequent primary neoplasms arising in the 
digestive system in survivors of childhood cancer; and (4) adverse outcomes beyond 
50 years of follow-up in survivors of heritable retinoblastoma. 
 
This thesis demonstrated that survivors of Wilms’ tumour are at substantial risk of 
premature mortality, particularly for those who have survived 30 years from original 
diagnosis. This particular group of survivors have the highest risk of hospitalisations 
due to renal morbidities, such as chronic renal failure, and subsequent primary 
neoplasms in specific organs in the lower digestive system. Survivors of heritable 
retinoblastoma who received external beam radiotherapy experienced an increased 
risk of subsequent primary neoplasms developing above the shoulder, whereas 
those who received brachytherapy were similar to those who did not receive any 
radiotherapy and did not experience an increased risk of subsequent primary 
neoplasms. 
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The aim of this chapter is to provide a background to the research presented in this 
thesis. The chapter will discuss the improvements in survival after childhood cancer 
and will describe in detail potential adverse outcomes, so called “late effects” of 
childhood cancer and its treatment. It will then describe the study populations that 
form the basis of the research. 
 
1.1 Childhood Cancer Survival 
Cancer in childhood, defined here as a neoplasm diagnosed under the age of 15 
years, is rare and constitutes only 0.5% of all cancers diagnosed in Great Britain1. 
Due to advances in anti-cancer therapy over several decades, survival from 
childhood cancer has improved substantially. In the UK, children diagnosed with 
cancer between 1966—1970 had overall, a 28% five-year survival rate. However, the 
five-year survival rate has increased substantially to 82% for those diagnosed with 
cancer during the period 2006–20102. Similar figures have been observed in the 
United States (US) where, overall, 78% of children diagnosed with cancer between 
the years 1991–2000 survived at least five years3. Similarly, in Europe five-year 
survival for children diagnosed with cancer between the years 2000–2007, was 78% 
following all types of childhood cancer4.  
 
1.2 Types of Childhood Cancer 
The substantial increase in survival rate amongst childhood cancer survivors is 
mainly due to improvements in anti-cancer therapy; including refinements to 
radiotherapy and the introduction of multi-agent combined chemotherapy. Inclusion 
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into clinical trials and referral to a specialist treatment centre has also had 
measurable impacts on survival rates5. 
 
Improvements in survival among those diagnosed with childhood cancer results in a 
growing population of childhood cancer survivors who are at an increased risk of 
specific adverse health and social outcomes later on in life6-9. These adverse health 
and social outcomes will be described in the next section. 
 
For the purpose of research studies, childhood cancer is often classified into different 
diagnostic groups using the International Classification of Childhood Cancers10. The 
categories include: leukaemia, lymphoma, central nervous system (CNS) tumours, 
neuroblastoma, retinoblastoma, renal tumour, hepatic tumour, bone tumour, soft 
tissue sarcoma, germ cell tumour and other/unspecified tumours (see Appendix 8.1). 
 
Chapter 2 and Chapter 5 of this thesis will focus on risks of adverse health and social 
outcomes amongst survivors of Wilms’ tumour (nephroblastoma) and heritable 
retinoblastoma, respectively. These two childhood cancer types will be briefly 
described in the following sections. 
 
1.2.1 Wilms’ tumour 
Wilms’ tumour (WT) is a type of renal tumour that usually develops in children under 
five years of age, accounting for approximately 7% of all childhood tumours, and 
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affects approximately 80 children in the UK per year11, however little regarding 
causes is known. Five-year survival has improved substantially over the last few 
decades from 55%, prior to the 1970s, to currently over 90%5,12. WT can occur in one 
or both kidneys (bilateral), which together with the stage of the disease, determines 
the treatment plan. There are five stages of Wilms’ tumour13: (1) the tumour is 
residing only within the kidney; (2) the tumour has spread to nearby structures 
beyond the kidney but is still possible to remove with surgery; (3) the tumour has 
metastasised adjacent to, but beyond the kidney; (4) the tumour has metastasised to 
other distant parts of the body such as the lungs or liver; (5) bilateral Wilms’ tumour. 
Most patients will receive chemotherapy before undergoing surgery to remove the 
whole tumour14,15. The surgery will try to remove the whole tumour whilst removing as 
little renal tissue as possible – however this is normally only performed on patients 
who have unilateral WT16. Current chemotherapy drugs often administered include 
Vincristine and Actinomycin-D for early stages of WT, and Doxorubicin, 
Cyclophosphamide, Etoposide and Carboplatin for later stages of WT17. Those who 
have bilateral WT (Stage 5) always receive chemotherapy along with surgery to both 
kidneys to remove as much of the tumour as possible. Radiotherapy is often given in 
conjunction with chemotherapy and surgery15. Radiotherapy doses can be varied for 
different stages of the tumour and depending whether it is unilateral or bilateral, but 
will cover a large proportion of the abdomen and also the thorax if the tumour has 
metastasised to the lungs18. Most children with WT can expect to be cured; if 
recurrence occurs, it is usually within 2-3 years from the original WT diagnosis16,19.  
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1.2.2 Retinoblastoma 
Retinoblastoma is a rare type of childhood cancer, which occurs in two forms: 
heritable and non-heritable. Heritable retinoblastoma (HRb) is caused by a 
constitutional mutation in the RB1 gene present from conception and thus lies in 
chromosome 13 and is inherited as an autosomal dominant with almost complete 
penetrance; and about 50% of offspring inherits this condition20. Retinoblastoma is 
considered as heritable if the patient has a family history of the disease or tests 
positive for the RB1 gene mutation21. Non-heritable retinoblastoma occurs through 
somatic mutation without any inherited predisposition. Retinoblastoma affects 
approximately 40 children in the UK per year and accounts for approximately 3% of 
all cancers in children22. Five-year survival of retinoblastoma has improved 
substantially over many decades from less than 70% in the 1970s to currently over 
95%23,24. Most patients with RB1 will have bilateral retinoblastoma, affecting both 
eyes, whereas non-heritable retinoblastoma always present with just one eye 
affected. Historically, when retinoblastoma was diagnosed in both eyes a treatment 
plan was adapted to save one eye as there was a greater chance of survival 
compared to trying to save both eyes; one eye was enucleated and the patient would 
undergo radiotherapy, chemotherapy or both to eradicate the tumour in the other 
eye25. Two different types of radiotherapy treatment may be used to treat the tumour; 
external beam or brachytherapy (also known as internal radiotherapy where the 
source is implanted into the body), most commonly insertion of a radioactive plaque 
onto the eye. External beam delivers a defined dose of radiation to the affected area 
but adjacent organs may be exposed to some scattered radiotherapy, whereas 
radioactive plaques delivers a more focused dose to the tumour26. Both historically 
16 
 
and currently, the main chemotherapy drug used in treating retinoblastoma is the 
alkylating agent Cyclophosphamide. Other treatment options with potentially less 
adverse effects include photocoagulation and cryotherapy27. Photocoagulation is a 
laser which is used to cauterise blood vessels that supply the tumour with blood, 
effectively cutting off the blood supply to the tumour28. Cryotherapy is a treatment 
where the tumour cells are cooled down to an extremely low temperature to stop cell 
growth and eliminate abnormal tissue29.  
 
1.3 Risk of Adverse Health and Social Outcomes (Late Effects) after 
Childhood Cancer 
As a result of the improvements in survival rates of childhood cancer, the number of 
childhood cancer survivors continues to grow and survivors still have their entire 
adult lifespan ahead of them30. Thus it is paramount that these survivors be 
monitored for potential long-term adverse outcomes that might occur as a result of 
the cancer or its treatment received. Such long-term adverse health and social 
outcomes – also known as “late effects” – include premature death8,31-37, 
development of a second primary cancer38-45, adverse pregnancy outcomes46-50, 
educational underachievement51-53, a decline in physical and cognitive abilities54-56, 
reduced likelihood of marriage57-60, change in smoking habits61-63, change in alcohol 
consumption63-66 and an increased risk of non-neoplastic health conditions67-71. Brief 
summaries of these late effects are described next. 
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1.3.1 Premature Mortality 
Despite the improvement in 5-year survival rates, mortality rates for survivors of 
childhood cancer continue to be significantly elevated after five-year survival 
compared to the general population8,31-37. The three largest cohort studies of 
survivors of childhood cancer from UK8, US34 and Nordic countries32  that 
investigated premature mortality reported an excess mortality over that seen in the 
general population with 10.7-fold, 8.4-fold and 10.8-fold the risk, respectively. The 
most common causes of death include recurrence or progression of the initial cancer, 
second primary neoplasms and circulatory diseases8. As the time after the initial 
cancer increases, the risk of dying from second cancers and circulatory disease 
increases substantially, whereas the risk of dying from recurrence or progression of 
the original cancer decreases8. By 50 years from diagnosis 30% of five-year 
survivors have died, where based on their demographic composition, 6% would be 
expected to have died8. 
 
1.3.2 Subsequent Primary Neoplasms 
The risks of subsequent primary neoplasms (SPNs) has been investigated in 
different cohorts of childhood cancer survivors including the UK, US, Netherlands, 
Nordic countries and many other countries; and the risk was reported to be between 
3 and 11-fold compared to the general population38,72-74. However, the risk of 
developing SPNs varies by initial cancer diagnosis, the treatment given and also the 
location of where the treatment was applied. Examples, relating to subsequent 
primary neoplasms in the digestive system, are provided in the following subsection.  
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1.3.2.1 Subsequent Primary Neoplasms in the Digestive System 
Cancers in specific parts of the digestive system are briefly described, as a Chapter 
of this thesis will focus on the risks of developing subsequent primary neoplasms in 
the digestive system; in particular the oesophagus, stomach, pancreas, liver and bile 
duct, small intestine, gallbladder, colon, rectum and anus. The rationale for focusing 
on SPNs in the digestive system is due to the high number of cases of digestive 
cancers worldwide. Colorectal cancer is the third most prevalent cancer in the world 
and in combination with liver, stomach and pancreatic cancers, constitutes 24.5% of 
all newly diagnosed cases of cancers in 2012 worldwide and is thereby the most 
prevalent category of cancers75. Overall, survivors of childhood cancer have a 5-fold 
risk of developing a digestive SPN compared to the general population38. The 
background relating to the most common digestive cancers (colorectal, liver, stomach 
and pancreatic) will be described next. 
 
1.3.2.2 Colorectal Cancer 
In the general population colorectal cancer affects approximately 75 in 100,000 men 
and 57 in 100,000 women per year in the UK76. Colorectal cancer typically occurs 
during mature adulthood, past 40 years of age, where the five-year survival is 
58.7%77. Childhood cancer survivors have a 7-fold risk of developing a colorectal 
cancer compared to the general population78. Wilms’ tumour survivors are at highest 
risk with 16-fold risk compared to the general population79. Survivors who received 
abdominal radiation had a much higher risk (9-fold) of developing a colorectal SPN 
compared to those who did not receive abdominal radiation (3-fold)79. 
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1.3.2.3 Liver Cancer 
Primary liver cancer (which excludes metastatic liver cancer) affects 1 in 10,000 men 
and 1 in 20,000 women per year in the UK80. Liver cancer typically occurs during 
adulthood, past 40 years of age, where the five-year survival varies substantially 
dependent on the stage of the cancer. If the tumour is (1) localised (i.e. the tumour is 
still fully restricted within the structure of the liver), the five-year survival rate is 28%; 
(2) regional (i.e. the tumour has spread to nearby organs or lymph nodes), the five-
year survival rate is 7%; or  (3) distant (i.e. the tumour has spread to distant organs 
or tissue), the five-year survival rate is 2%81. To date, only one study has investigated 
the risk of liver SPN after childhood cancer and reported that childhood cancer 
survivors have a 25-fold risk of developing liver SPNs compared to the general 
population78. Further research is required to confirm this result and no previous study 
has reported the risk of liver SPN by type of First Primary Neoplasm (FPN) diagnosis 
– these results will be presented in Chapter 4 of this thesis. 
 
1.3.2.4 Stomach Cancer 
Stomach cancer affects 3 in 20,000 men and 2 in 25,000 women per year in the 
UK82. Stomach cancers typically occur during adulthood, past 40 years of age, where 
the five-year survival is 18.9%83. Again, only one study to date has investigated the 
risk of stomach SPNs after childhood cancer and reported that survivors of childhood 
cancer have a 13-fold risk of developing stomach SPNs compared to the general 
population78. Further research is required to confirm this result and no previous study 
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has reported the risk of stomach SPN by type of FPN diagnosis – these results will 
be presented in Chapter 4 of this thesis. 
 
1.3.2.5 Pancreatic Cancer 
Pancreatic cancer affects 7 in 50,000 men and 7 in 50,000 women per year in the 
UK84. Pancreatic cancers typically occur during adulthood, past 40 years of age, 
where the five-year survival is 3.3%85. Only one study, to date, investigated the risk 
of pancreatic SPN after childhood cancer and reported that survivors of childhood 
cancer have a 10-fold risk of developing pancreatic SPN compared to the general 
population78. Further research is required to confirm this result and no previous study 
has reported the risk of pancreatic SPN by type of FPN diagnosis – these results will 
be presented in Chapter 4 of this thesis. 
 
1.3.3 Non-Neoplastic Health Conditions 
Survivors of childhood cancer are at risk of non-neoplastic health conditions such as 
cardiotoxicity and nephrotoxicity67-71 – approximately 75% of childhood cancer 
survivors will develop a chronic health condition at some point in their life68,86.  
Nephrotoxicity will be described in more detail, as a chapter of this thesis will focus 
on the risk of hospitalisation due to renal disease. 
 
Cardiotoxicity is damage to the heart induced by radiotherapy or chemotherapy given 
to survivors of childhood cancer87. After 30 years from the initial diagnosis of cancer, 
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up to 16% of childhood cancer survivors will have experienced heart failure due to 
exposure to anthracyclines88,89, such as doxorubicin68,90-93. The main conditions 
relating to cardiotoxicity include congestive heart failure (CHF), cardiomyopathy/heart 
failure, ischaemic health disease and pericardial disease. Survivors have a 6-fold risk 
of CHF and pericardial disease and a 5-fold risk of myocardial infarction compared to 
healthy siblings. The most at risk were survivors of Hodgkin’s lymphoma with 7-times 
the risk of CHF, 12-times the risk of myocardial infarction and 10-times the risk of 
pericardial disease compared to healthy siblings67 – which is likely due to the effect of 
radiotherapy. 
 
Nephrotoxicity is kidney damage as a result of exposure of the kidney to toxic agents 
such as radiotherapy or chemotherapy given as cancer treatment. Chronic Kidney 
Disease (CKD) is currently affecting 6.5% of the population in England (6% male and 
7% female)94 and, in 2008, 13,895 died with chronic renal failure95. In comparison, a 
previous cohort study showed that 10.1% of childhood cancer survivors experience 
CKD96,97. There are various types of renal conditions, some of which people may be 
hospitalised for; which include glomerular disease (excess blood and protein in the 
urine), renal tubulo-interstitial disease (inflammation of the kidneys affecting 
interstitial area surrounding the tubules), renal failure (kidneys failing to filter waste 
products from the blood which is measured by the glomerular filtration rate) and 
urolithiasis (kidney stones). There are various potential causes of nephrotoxicity after 
childhood cancer including radiotherapy, chemotherapy, immunotherapy, cancer 
(damage to renal tissue)98 and conditions that put a strain on the kidney such as 
hypertension and diabetes99. Chemotherapeutic drugs associated with acute 
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nephrotoxicity include Cisplatin and Ifosfamide and may cause chronic nephrotoxicity 
in up to 60% of children with cancer100,101. Other chemotherapeutic drugs which may 
cause serious damage to the kidneys are Carboplatin, Methotrexate and 
Nitrosoureas, although this occurrence is less common102. Using radiotherapy to treat 
children with childhood cancer may lead to radiation-induced nephritis which may 
further progress into renal failure98.  
 
1.3.4 Adverse Pregnancy Outcomes 
Previous studies have shown that female survivors of childhood cancer are at risk of 
infertility103-108, ovarian failure109-114 and adverse pregnancy outcomes46,115-117. 
Survivors of specific types of childhood cancers, such as Wilms’ tumour, are more 
prone to such adverse effects due to radiation treatment being given to the 
abdominal or uterine region115,118,119. Several previous studies found that female 
survivors of specific types of childhood cancers, in particular Wilms’ tumour, were 
significantly more susceptible to adverse pregnancy outcomes including delivering 
offspring with  low birth weight and preterm birth46,118,120. One American study found 
a significant trend between increasing radiation dose to the abdomen and increased 
risk of developing hypertension complicating pregnancy, early or threatened labour 
and malposition of foetus47,48.  
 
1.3.5 Health Status 
Overall, health related quality of life (HRQL) for the majority of survivors of childhood 
cancer is reported to be very good, even when compared to the general 
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population121-123. However, this is not the case for survivors of specific types of 
childhood cancer: survivors of Hodgkin’s disease, CNS tumours and bone tumours 
have been shown to have significantly reduced physical and social functioning as 
measured by day-to-day tasks54,124. A large population-based study in the UK found 
that survivors of bone tumours had significantly lower scores in all physical and 
mental components compared to the general population54. Others have reported that 
survivors experienced no difference in bodily pain, vitality and mental status after 
treatment for childhood cancer compared to healthy siblings125. Survivors of bone 
tumour were most at risk of reduced physical functioning in relation to day-to-day 
tasks whilst survivors of CNS tumours were most at risk of a reduced social 
functioning as measured by day-to-day tasks54. 
 
1.3.6 Education 
Several studies have shown that survivors of childhood cancer are at risk of 
underachieving in terms of educational qualifications compared to the general 
population51,126,127. Survivors of childhood cancer who received cranial radiotherapy, 
specifically CNS tumours and leukaemia, and those who experienced neurological 
late effects were significantly less likely to achieve a university degree or equivalent; 
educational outcomes of survivors who did not receive cranial radiotherapy were 
found to be comparable to healthy siblings128-130. Two large studies from the UK51 
and the US130 (including 10,183 and 12,430 survivors respectively) reported that 
survivors of Leukaemia and CNS tumours were significantly less likely to achieve a 
degree, or equivalent, compared to the controls. However survivors of bone tumours 
are more likely to achieve better educational outcomes compared to the general 
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population131 – currently the majority of the research relating to educational 
achievement after childhood cancer is specific to CNS tumours as many survivors 
would have received cranial radiotherapy and therefore at risk of cognitive late 
effects132. It is equally important to analyse and disseminate results relating to 
educational achievement after childhood cancer for other specific subgroups of 
cancer62,133-140. 
 
1.3.7 Marriage 
Approximately 30% of childhood cancer survivors get married and are approximately 
20% less likely to be married compared to the general population57,141-144. Survivors 
who received radiotherapy were 31% less likely to marry compared to those who did 
not receive radiotherapy and males were also 20-48% less likely to be married 
compared to females57,59,145. Several studies have reported that only survivors of 
CNS tumour were less likely to marry compared to the general population57,59,141,144. 
However, a large UK study (including 8,155 survivors) revealed that survivors of 
childhood cancer were no different to the general population in terms of divorce 
rates. In fact survivors of non-Hodgkin’s lymphoma were 45% less likely to get 
divorced compared to the general population58.  
 
1.3.8 Smoking and Alcohol 
Smoking and alcohol are proven to be causes of many cancers62,133-140. Thus it is 
likely that survivors of childhood cancer, who already have an increased risk of 
developing a subsequent primary neoplasm, could have an even greater risk of 
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developing a subsequent cancer if they were smokers or consume excessive 
amounts of alcohol. Survivors of childhood cancer were 49% less likely to smoke with 
19.8% of the survivors reported to regularly smoke and 60% less likely to consume 
harmful amounts of alcohol with 3.9% of the survivors reported to consume harmful 
amounts of alcohol61,64. Survivors of all types of childhood cancer, except non-
heritable retinoblastoma, were significantly less likely than the general population to 
smoke and survivors of all types of childhood cancer, except for non-irradiated 
leukaemia, soft tissue sarcoma and bone tumours, were significantly less likely to 
consume harmful amounts of alcohol61,64. 
 
The research to be presented in this thesis should help clinicians risk stratify 
survivors in long-term follow-up clinics and provide evidence for updating clinical 
follow-up guidelines for survivors of childhood cancer. In this thesis, four original 
studies will be presented, with each study contributing new results which have 
previously not been investigated; adverse outcomes will be investigated in survivors 
of Wilms’ tumour with up to 50 years of follow up; adverse outcomes will be 
investigated in survivors of heritable retinoblastoma by specific types of radiotherapy 
using a population-based cohort; risks of hospitalisation due to specific renal 
diseases in childhood cancer survivors will be investigated; and risks of SPNs in 
specific sites of the digestive system will be investigated. 
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1.4 Data 
Data relating to two cohorts were used for the analysis of this thesis; The British 
Childhood Cancer Survivor Study (BCCSS) and the PanCareSurFup (PCSF) study. 
The BCCSS cohort was used for investigations into (i) the risk of long-term adverse 
health and social outcomes among Wilms’ tumour survivors, (ii) the risk of long-term 
adverse health and social outcomes in survivors of heritable retinoblastoma, and (iii) 
the risk of hospitalisation due to a renal disease after childhood cancer. The PCSF 
cohort was used to investigate the risks of developing a second primary cancer of a 
digestive organ in a European setting. A detailed description of both cohorts 
presented below. 
 
1.4.1 The British Childhood Cancer Survivor Study 
The British Childhood Cancer Survivor Study is a population-based cohort study of 
17,980 five-year survivors of childhood cancer diagnosed with cancer between 1940 
and 1991 under the age of 15 in the UK. The study was recently extended to include 
survivors diagnosed with childhood cancer up to 2006, bringing the total to 34,489 
five-year survivors of childhood cancer. The BCCSS study was established to 
investigate the risks of adverse health and social outcomes after surviving cancer for 
five years.  
 
Survivors of childhood cancer were eligible to be included in the BCCSS cohort if 
they were diagnosed during the period 1940 to 2006, less than 15 years of age and 
subsequently survived for at least five years. The cohort was ascertained using the 
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population based National Registry of Childhood Tumours (NRCT). Since the 1970’s, 
over 97% of all childhood cancer registrations were picked up by the NRCT146. All of 
these childhood cancer registrations were extracted for the BCCSS and because we 
had received approval from the multicentre research ethics committee and all the 
local research ethics committees, we did not require individual patient consent. 
However, survivors had the choice of opting out of the study which was fewer than 10 
in total. 
 
All survivors who were eligible within the original cohort, diagnosed between 1940–
1991, were sent a package via their primary care physician (PCP), or GP. To be 
eligible they needed to be alive and at least 16 years of age. The package sent to the 
GP contained four items; (i) a cover letter that explained the objectives of the 
BCCSS, (ii) a consent form for the survivor should they decide to participate in the 
study along with a pre-paid return envelope, (iii) a drafted invitation letter for the PCP 
to send to the survivor along with the BCCSS questionnaire and (iv) a pre-paid 
package to be mailed to the survivor with the items from iii. The package sent, by the 
GP, to survivors contained; (i) the suggested covering letter from the GP inviting 
survivors to participate in the BCCSS, (ii) a covering letter from the study co-
ordinating centre; (iii) a leaflet with brief explanation of the study; (iv) a copy of the 
male or female study questionnaire (this would depend on whether the survivor was 
male or female) and (v) a pre-paid envelope for the survivor to return the completed 
questionnaire to the study co-ordinating centre.  
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It was predicted that some survivors, as a result of their childhood cancer, would not 
be able to complete the questionnaire by themselves – in these circumstances, a 
third party (usually a relative) would complete the form with as much information from 
the survivor as possible. A free telephone helpline was established for both survivors 
and PCP if they had difficulties, problems or wished to ask questions pertaining to the 
BCCSS study or the questionnaire. Treatment information relating to the survivors’ 
initial cancer diagnosis was extracted from previous medical records by the 
Childhood Cancer Registry Group (CCRG) in a ‘yes’, ‘no’ or ‘no record’ format for 
each of the possible treatments; surgery, radiotherapy and chemotherapy. 
 
The Multi-Centre Research Ethics Committee (MREC) and each of the 212 Local 
Research Ethics Committees (LREC) in Britain gave approval for the British 
Childhood Cancer Survivor Study. 
 
Specific results arising from the questionnaire will be presented in Chapter 2 and 
Chapter 5, which utilises the cohort from the BCCSS, such as pregnancy outcomes, 
educational achievements, smoking status, alcohol consumption, marital status, 
health-status (SF-36) and the use of health services.  
 
1.4.2 PanCareSurFup Cohort 
The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up 
Studies cohort, abbreviated to PanCareSurFup, comprises of more than 115,000 
survivors of childhood cancer who were diagnosed under the age of 20 from 1940 to 
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2008 and identified in both national and hospital-based registries in France, Hungary, 
Italy, Netherlands, Denmark, Sweden, Norway, Finland, Iceland, Slovenia, 
Switzerland and UK147. The PCSF cohort comprises 3,138 five-year survivors from 
France diagnosed between the period 1946 and 1986; 4,885 five-year survivors from 
Hungary diagnosed between the period 1971 and 2008; 10,781 five-year survivors 
from the population-based registries in Italy diagnosed between the period 1964 and 
2005; 9,192 five-year survivors from the hospital-based registries in Italy diagnosed 
between the period 1960 and 2008; 6,044 five-year survivors from Netherlands 
diagnosed between the period 1963 and 2001; 4,832 five-year survivors from 
Denmark diagnosed between the period 1943 and 1998; 7,709 five-year survivors 
from Sweden diagnosed between the period 1958 and 1998; 3,877 five-year 
survivors from Norway diagnosed between the period 1953 and 1997; 6,229 five-year 
survivors from Finland diagnosed between the period 1953 and 2006; 274 five-year 
survivors from Iceland diagnosed between the period 1955 and 1998; 1,252 five-year 
survivors from Slovenia diagnosed between the period 1960 and 2002; 4,373 five-
year survivors from Switzerland diagnosed between the period 1964 and 2005; 
17,960 five-year survivors from UK diagnosed between the period 1940 and 1991. 
 
One of the main objectives of the PCSF case-control study is to ascertain the risks of 
three outcomes following survival from childhood cancer; (1) cardiac conditions, (2) 
subsequent primary cancers and (3) late mortality. This will be achieved by analysing 
the European-wide data and to publish and disseminate the results. 
 
Although this thesis only presents results from the PCSF cohort study, three case-
control studies are currently being established that includes childhood cancer 
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survivors relating to late mortality, subsequent primary cancers and cardiac events 
which have been systematically ascertained and validated. The PCSF case-control 
study, relating to subsequent primary cancers, will specifically focus on carcinomas 
that are common to the general population after 40 years of age; specifically 
digestive and genitourinary sites. Radiation dosimetry will be undertaken for survivors 
included within these case-control studies to obtain estimates of radiation doses 
corresponding to the sites of the FPN and compared to controls. The absolute risk of 
each of the three outcomes (specified above) will be estimated and comparisons will 
be made to general population rates, especially for those aged 40 years or more. 
 
1.5 Rationale and Aim 
Treatment for cancer can lead to many adverse health and social outcomes later on 
in life. Important outcomes to consider are premature death, second cancers, health 
status, marriage, pregnancy, educational achievement, smoking and alcohol 
consumption which all have an impact on the quality of life after cancer8,31-66. 
Generally, childhood cancer survivors have a longer life ahead of them compared to 
survivors of adult cancers and therefore have a longer period to experience adverse 
effects from the treatment given for the initial cancer. The evidence of risks of 
adverse health and social outcomes presented should help in the risk stratification of 
survivors for appropriate level of intensity of clinical follow-up, help updating clinical 
follow-up guidelines and provide evidence relevant to the evaluation of components 
of future treatment protocols from a risk, as well as a benefit, perspective. 
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A large number of previous studies on the late effects following childhood cancer 
were not population-based or have been based on relatively small numbers of 
childhood cancer survivors or limited follow-up of survivors. This thesis aims to 
contribute to the knowledge of adverse outcomes following survival after childhood 
cancer by addressing some of these limitations. In order to achieve this we will focus 
on four key areas by using the BCCSS and PCSF cohorts, which will allow us to 
provide reliable evidence—using large numbers of childhood cancer survivors from 
population-based cohorts—to health care providers and survivors of childhood 
cancer as well as government funded bodies to re-evaluate risks of late effects so 
that current follow-up and surveillance plans may be improved. 
 
In particular, the four aspects of focus is to investigate: 
 
(1) The risks of adverse health and social outcomes in survivors of Wilms’ tumour up 
to 50 years from diagnosis in the BCCSS cohort;  
 
(2) The risk of hospitalisations due to specific renal diseases following survival from 
childhood cancer in the BCCSS cohort;  
 
(3) The risks of developing second cancers in the digestive system after childhood 
cancer in the PCSF cohort;  
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(4) The risks of adverse health and social outcomes in survivors of heritable 
retinoblastoma beyond 50 years from diagnosis in the BCCSS cohort. 
 
These key areas were dictated by my particular interest in renal tumours and the 
following late effects such as renal diseases and secondary malignancies in the 
abdominal region. Originally, the fourth topic was intended to be a case-control study 
investigating the risks of second digestive cancers with full radiotherapy and 
chemotherapy dosimetry in the PanCareSurFup study, which would have followed 
from the third topic. However, due to unforeseen circumstances, the data was not 
available in time for analysis and we decided to conduct research into another group 
of cancer survivors using the BCCSS data. 
 
1.6 Thesis Framework 
Chapter 2 of the thesis will explore survivorship following Wilms’ Tumour 
investigating various adverse health and social outcomes. This will include late 
mortality, subsequent cancers, adverse pregnancy outcomes, health status using the 
SF-36 questionnaire, use of health care services and social outcomes. In Chapter 3, 
the risks of being hospitalised due to specific renal diseases are investigated. We 
explore the different types of renal morbidities, such as glomerular disease, renal 
tubulo-interstitial (RTI) disease, renal failure, urolithiasis and other types of kidney 
and urinary diseases, which patients are admitted to hospital for and compare these 
admissions to those from the general population to assess the risk. Chapter 4 
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investigates the risk of developing subsequent cancers in the digestive system using 
the largest European cohort assembled to date. This is the first study to investigate 
the risks of cancers in specific sites of the digestive system by FPN type. Chapter 5 
explores the adverse health and social outcomes (similar to that in Chapter 2) but 
following heritable retinoblastoma and investigating primarily the risk of developing 
subsequent cancers in survivors who received different applications of radiotherapy. 
In Chapter 6 the main findings, potential implications for guidelines, study limitations 
and recommendations for future research are discussed. 
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2 RISK OF ADVERSE HEALTH AND SOCIAL OUTCOMES UP TO 
50 YEARS AFTER WILMS’ TUMOUR: THE BRITISH CHILDHOOD 
CANCER SURVIVOR STUDY. 
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Abstract 
Purpose: Wilms’ tumour (WT) survivors are at risk of adverse health and social 
outcomes but risks beyond 30 years from diagnosis remain uncertain. We 
investigated risks of adverse outcomes among 5-year survivors of WT, particularly 
between 30 and 50 years from diagnosis. 
Patients and Methods: British Childhood Cancer Survivor Study includes 1,441 5-
year survivors of WT.  We investigated cause-specific mortality, risk of subsequent 
primary neoplasms (SPNs)—and for those who completed a questionnaire—extent of 
smoking and drinking, educational achievement, health-status and health service use 
compared to the general population.  
Results: Cumulative risk of death, from all causes excluding recurrence, increased 
substantially from 5.4% by 30 years after WT diagnosis to 22.7% by 50 years—75% 
of excess deaths beyond 30 years from diagnosis were attributable to SPNs (50%) 
and cardiac diseases (25%). Digestive cancer (most frequently bowel) accounted for 
41% of the excess cancers beyond 30 years. 
Conclusion: Between 30 and 50 years from diagnosis, survivors of WT are at a 
substantially increased risk of premature mortality and 75% of the excess deaths 
were accounted for by SPNs and cardiac diseases. Radiotherapy exposure was a 
risk factor for both outcomes. The proportion of WT patients exposed to radiotherapy 
has reduced substantially in recent decades from initiatives like the SIOP WT 2001 
clinical trial which sought to reduce late effects. However the majority of current 
survivors, at least 30 years from diagnosis, received radiotherapy. Surveillance of this 
group should focus on SPNs (particularly bowel and breast cancers) and cardiac 
conditions.  
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2.1 Introduction 
Advances in anti-cancer therapy have led to five-year survival after WT improving to 
90%5. Although WT is increasingly curable, survivors are at risk of a range of 
treatment related long-term adverse health and social outcomes. WT survivors have 
increased mortality compared to the general population8,148, are at excess risk of 
developing second primary cancers38,148-150, adverse pregnancy outcomes46-48, 
cardiac disease and renal dysfunction151.  
 Although a number of previous studies investigated the risks of adverse health 
and social outcomes among WT survivors12,48,50,103,109,152,153, none had sufficient 
follow-up to investigate the risks beyond 30 years from WT diagnosis satisfactorily, 
hence there remains considerable uncertainty regarding the magnitude of these 
risks. The main advantage of the current study—in addition to being large-scale and 
population-based—is that 65% of the cohort survived for more than 30 years from 
WT diagnosis.  
 The objective of this study was to investigate risks of adverse health and 
social outcomes among 5-year survivors of WT up to 50 years from diagnosis. 
Specific objectives were to investigate: (i) cause-specific late mortality; (ii) risks of 
developing subsequent primary neoplasms (SPNs); (iii) risks of adverse pregnancy 
outcomes; (iv) health-status; (v) smoking and alcohol consumption, educational 
attainment and marriage status; (vi) health services use. 
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2.2 Methods 
British Childhood Cancer Survivor Study (BCCSS) 
The British Childhood Cancer Survivor Study (BCCSS) is a large-scale population-
based cohort study established to investigate adverse health and social outcomes 
among such survivors. The BCCSS includes 1,441 survivors of WT—who were 
diagnosed before 15 years of age, between 1940 and 1991 in Great Britain, and who 
survived for at least five years154. The BCCSS cohort was ascertained through the 
population-based National Registry of Childhood Tumours. Limited treatment 
information was obtained from clinical records to the level of detail given in Table 
2.5.1. 
 
Ascertainment of deaths and subsequent primary neoplasms 
Ascertainment of deaths (including underlying cause of death) and SPNs in the 
BCCSS was achieved through flagging of the entire cohort of childhood cancer 
survivors at the NRCT. Flagging informs the BCCSS when a survivor dies or 
develops a SPN by providing linkage between the population-based cohort and the 
national population-based death and cancer registration systems. Confirmation of all 
SPNs was undertaken by writing to relevant clinician(s) to obtain all diagnostic, 
particularly pathology reports38. Validation of causes of deaths was undertaken by 
two clinicians (Elaine Sugden and Gill Levitt) by reviewing all available clinical 
records, in addition to the death certificates, to ascertain the underlying cause of 
death. Consequently, all SPNs and causes of death were validated. 
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BCCSS Questionnaire 
Between 2001 and 2007, all survivors who were alive and aged over 16 years were 
sent a 40-page questionnaire by their primary care physician on behalf of the 
BCCSS. In total, 947 (70.5%) of all eligible Wilms’ survivors completed and returned 
the questionnaire154. The BCCSS questionnaire inquired about potential adverse 
health and social outcomes of childhood cancer and its treatment including questions 
regarding health-status (SF-36), health services use, medical conditions, medical 
procedures, marriage, adverse pregnancy outcomes (e.g. miscarriage, stillbirth, 
preterm birth), smoking and alcohol consumption and educational achievements.  
 
Ethical approval for the BCCSS was obtained from the relevant Multi-Centre 
Research Ethics Committee and every Local Research Ethics Committee in Britain 
(212 in total). 
 
Statistical Analysis 
Cause-Specific Mortality 
Numbers of observed deaths among WT survivors were compared with the number 
of expected deaths based on the population of England & Wales. The period at risk 
began 5 years following initial diagnosis of childhood WT until the first occurrence of 
emigration, death or exit (31st December 2010). Standardised mortality ratios (SMR) 
for specific causes of death were calculated as the ratio of observed over expected 
number of deaths. Absolute excess risks (AERs) were calculated from the observed 
minus expected number of deaths divided by the number of person-years at risk 
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multiplied by 10,000. Cumulative mortality for specific causes of death was estimated 
by treating other causes of death as competing risks155. 
 
 
Subsequent Primary Neoplasms 
The period at risk of developing a SPN began 5 years from diagnosis of WT and 
continued until the first occurrence of SPN, emigration, death or exit (31st December 
2006). Multiple observed SPNs per survivor were permitted for comparisons with 
those expected from the general population to avoid bias, but only the first SPN was 
considered in measures of cumulative risk. Standardised incidence ratios (SIRs), 
AERs and cumulative risk of developing an SPN were calculated as described above 
in relation to death. 
 
Health-status – “Short Form 36” 
Health-status was measured using the SF-36 questionnaire54. To compare SF-36 
scale scores observed among WT survivors with the general population, normative 
data from the Oxford Healthy Life Survey (OHLS) were used156. The OHLS is a 
general population survey conducted between 1991 and 1992 that included 13,042 
individuals aged 18-64 years randomly sampled from the Family Health Service 
Authority registers in Oxfordshire, Berkshire, Buckinghamshire and 
Northamptonshire. For each SF-36 scale, the difference in mean scores between 
survivors of WT and OHLS was calculated using linear regression which adjusted for 
age and sex. Also, we examined responses to the individual questions (items) 
underlying the specific SF-36 scales by comparing the directly standardised 
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percentage (for age and sex) of WT survivors that reported a limitation or other 
problem to that reported by the general population.  
 
Adverse Pregnancy Outcomes 
To investigate the risks of adverse pregnancy outcomes, logistic regression models 
were used to calculate odds ratios (ORs) to compare likelihood of low birth weight, 
preterm births and miscarriage between pregnancy outcomes among female 
survivors of WT who were treated with abdominal radiotherapy with female survivors 
of non-WT childhood cancers who did not receive abdominal radiotherapy 
(comparison with UK population pregnancy rates was not possible as there is 
currently no database which holds information relating to the rates of adverse 
pregnancy outcomes). Most female WT survivors, who reported being pregnant at 
least once, had been treated with abdominal irradiation (87%). 
 
Smoking status, alcohol consumption and education level 
Among those WT survivors who completed the BCCSS questionnaire, smoking and 
alcohol consumption and educational attainment were compared to the general 
population by using data from the nationwide General Household Survey (GHS)157. 
Adjustment for confounders and classification of current regular smokers, alcohol 
consumption and educational attainment has been defined in previous BCCSS 
studies51,61,64. For each outcome, ORs comparing WT survivors to the GHS were 
calculated using multivariable logistic regression with a generalized estimating 
equation modification that took into account clustering within the GHS; these ORs 
were adjusted for attained age and sex. 
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Marital status 
To investigate marital status among WT survivors, ORs of ever being married—
stratified by sex and attained age—were calculated using data from the National 
Marriage Registry as the reference population57. Age-specific ORs were then pooled 
into one overall OR by using the Mantel-Haenszel method for combining ORs158. 
 
Health services use 
Frequency of consultations with a doctor, hospital outpatient visits, day-patient 
hospitalisations and inpatient hospitalisations were evaluated by calculating ORs—
comparing WT survivors with the GHS— using a multivariable logistic regression 
model. ORs were adjusted for attained age, sex, educational attainment and stratified 
by whether survivors were on regular long-term hospital follow-up in relation to their 
childhood cancer and its treatment159.   
 
Statistical significance for all analyses was defined as a 2-sided P<0.05. All analyses 
were carried out in Stata 12 (StataCorp, College Station, Texas). 
 
2.3 Results 
Cohort Characteristics 
From the total of 1,441 WT survivors in the cohort, 10% (N=146) had died, 2% 
(N=31) emigrated and 88% (N=1264) were alive at the exit date (31st December 
2010). Characteristics of WT survivors who completed the questionnaire were similar 
to all WT survivors in the BCCSS cohort (Table 2.5.1). In relation to mortality there 
were 38,803 person-years subsequent to 5-year survival with mean and median 
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follow-up of 26.9 and 26.0 years, respectively. Table 2.5.1 indicates that 82% 
(756/920) of the survivors were exposed to direct abdominal radiotherapy and only 
164 were known to be unexposed. Consequently analysis of the entire cohort, used 
for analysis of deaths and SPNs, corresponds to a group overwhelmingly exposed to 
direct abdominal radiotherapy. 
 
Causes-Specific Mortality 
Survivors experienced over 5 times the number of deaths expected (SMR=5.4; 
95%CI: 4.6,6.4) with 30.7 additional deaths (95%CI: 24.6,36.8) per 10,000 person-
years in excess of that expected (Table 2.5.2). For specific causes of death with at 
least 20 observed deaths results are reported separately. In multiplicative terms, 
cause-specific mortality was highest for SPNs (SMR=7.3; 95%CI: 5.3,9.8) and 
cardiac disease (SMR=10.1; 95%CI: 6.5,14.9). In terms of the AER, the highest 
excess which accounted for 32% of all excess deaths related to SPNs, followed by 
deaths due to recurrence and cardiac causes which accounted for 21% and 19% of 
the excess deaths, respectively. Deaths due to recurrence mostly occurred relatively 
early with 22/25 such deaths between 5-14 years, 3/25 between 15-24 years and 
none from 25 years from diagnosis (not shown in tables). The AER due to all causes 
of death except recurrence was 14 excess deaths (per 10,000 person-years) 
between 5-29 years after WT diagnosis, but increased 8-fold to 108.4 excess deaths 
beyond 30 years – which is equivalent to 1 extra death per 100 survivors each year 
(Table 2.5.3). From 30 years subsequent to WT diagnosis deaths from SPNs and 
cardiac disease accounted for 50% and 25% of the total number of excess deaths, 
respectively. 
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Cumulative mortality due to recurrence was 1.8% by 30 years after WT diagnosis, 
and remained the same by 50 years as there were no more deaths due to 
recurrence. Cumulative mortality due to all causes except recurrence was 5.4% by 30 
years after WT diagnosis, but increased substantially to 22.7% by 50 years. By 50 
years from WT diagnosis, the cumulative mortality from SPNs and cardiac diseases 
were 8.2% and 6.3%, respectively (Figure 2.5.1).  
 
There were 25 cardiac deaths according to the underlying cause of death on the 
death certificate and we summarise the results of a comprehensive review of these 
causes of death taking account of all hospital records and autopsy reports still 
available (Table 2.5.7). This comprehensive review ascertained that 4 deaths were 
due to renal failure; 9 myocardial infarction (4 with chest irradiation and/or lung 
metastases); 7 cardiomyopathy/heart failure (6 with chest irradiation); 3 pulmonary 
embolism; 2 other causes. 
 
Subsequent Primary Neoplasms 
The cumulative risk of developing an SPN was 3.7% (95%CI: 2.7,5.0) by 30 years 
after WT diagnosis increasing to 16.4% (95%CI: 10.7,23.2) by 50 years (Figure 
2.5.2). The most common SPN were those of digestive sites, which occurred in 17 
WT survivors, 7 were bowel cancers and the other affected sites are specified in 
Table 2.5.4; all 17 had previously received abdominal radiotherapy. Over 40% of 
SPNs developed beyond 30 years from diagnosis of WT, for digestive SPNs 10 of 17 
developed in this period and these accounted for 41% of the excess number of 
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cancers in this period of follow-up. All WT survivors who developed breast cancer 
had previously received either abdominal or chest radiotherapy. 
 
Health-status (SF-36) 
WT survivors scored significantly lower than the general population on two of the 
eight SF-36 scales: physical functioning (difference in means, D=-1.8; 95%CI: -3.3,-
0.9) and general health perception (D=-6.7; 95%CI: -8.1,-5.2) (Table 2.5.5). However, 
WT survivors reported significantly better role-emotional functioning (D=3.4; 95%CI: 
1.2,5.6) than the general population.  When examining the responses to individual 
questions which comprise the physical functioning scale, WT survivors reported 
significantly higher limitations on most items compared to the general population 
(Figure 2.5.3). When examining responses to the individual questions which 
comprise the general health perception scale, WT survivors reported higher 
agreement that their health was worse in relation to each question compared to the 
general population (Figure 2.5.4).  
 
Pregnancy Outcomes 
Of the 511 female WT survivors who completed the BCCSS questionnaire, 412 
pregnancies were reported by 184 females of which 32% resulted in low birth weight, 
35% in a preterm delivery and 22% in a miscarriage for those who responded to the 
relevant questions and had received abdominal irradiation. Female survivors of WT 
treated with abdominal radiotherapy were at higher risk of giving birth to a low birth 
weight baby (OR=3.3; 95%CI: 2.2,4.9) and giving birth preterm (OR=3.1; 95%CI: 
2.1,4.7) compared to non-WT survivors of childhood cancer not treated with 
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abdominal radiotherapy. Pregnancy analyses were stratified by eras of treatment 
(<1970 and ≥1970), however no statistical differences were found (p≥0.386). 
 
Smoking, Alcohol, Education and Marriage 
Compared to the general population, WT survivors were less likely to be a regular 
smoker (OR=0.7; 95%CI: 0.6,0.8), consume alcohol (OR=0.7; 95%CI: 0.6,0.9) or 
consume harmful amounts of alcohol (OR=0.5; 95%CI: 0.3,0.7). WT survivors did not 
significantly differ from the general population in achieving specific levels of 
education (all p-values>0.05). Male survivors were significantly less likely to be 
married (OR=0.7; 95%CI: 0.5,0.9) compared to the general population. 
 
 
 
Health services use 
Compared to the general population, survivors of WT were significantly more likely to 
attend hospital outpatients (OR=2.6; 95%CI: 2.2,3.1) at least once in the last 3 
months, be hospitalised as a day patient (OR=1.7; 95%CI: 1.3,2.1) at least once in 
the last year and be hospitalised as an inpatient (OR=2.0; 95%CI: 1.6,2.6) at least 
once in the last year. When stratified by whether WT survivors were on long-term 
hospital follow-up in relation to their childhood cancer or its treatment, survivors not 
on long-term hospital follow-up (N=546) were still significantly more likely to be 
hospitalised as an outpatient (OR=2.1; 95%CI: 1.7,2.6), day patient (OR=1.5; 95%CI: 
1.1,2.0) and inpatient (OR=1.9; 95%CI: 1.4,2.6) compared to the general population; 
whilst survivors on such long-term hospital follow-up (N=360) were even more likely 
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to be hospitalised as an outpatient (OR=3.5; 95%CI: 2.7,4.6), day patient (OR=1.9; 
95%CI: 1.3,2.7) and inpatient (OR=2.3; 95%CI: 1.6,3.5). 
 
2.4 Discussion 
New findings include the identification of a substantial increase in cumulative 
mortality due to causes of death other than recurrence in the period from 30 to 50 
years after WT diagnosis increasing from 5.4% to 22.7%, corresponding to 1 extra 
death per 100 survivors per year. Consistent with our study, a previous US based 
large-scale study148 found that cumulative mortality at 30 years from WT diagnosis 
was approximately 3%, but thus far—to our knowledge—no study has demonstrated 
the substantial increase in mortality from 30 to 50 years from WT diagnosis. The 
excess of deaths after 30 years was mainly attributable to SPNs (50%) and cardiac 
(25%) related deaths which together accounted for 75% of all excess deaths. The 
absolute excess risk for the first 30 years following diagnosis is consistent with that 
found in the National Wilms’ Tumor Study160; but this study also did not have 
sufficient follow-up to demonstrate a substantial increase in the absolute excess risk 
beyond 30 years from diagnosis as observed in the present study.  
 
The excess of SPNs during the initial 30 years from WT was comparable to that 
reported in previous studies44,145. Beyond 30 years from WT, previous studies had 
insufficient follow-up to satisfactorily assess evidence for an excess. Our cumulative 
risk increased from 3.7% by 30 years to 16.4% by 50 years. Beyond 30 years from 
WT there were 4.5 excess cancers observed per 1,000 per year, this excess was 
mainly attributable to digestive cancers (41%) and breast cancers (7%) – together 
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accounting for 48% of the total excess of cancers. All WT survivors who developed a 
digestive SPN had received abdominal radiotherapy and all survivors who developed 
breast cancer received either abdominal or chest radiotherapy. We have previously 
reported the strong link between abdominopelvic irradiation and subsequent bowel 
cancer161, specifically the risk of developing bowel cancer among childhood cancer 
survivors treated with direct abdominopelvic irradiation is at least that observed 
among individuals who have at least 2 first-degree relatives diagnosed with bowel 
cancer, and for whom colonoscopy is currently recommended from ages 35 to 45162 
or from age 50163. This raises the serious question of whether irradiated Wilms’ 
survivors, which comprise the majority of childhood cancer survivors treated with 
direct abdominopelvic irradiation, should be similarly recommended for colonoscopy. 
 
Previous studies have shown that survivors of WT reported adverse health-status 
outcomes comparable to our study148,164, that is, lower general health perception and 
physical function. In addition, WT survivors also reported lower overall health-status 
in previous studies153,165-167. WT survivors in our study reported that role-emotional 
was significantly higher than OHLS, however, this is likely due to ceiling effects as 
role-emotional were measured by 3 categories causing a clustering of scores at the 
maximum level168. 
 
Consistent with previous studies46-48,50,169, completed pregnancies were more likely to 
be premature and result in low birth weight. The results of the current and previous 
studies suggest that female survivors treated with abdominal radiation should be 
carefully monitored during pregnancy. 
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With respect to social outcomes, and consistent with previous studies, WT survivors 
appear to have a healthier life style being less likely a regular smoker63,170 and 
consuming lower amounts of alcohol than the general population. Similar to a 
previous study, male survivors were less likely to be married than the general 
population171. 
 
WT survivors were more likely to visit the hospital and also were more likely to be 
hospitalised irrespective of whether they were on regular long-term hospital follow-up 
in relation to their childhood cancer or its treatment, a finding that is similar to 
previous studies148,172.  
 
Study Limitations 
A limitation of our study was the lack of detailed information on radiotherapy and 
chemotherapy exposures given for WT – detailed review of the results may allow 
inferences to be suggested and hypotheses to be generated that could be tested in 
future studies. It is also important to acknowledge that survivors included in the 
cohort were treated between 1940 and 1991 and hence our findings are unlikely to 
be generalisable to survivors treated in more recent years due to changes in 
exposure to different treatments. For example, the vast majority (82%) of the 
survivors presented here had received radiotherapy as part of initial treatment. In 
contrast, only 27% of non-anaplastic Wilms’ tumour patients included within a 
relatively recent randomised clinical trial (UKW3)173, which recruited between 1991 
and 2001, received radiotherapy as part of initial treatment. Nevertheless there is still 
an entire cohort of survivors being seen in follow-up clinics, or discharged into the 
community, who were treated before 1991 and our evidence relates directly to them. 
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Conclusion 
Between 30 and 50 years from diagnosis, survivors of WT are at a substantially 
increased risk of premature mortality and 75% of the excess deaths were accounted 
for by SPNs and cardiac diseases. Radiotherapy exposure was a risk factor for both 
outcomes. The proportion of WT patients exposed to radiotherapy has reduced 
substantially in recent decades, from initiatives like the SIOP WT 2001 clinical trial 
which sought to reduce late effects173. However the majority of current survivors, at 
least 30 years from diagnosis, received radiotherapy. Surveillance of this group 
should focus on SPNs (particularly bowel and breast cancers) and cardiac conditions 
as these account for 50% and 25% of the total excess deaths observed, respectively.  
50 
 
2.5 Tables and Figures 
Table 2.5.1 Characteristics of all 1,441 Wilms’ tumour (WT) survivors in the British Childhood Cancer 
Survivor Study and of all those who completed a questionnaire. 
  All WT 
Survivors 
Completed  
Questionnaire Returned 
No Completed 
Questionnaire Returned 
  (N = 1,441) (N = 947) (N = 494) 
Sex  Male 733 (51%) 436 (46%) 297 (60%) 
 Female 708 (49%) 511 (54%) 197 (40%) 
     
Age at Mean 3.3 3.3 3.3 
Diagnosis Median 2.8 2.9 2.7 
(years) 0 – 4 1156 (80.2%) 760 (80.3%) 396 (80.2%) 
 5 – 9 252 (17.5%) 166 (17.5%) 86 (17.4%) 
 10 – 14 33 (2.3%) 21 (2.2%) 12 (2.4%) 
     
Age at  Mean n/a 28.3 n/a 
Questionnaire 5 – 9 n/a 0 (0.0%) n/a 
Completion1 10 – 19 n/a 221 (23.3%) n/a 
(years) 20 – 29 n/a 350 (37.0%) n/a 
 30 – 39 n/a 261 (27.6%) n/a 
 40 – 49 n/a 90 (9.5%) n/a 
 50 – 59 n/a 22 (2.3%) n/a 
 60+ n/a 3 (0.3%) n/a 
     
Years from  5-9 30 (2.1%) 0 (0.0%) 30 (6.1%) 
WT diagnosis
2
 10-19 94 (6.5%) 27 (2.9%) 67 (13.6%) 
(years) 20-29 349 (24.2%) 234 (24.7%) 115 (23.3%) 
 30-39 652 (45.2%) 455 (48.0%) 197 (39.9%) 
 40+ 316 (21.9%) 231 (24.4%) 85 (17.2%) 
     
On long-term  Yes n/a 360 (38.3%) n/a 
hospital  No n/a 546 (58.0%) n/a 
follow up3 Missing n/a 35 (3.7%) n/a 
     
Treated with  Yes 756 (52.5%) 489 (51.7%) 267 (54.1%) 
abdominal  No 164 (11.4%) 111 (11.7%) 53 (10.7%) 
radiotherapy Missing 521 (36.1%) 347 (36.6%) 174 (35.2%) 
     
Treated with  Yes 701 (48.6%) 460 (48.6%) 241 (48.8%) 
chemotherapy No 203 (14.1%) 125 (13.2%) 78 (15.8%) 
 Missing 537 (37.3%) 362 (38.2%) 175 (35.4%) 
     
Surgery Yes 921 (63.9%) 598 (63.2%) 323 (65.4%) 
 No 13 (0.9%) 9 (0.9%) 4 (0.8%) 
 Missing 507 (35.2%) 340 (35.9%) 167 (33.8%) 
 
1 The BCCSS questionnaire was sent out to survivors aged 16 or over. 
 
2 Years of follow-up after initial diagnosis; percentages correspond to the total number in cohort or 
completed questionnaire. 
 
3 Regular hospital follow-up appointments in relation to the childhood cancer or its treatment.  
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Table 2.5.3. AER of specific causes of death by years of follow-up as a proportion of total absolute excess risk. 
Cause of Death AER < 30 Years from diagnosis AER ≥ 30 Years from diagnosis 
Obs/Exp AER (95%CI) % of Total AER Obs/Exp AER (95%CI) % of Total AER 
Recurrence 25 / 0 7.2 (4.4-10.0) 34% 0 / 0 0.0 (NA) 0% 
SPN 18 / 2.8 4.4 (2.0-6.8) 21% 26 / 3.2 53.8 (30.2-77.4) 50% 
Cardiac 12 / 0.9 3.2 (1.2-5.2) 15% 13 / 1.5 27.0 (10.3-43.7) 25% 
External 14 / 8.3 1.6 (-0.5-3.7) 7% 5 / 1.2 8.9 (-1.4-19.2) 8% 
All Other Causes 22 / 5.5 5.0 (2.3-7.7) 23% 11 / 2.9 19.1 (3.8-34.4) 17% 
All Deaths
ǂ
 91 / 17.8 21.2 (15.8-26.6) 100% 55 / 9.0 108.4 (74.1-142.7) 100% 
Absolute Excess Risks presented per 10,000 person-years. ǂ AER for all causes of death was 21.2 per 10,000 person-years prior to 30 years from diagnosis and 
108.4 per 10,000 person-years poster 30 years from diagnosis, but due to rounding the specific causes of death sum to 21.4 and 108.8 respectively. 
 
Table 2.5.2. Cause-specific standardised mortality ratios (SMRs) and absolute excess risks (AERs) for 1,441 
survivors of Wilms tumour. 
Cause of death Obs/Exp SMR (95%CI) AER (95%CI)
ǂ % of Total AER 
     
All Causes Overall 
Years from diagnosis 
5 – 9 Years 
10 – 19 Years 
20 – 29 Years 
30 – 39 Years 
40+ Years 
146 / 26.8 
 
 
25 / 1.6 
29 / 6.1 
37 / 6.8 
27 / 5.9 
28 / 6.5 
 
5.4 (4.6 ,  6.4) 
 
 
15.7 (10.2, 23.2) 
4.8 (3.2, 6.9) 
5.5 (3.8, 7.5) 
4.6 (3.0, 6.6) 
4.3 (2.9, 6.3) 
30.7 (24.6, 36.8) 
 
 
36.2 (21.0, 51.3) 
16.5 (8.9, 24.0) 
21.1 (11.1, 31.1) 
38.2 (19.8, 56.7) 
92.7 (48.1, 137.4) 
100% 
 
 
 
 
 
 
Infection 
 
5 / 0.6 8.7 (2.8 , 20.2) 1.1 (0.0, 2.3) 4% 
Recurrence 
 
25 / 0 - 6.4 (3.9, 9.0) 21% 
SPN 
 
44 / 6.0 7.3 (5.3 , 9.8) 9.8 (6.4 , 13.1) 32% 
Blood 0 / 0.1 NA 0.0 (NA) 0% 
     
Endocrine 0 / 0.6 NA -0.1 (-0.1, -0.1) 0% 
     
Mental 
 
1 / 0.9 1.1 (0.0 , 6.2) 0.0 (-0.5, 0.5) 0% 
Nervous 
 
3 / 1.3 2.2 (0.5 , 6.6) 0.4 (-0.4, 1.3) 1% 
Cardiac 
 
25 / 2.5 10.1 (6.5 , 14.9) 5.8 (3.3, 8.3) 19% 
Respiratory 
 
6 / 1.2 4.9 (1.8 , 10.7) 1.2 (0.0, 2.5) 4% 
Digestive 
 
6 / 1.5 3.9 (1.4 , 8.5) 1.2 (-0.1, 2.4) 4% 
Muscoskeletal 0 / 0.2 NA 0.0 (NA) 0% 
     
Genitourinary 
 
6 / 0.2 33.1 (12.2 , 72.1) 1.5 (0.3 , 2.7) 5% 
Perinatal 
 
2 / 0.7 3.0 (0.4 , 10.8) 0.3 (-0.4 , 1.1) 1% 
External 
 
19 / 9.6 2.0 (1.2 , 3.1) 2.1 (0.2 , 4.6) 7% 
Other 4 / 1.4 2.9 (0.8 , 7.3) 0.7 (-0.3 , 1.8) 2% 
Calculation of SMR for deaths due to recurrence of Wilms’ tumour would not be appropriate since the expected  mortality rate in the general  
population would be 0. AER for recurrence was calculated as the incidence rate per 10,000 person-years. Confidence intervals for SMR were  
calculated using the approximate method where the number of deaths≥100 and the Poisson exact method where number of deaths<100 174.  
Perinatal deaths refer to causes resulting from congenital abnormalities (2). External causes of death comprise accidents (7 motor accidents  
and 5 accidental poisoning), suicides (2) and other (one death could not be determined as accident or suicide and one death was due to a  
medical procedure). Other causes of death were either unknown or ill-defined (2) or due to general symptoms (1)and stroke (1). ǂ Overall  
AER for all causes of death was 30.7 per 10,000 person-years, but due to rounding, the specific causes of death sum to 30.4.  
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Table 2.5.4. SIRs and AERs for developing specific SPNs after Wilms’ tumour  
Outcome Obs/Exp SIR (95%CI) AER (95%CI)1 AER (95%CI)1, (N) 
< 30 Years from diagnosis 
AER (95%CI)1, (N) 
≥ 30 Years from diagnosis 
All 71/15.1 4.7 (3.7-5.9)  16.6 (11.7-21.5)  11.8 (7.4-16.1) (41) 44.6 (23.0-66.3) (30) 
Digestive2 17/1.3 13.0 (7.6-20.9)  4.7 (2.3-7.1)  2.3 (0.5-4.1) (7) 18.2 (5.7-30.7) (10) 
Genitourinary 9/3.5 2.6 (1.2-4.9)  1.6 (-0.1-3.4)  1.8 (0.0-3.6) (7) 0.5 (-5.1-6.1) (2) 
Breast 9/2.9 3.1 (1.4-5.8)  1.8 (0.1-3.5)  1.5 (-0.4-1.8) (5) 3.3 (-4.6-11.2) (4) 
Bone 6/0.3 20.6 (7.5-44.8) 1.7 (0.3-3.1)  1.6 (0.1-3.2) (5) 2.0 (-2.0-5.9) (1) 
1 indicates that AER is shown per 10,000 person – years. 30 other SPNs include: soft tissue sarcoma (6), unknown primary site (5), glioma (3), leukaemia (3), 
NHL (3), thyroid (3), melanoma (2), adrenal (1), Hodgkin’s lymphoma (1), mesothelioma (1), leiomyosarcoma (1) and oral (1). 2The 17 digestive SPNs comprise: 
Bowel (7), Retroperitoneum/Peritoneum (4), Liver (2), Pancreas (1), Small Intestine (1), Pyloric Antrum (1) and Unknown Digestive Site (1). 
 
 
 
 
 
Table 2.5.5 Differences in mean SF–36 scores between Wilms’ 
 tumour survivors and OHLS reference population 
SF-36 Scale Difference in mean (95%CI)1  
Reported Health Change 0.0 (–1.1, 1.1)  
Physical Function –1.8 (– 3.3, –0.9)  
Role–Physical   –1.2 (–3.3, 0.9)  
Role–Emotional 3.4 (1.2, 5.6)  
Social Functioning –0.1 (-1.4, 1.3)  
Mental Health 0.6 (–0.6, 1.8)  
Vitality 0.0 (–1.4, 1.4)  
Bodily Pain 0.3 (–1.2, 1.9)  
General Health Perception –6.7 (–8.1, –5.2)  
1 Calculated scores were adjusted for age and sex. 
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Table 2.5.6 Odds Ratios (ORs) of pregnancy outcomes, smoking status, alcohol consumption, 
education level, marriage status and hospitalisation of Wilms’ Tumour Survivors. 
 
 Proportion of Affected 
Outcomes (%) 
OR (95%CI) 
Pregnancy outcome1   
Females Survivors   
     Low Birth Weight 61 / 412 (14.8%) 3.3 (2.2, 4.9) 
     Premature 66 / 412 (16.0%) 3.1 (2.1, 4.7) 
     Miscarriage 67 / 412 (16.3%) 1.4 (0.9, 2.1) 
   
Partners of Males Survivors   
     Low Birth Weight 11 / 235 (4.7%) 0.7 (0.4, 1.5) 
     Premature 15 / 235 (6.4%) 0.6 (0.3, 1.3) 
     Miscarriage 34 / 235 (14.5%) 1.2 (0.7, 1.9) 
   
Smoking2   
Current Regular Smoker 220 / 934 (23.6%) 0.7 (0.6, 0.8) 
    
Alcohol3   
Alcohol Consumption 766 / 942 (81.3%) 0.7 (0.6, 0.9) 
Consumption Over Recommendation 210 / 766 (27.4%) 0.8 (0.7, 1.0) 
Consuming Harmful Doses 34 / 766 (4.4%) 0.5 (0.3, 0.7) 
   
Education (Achievement)4   
Degree 133 / 672 (19.8%) 0.9 (0.7, 1.1) 
Teaching Qualification 204 / 672 (30.4%) 0.9 (0.7, 1.1) 
A–level 385 / 774 (49.8%) 0.9 (0.8, 1.1) 
O–level 690 / 924 (74.7%) 1.0 (0.8, 1.1) 
   
Marital status5   
Males 123 / 426 (28.9%) 0.7 (0.5, 0.9) 
Females 197 / 505 (39.0%) 1.0 (0.8, 1.3) 
   
Hospitalisations6   
Talked to a doctor in the last 2 weeks 152 / 900 (16.9%) 1.2 (1.0,1.5) 
     Not on long-term follow up 88 / 549 (16.0%) 1.1 (0.9,1.4) 
     On long-term follow up 57 / 329 (17.3%) 1.3 (1.0,1.8) 
   
Attended Hospital Outpatient 229 / 897 (25.5%) 2.6 (2.2,3.1) 
     Not on long-term follow up 123 / 546 (22.5%) 2.1 (1.7,2.6) 
     On long-term follow up 101 / 329 (30.7%) 3.5 (2.7,4.6) 
   
Hospitalised as a Day Patient 118 / 904 (13.1%) 1.7 (1.3,2.1) 
     Not on long-term follow up 71 / 552 (12.9%) 1.5 (1.1,2.0) 
     On long-term follow up 43 / 330 (13.0%) 1.9 (1.3,2.7) 
   
Hospitalised as an Inpatient 93 / 904 (10.3%) 2.0 (1.6,2.6) 
     Not on long-term follow up 55 / 553 (10.0%) 1.9 (1.4,2.6) 
     On long-term follow up 36 / 329 (10.9%) 2.3 (1.6,3.5) 
Total numbers represent the number of Wilms’ Tumour survivors that answered a question relating to the specific 
outcome on the BCCSS questionnaire or in the case of pregnancies, the total number of pregnancies in female 
survivors of Wilms’ Tumour. 
1 pregnancies of WT survivors who received abdominal radiotherapy versus pregnancies of survivors of any other 
childhood cancer who did not receive abdominal radiotherapy.  
2 adjusted for sex, attained age, marital status, socioeconomic classification, level of educational attainment. 
3 controlled for attained age, gender, legal marital status, socioeconomic classifications, educational attainment, and 
region, and took into account the GHS weighting factor, for the likelihood of consuming over the recommendations for 
weekly alcohol units or consuming harmful weekly amounts of alcohol.  
4 adjusted for, sex and attained age.  
5 compared to British population marriage statistics from ONS 2002. 
6 versus never compared to the general British population. 
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Table 2.5.7. Results of a comprehensive review, using hospital records and autopsy reports, of 25* causes of death relating 
to the 25 deaths coded as cardiac on the death certificate. 
 
*4 were considered deaths due to renal failure. The age of death was over 50 years in only 4 persons. 
  
Type of Circulatory Death Frequency Comments 
Myocardial Infarction 9 
 
4 had chest radiotherapy and/or 
lung metastasis documented. 
 
Cardiac Failure 7 
6 had chest radiotherapy 
documented, 2 also had renal 
failure. Myocardial, lung and liver 
fibrosis at autopsy in 2. 
Pulmonary Embolism 3 
 
 
 
 
Other 2 
 
Comprises 1 atrial myxoma, 1 
alcoholic cardiomyopathy. 
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Figure 2.5.1 Observed and expected cumulative mortality among 1,441 survivors of childhood Wilms’ tumour. 
 
Figure 2.5.2 Observed and expected cumulative incidence of developing a SPN among 1,441 survivors of Wilms’ 
tumour with 95% Confidence Intervals 
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Figure 2.5.3 Specific questions underlying the SF36 Physical Function scale – directly standardised proportions 
with limitation in specific activities. 
Figure 2.5.4 Specific questions underlying the SF36 General Health Perception scales – directly standardised 
proportions with specified level of agreement in relation to each question. 
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3 LONG-TERM RENAL MORBIDITY IN SURVIVORS OF 
CHILDHOOD CANCER IN THE BRITISH CHILDHOOD CANCER 
SURVIVOR STUDY USING DATA FROM THE NATIONAL HOSPITAL 
EPISODE STATISTICS. 
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Abstract 
Background: Survivors of childhood cancer are at risk of renal conditions occurring 
many years after their childhood cancer diagnosis. However, no large-scale study 
has yet to investigate the risk of hospitalisation due to specific renal diseases. We 
investigated the risks of hospitalisation due to specific renal diseases among five-
year survivors of childhood cancer. 
Methods: The British Childhood Cancer Survivor Study includes 34,489 five-year 
survivors of childhood cancer. We measured the risk of hospitalisation due to 
glomerular disease (i.e. excess blood and protein in the urine), renal tubulo-interstitial 
disease (i.e. inflammation of the kidneys affecting interstitial area surrounding the 
tubules), renal failure (i.e. kidneys failing to filter waste products from the blood which 
is measured by the glomerular filtration rate), urolithiasis (i.e. kidney stones), urinary 
tract infection, other kidney disorders and other urinary system diseases by type of 
childhood cancer, gender, age at cancer diagnosis, year of cancer diagnosis and 
attained age of the hospitalisation. 
Results: Risk of being hospitalised due to a renal condition was 2-fold expected for 
survivors compared to the general population with nearly 1 excess hospitalisation per 
500 survivors per year. Survivors of neuroblastoma (4-fold), Wilms’ Tumour (3-fold) 
and soft tissue sarcoma (3-fold) experienced the highest excess risks of renal 
morbidities with 45, 37 and 41 excess hospitalisations per 10,000 survivors per year 
respectively. Survivors of Wilms’ tumour had a 30-fold risk of being hospitalised for 
chronic renal failure and a 15-fold risk of being hospitalised for acute renal failure 
compared to the general population. 
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Conclusion: Survivors of childhood cancer are at twice the risk of being hospitalised 
due to any renal disease compared to the general population. Specific risks were 
highest for survivors of Wilms’ tumour whom had a 30-fold risk of being hospitalised 
due to chronic renal failure compared to the general population. Monitoring of 
glomerular filtration rate (GFR) levels in survivors of Wilms’ tumour is advisable, 
especially in those who are aged 5-29. 
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3.1 Introduction 
Five-year survival after childhood cancer has improved, over recent decades, to 
approximately 80% among those diagnosed between 2000 and 20074. Although 
survival rates are increasing, survivors ,particularly of Wilms’ tumour (WT), are at risk 
of a range of renal related morbidities such as acute and chronic renal failure175. A 
previous study relating to survivors of non-Hodgkin’s lymphoma (NHL), found that 
survivors were at higher risk of glomerular disease176 with a third of the survivors 
exhibiting proteinuria, and at a 34% increased risk of renal failure and survivors 
experienced significantly decreased glomerular filtration rates7,69-71,177,178. Other 
studies showed that survivors of childhood cancer who receives Cisplatin, 
Carboplatin, high-dose Cyclophosphamide, nephrectomy and abdominal radiation 
also had an increased risk of developing renal disease70,100,179. 
 
However, these studies focused on all childhood cancer survivors or survivors of 
specific diagnoses rather than survivors who were exposed to specific risk 
exposures. The majority of previous studies had fewer than 50 observed renal events 
which were insufficient to satisfactorily address the risks of renal diseases. No 
previous large-scale study has investigated the risks of renal tubulo-interstitial 
disease, urolithiasis and acute renal failure in survivors of childhood cancer. 
 
To our knowledge, this is the first study to analyse the risk of hospitalisation due to 
long-term renal morbidities in five-year survivors of childhood cancer in a UK 
population-based environment. The main advantage of this current study – in 
addition to being large-scale and population-based – is that 60% of the cohort, who 
were born at least 25 years from the date of exit, survived for at least 25 years from 
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the date of their first primary neoplasm diagnosis (FPN) indicating a large pool of 
survivors still on follow-up. 
 
The principal objective of this study was to investigate risk of hospitalisation due to 
long-term renal morbidities among five-year survivors of childhood cancer, 
specifically: (1) glomerular disease (i.e. excess blood and protein in the urine), (2) 
renal tubulo-interstitial disease (i.e. inflammation of the kidneys affecting interstitial 
area surrounding the tubules), (3) renal failure (i.e. kidneys failing to filter waste 
products from the blood which is measured by the glomerular filtration rate), (4) 
urolithiasis (i.e. kidney stones), (5) urinary tract infection, (6) other kidney disorders 
and (7) other urinary system diseases. 
 
3.2 Methods 
British Childhood Cancer Survivor Study (BCCSS)  
The British Childhood Cancer Survivor Study (BCCSS) is a large-scale population 
based cohort study established to investigate adverse health and social outcomes of 
childhood cancer and its treatment. The BCCSS includes 34,489 five-year survivors 
of childhood cancer who were diagnosed before 15 years of age, between 1940 and 
2006 in Britain. Of these, 27,976 five-year survivors remained at risk after the period 
at which the Hospital Episode Statistics (HES) began (1st April 1997). The BCCSS 
cohort was ascertained through the population-based National Registry of Childhood 
Tumours. Ascertainment of deaths (including underlying cause of death) in the 
BCCSS was achieved through flagging the entire cohort of childhood cancer 
survivors at the population-based Health and Social Care Information Centre 
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(HSCIC). Flagging informs the BCCSS when a survivor dies and provides linkage 
between the population-based cohort and the national population-based death and 
cancer registration systems.  
 
Hospital Episode Statistics (HES)  
The national Hospital Episode Statistics database records all in-patient hospital 
admissions, outpatients and A&E admission in NHS hospitals in England. The British 
Childhood Cancer Survivor Study was linked to HES to investigate the risks of 
hospitalisation due to renal morbidities—of those who were still alive when HES 
began (1st April 1997) 81% linkage to HES was achieved. In the cohort, 27,976 five-
year survivors remained at risk after the date at which Hospital Episode Statistics 
(HES) were initiated (1st April 1997). We defined renal morbidities using codes from 
the International Classification of Diseases (Tenth Revision)180, specifically; 
glomerular disease (ICD10: N00-N08), renal tubulo-interstitial disease (ICD10: N10-
N16), renal failure (ICD10: N17-N19), urolithiasis (ICD10: N20-N23), urinary tract 
infection (ICD10: N39.0), other disorders of kidney and ureter (ICD10: N25-N29) and 
other diseases of the urinary system (ICD10: N30-N39, excluding N39.0) (see 
Appendix 8.3). 
 
Statistical Analysis 
Hospitalisation due to Renal Morbidities 
To investigate hospitalisations, numbers of first observed hospitalisations due to all 
renal morbidities among all five-year childhood cancer survivors were compared with 
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the comparable number of expected hospitalisations from the general population. 
Secondary analyses investigated the numbers of first observed hospitalisations due 
to seven unique renal diseases among all five-year childhood cancer survivors and 
were compared with the comparable number of expected hospitalisations from the 
general population. Expected hospitalisations were calculated by using the rates of 
hospitalisation in the general population, population denominators were obtained 
from the Office for National Statistics (ONS), and indirectly standardised on the 
survivor cohort using the person-years from the numerator obtained from the survivor 
cohort. The period at risk began 1st April 1997 for those who were at least five-year 
survivors on this date, or date of becoming a five-year survivor if this was after 1st 
April 1997, and ended at the date of first occurrence of loss of follow up (N=294), 
death (N=1,953) or exit (31st December 2012) (N=25,729). Standardised 
hospitalisation ratios (SHR) for specific renal morbidities were calculated as the ratio 
of first observed hospitalisations over expected number of hospitalisations for each 
specific type of renal morbidity. Absolute excess risks (AER) were calculated by 
taking the number of observed first hospitalisations minus expected number of first 
hospitalisations divided by the number of person-years at risk multiplied by 10,000. 
An external Poisson regression model was performed to assess the risk of 
hospitalisations due to renal morbidities, by calculating relative risks (RR) and relative 
excess risks (RER), adjusting for possible risk factors. The model was adjusted for 
gender, specific categories of attained age, age of diagnosis, decade of diagnosis 
and type of childhood cancer. 
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Statistical significance for all analyses was defined as a 2-sided P<0.05. All analyses 
were carried out in Stata 13 (StataCorp, College Station, Texas). 
 
3.3 Results 
Cohort Characteristics 
From the total of 27,976 five-year survivors of childhood cancer in the cohort, 1,183 
(4.2%) had been hospitalised for a renal morbidity at least once. When analysing 
specific renal diseases, 28 (0.1%) survivors were admitted for glomerular disease, 
206 (0.7%) for renal tubulo-interstitial disease, 172 (0.6%) for renal failure, 183 
(0.7%) for urolithiasis, 481 (1.7%) for urinary tract infection, 48 (0.2%) for other 
disorders of the kidney and 375 (1.3%) for other urinary system diseases (Table 
3.5.1). Total follow-up of five-year survivors, in relation to hospitalisations, was 
308,612 person-years with mean and median follow-up of 11.1 and 13.2 years for the 
duration of HES (1997–2012) respectively. 
 
Hospitalisations due to all Renal Morbidities 
Overall, survivors experienced a 2-fold increased risk of being hospitalised for any 
renal morbidity (SHR=1.9; 95%CI: 1.8-2.0) with 18 excess hospitalisations per 
10,000 person-years (AER=18.0; 95%CI: 15.8-20.2) compared to the general 
population (Table 3.5.2). Survivors who experienced the highest excess risk of renal 
morbidities were neuroblastoma (SHR=3.6; 95%CI: 2.9-4.4), Wilms’ Tumour 
(SHR=2.9; 95%CI: 2.4-3.4) and soft tissue sarcoma (SHR=2.9; 95%CI: 2.4-3.5) with 
45, 37 and 41 excess hospitalisations per 10,000 person-years respectively. After 
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adjustment for potential confounders, survivors of soft tissue sarcoma had the 
highest risk (RR=2.4; 95%CI: 2.0-3.0) compared to the reference group (i.e. 
leukaemia). Both males and females had an elevated risk of being hospitalised, 1.9-
fold and 1.8-fold expected respectively, but females were significantly less likely to be 
hospitalised compared to males (RR=0.7; 95%CI: 0.6-0.8). Following 5-year survival, 
the excess risk of being hospitalised due to a renal disease (both RR and RER) 
decreased significantly with increasing attained age (P < 0.01). 
 
Hospitalisations due to Glomerular Disease 
Survivors of childhood cancer experienced an increased risk of hospitalisations due 
to glomerular disease (SHR=1.6; 95%CI: 1.1-2.3). When examining survivors by 
childhood cancer diagnosis, only survivors of Wilms’ tumour (SHR=4.5; 95%CI: 2.0-
9.9) and non-Hodgkin lymphoma (SHR=3.3; 95%CI: 1.1-10.2) were at an increased 
risk of being hospitalised for glomerular disease (Table 3.5.3). Females were 
significantly more likely than expected to be hospitalised due to a glomerular disease 
(SHR=2.1; 95%CI: 1.3-3.6). 
 
Hospitalisations due to Renal Tubulo-Interstitial Disease 
Overall, survivors had a 1.9-fold increased risk of being hospitalised for a renal 
tubulo-interstitial disease (SHR=1.9; 95%CI: 1.7-2.2) with 3.1 excess hospitalisations 
per 10,000 person-years (AER=3.1; 95%CI: 2.2-4.0). When examining by type of 
childhood cancer diagnosis, survivors of soft tissue sarcoma (SHR=5.4; 95%CI: 3.9-
7.4), neuroblastoma (SHR=4.6; 95%CI: 3.0-7.1) and Wilms’ tumour (SHR=3.7; 
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95%CI: 2.6-5.3) were at the highest multiplicative excess risk of being hospitalised 
for a renal tubule-interstitial disease (Table 3.5.4). These survivors also contributed 
the highest number of excess cases of hospitalisation due to renal tubulo-interstitial 
disease; neuroblastoma (AER=10.9; 95%CI: 4.8-17.0), Wilms’ tumour (AER=9.2; 
95%CI: 4.8-13.6) and soft tissue sarcoma (AER=14.3; 95%CI: 8.6-20.1). Compared 
to survivors of leukaemia, those who survived soft tissue sarcoma had the highest 
excess risk (RR=5.2; 95%CI: 3.0-8.9).  Following 5-year survival, the excess risk of 
being hospitalised due to renal tubulo-interstitial disease (both RR and RER) 
decreased significantly with increasing attained age (P < 0.01). 
 
Hospitalisations due to Renal Failure 
Survivors had a 6-fold expected risk of being hospitalised due to renal failure 
(SHR=5.8; 95%CI: 5.0-6.7) with 4.6 excess hospitalisations per 10,000 person-years 
(AER=4.6; 95%CI: 3.8-5.4). Almost all first primary diagnosis groups had a 
significantly elevated excess risk – except non-Hodgkin’s lymphoma (NHL) and non-
heritable retinoblastoma survivors (Table 3.5.5). At highest excess risk were 
survivors of Wilms’ tumour (SHR=21.8; 95%CI: 16.4-29.1), neuroblastoma (SHR=9.4; 
95%CI: 5.1-17.5), bone (SHR=7.1; 95%CI: 3.8-13.2) and soft tissue sarcoma 
(SHR=8.5; 95%CI: 5.4-13.3). The highest excess number of hospitalisations were 
from survivors of Wilms’ Tumour (AER=17.8; 95%CI: 12.4-23.2) and soft tissue 
sarcoma (AER=8.2; 95%CI: 4.0-12.3). Compared to survivors of Leukaemia, those 
who survived Wilms’ tumour had the highest multiplicative excess risk (RR=6.7; 
95%CI: 4.0-11.3). Both males and females had an elevated risk of being hospitalised 
(SHR=5.3; 95%CI: 4.6-6.4) and (SHR=6.8; 95%CI: 5.4-8.5) respectively. Following 5-
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year survival, the excess risk of being hospitalised due to a renal failure (both RR 
and RER) decreased with increasing age (P < 0.05). 
 
Of the 172 renal failures (Table 3.5.1), 37% were acute (N=64), 48% were chronic 
(N=82) and 15% were unknown (N=26). Survivors had a similar excess risk of being 
hospitalised for a chronic renal failure (SHR=6.4; 95%CI: 5.1-7.9) and acute renal 
failure (SHR=5.0; 95%CI: 3.9-6.4). Survivors of Wilms’ tumour had the greatest 
multiplicative excess risk of being hospitalised for both chronic (SHR=29.6; 95%CI: 
20.4-42.8) and acute (SHR=14.9; 95%CI: 8.7-25.7) renal failure. The number of 
excess cases of hospitalisations due to chronic renal failure and acute renal failure 
for survivors of Wilms’ tumour was 10.9 (95%CI: 6.7-15.1) and 4.9 (95%CI: 2.0-7.7) 
respectively (Table 3.5.6, Table 3.5.7). Survivors of other childhood cancers also had 
increased risks, but not as high as Wilms’ tumour survivors and also very few groups 
had increased excess numbers of hospitalisation compared to expected. Both males 
and females had significantly elevated risk of being hospitalised due to acute renal 
failure (SHR=4.8; 95%CI: 3.5-6.5) and (SHR=5.5; 95%CI: 3.6-8.2) and to chronic 
renal failure (SHR=5.6; 95%CI: 4.2-7.5) and (SHR=7.7; 95%CI: 5.6-10.6) 
respectively. Following 5-year survival, the multiplicative excess risk of being 
hospitalised due to both acute and chronic renal failure decreased with increasing 
age (P < 0.001). 
 
Hospitalisations due to Urolithiasis 
Overall, survivors were more likely to be hospitalised for urolithiasis than the general 
population (SHR=1.3; 95%CI: 1.1-1.5) and only survivors of neuroblastoma 
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(SHR=2.7; 95%CI: 1.6-4.7) and soft tissue sarcoma (SHR=2.3; 95%CI: 1.5-3.4) had 
elevated risk of being hospitalised for urolithiasis (Table 3.5.8). Following 5-year 
survival, the multiplicative excess risk of being hospitalised due to urolithiasis 
significantly decreased with increasing attained age (P < 0.001). 
 
 
Hospitalisations due to Urinary Tract Infections 
Survivors of childhood cancer experienced twice the risk of being hospitalised for 
urinary tract infection (SHR=2.2; 95%CI: 2.0-2.4) compared to the general 
population. Survivors of all types of childhood cancer, except for lymphomas and 
retinoblastomas, had a significantly increased risk of being hospitalised for urinary 
tract infection compared to the general population. This risk was highest for survivors 
of neuroblastoma (SHR=3.6; 95%CI: 2.6-5.0), CNS tumours (SHR=3.1; 95%CI: 2.7-
3.7) and Wilms’ tumour (SHR=3.0; 95%CI: 2.3-4.0) with 17, 16 and 14 excess 
hospitalisations per 10,000 survivors per year compared to the general population, 
respectively (Table 3.5.9). After adjusting for confounders, survivors of CNS tumours 
and bone tumours had the highest multiplicative excess risk (RR=1.9; 95%CI: 1.4-
2.5) and (RR=1.9; 95%CI: 1.2-3.2) compared to survivors of leukaemia, respectively. 
Females were significantly less likely to be hospitalised for urinary tract infection 
compared to males (RR=0.7; 95%CI: 0.5-0.9). Following 5-year survival, the excess 
risk of being hospitalised due to urinary tract infection (both RR and RER) 
significantly decreased with increasing attained age (P < 0.001) and also significantly 
decreased for survivors who were diagnosed with their childhood cancer in more 
recent years (P < 0.001). 
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Hospitalisations due to Other Kidney Diseases 
Survivors had a 6.5-fold excess risk of being hospitalised for other kidney conditions 
(SHR=6.5; 95%CI: 4.9-8.6), which include impaired renal tubular function (N=4), 
atrophy of kidney (N=3), small kidney (N=2), unspecified disorders (N=39). When 
examining survivors by their childhood cancer diagnosis, survivors of neuroblastoma 
(SHR=20.1; 95%CI: 9.0-44.8), Wilms’ tumour (SHR=14.3; 95%CI: 7.1-28.6) and soft 
tissue sarcoma (SHR=13.3; 95%CI: 6.4-28.0) were the three groups with the highest 
excess risk of being hospitalised for other kidney diseases compared to the general 
population (Table 3.5.10). Compared to survivors of leukaemia, those who survived 
soft tissue sarcoma had the highest relative risk (RR=6.2; 95%CI: 1.6-23.6). Both 
males and females had an elevated risk of being hospitalised (SHR=5.5; 95%CI: 3.6-
8.4) and (SHR=7.7; 95%CI: 5.2-11.3) respectively. Following 5-year survival, the 
multiplicative excess risk of being hospitalised due to other kidney diseases 
significantly decreased with increasing attained age (P = 0.006). 
 
Hospitalisations due to Other Urinary System Diseases 
Overall, survivors experienced a borderline statistically significant increased risk 
(SHR=1.1; 95%CI: 1.0-1.2) of being hospitalised for other urinary system diseases, 
which include cystitis (N=51), neuromuscular dysfunction of bladder (N=75), other 
disorders of bladder (N=78), complications of urethral system (N=96), proteinuria 
(N=1), incontinence (N=49) and other specified and unspecified disorders of the 
urinary system (N=25). Only survivors of CNS tumours, neuroblastoma and soft 
tissue sarcoma had significantly elevated risk of being hospitalised due to other 
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urinary system diseases; these were neuroblastoma (SHR=3.4; 95%CI: 2.5-4.5), soft 
tissue sarcoma (SHR=2.4; 95%CI: 1.8-3.1) and CNS (SHR=1.2; 95%CI: 1.0-1.5) with 
23, 15 and 3 excess hospitalisations per 10,000 person-years respectively (Table 
3.5.11). After adjusting for confounders, those who survived neuroblastoma and soft 
tissue sarcoma had the highest relative risk (RR=3.8; 95%CI: 2.5-5.6) and (RR=3.4; 
95%CI: 2.3-5.0) compared to survivors of leukaemia, respectively. Females were 
significantly less likely to be hospitalised for other urinary system disease compared 
to males (RR=0.4; 95%CI: 0.3-0.5). Following 5-year survival, the multiplicative 
excess risk of being hospitalised due to other urinary system disease significantly 
decreased with increasing attained age (P < 0.001). 
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3.4 Discussion 
To our knowledge, this is the first study that identifies the increased risk of 
hospitalisation due to specific renal diseases of survivors of childhood cancer in a 
large-scale population-based cohort. Overall, survivors had twice the risk of being 
hospitalised for any renal disease with nearly 1 extra hospitalisation per 500 
survivors per year. This study demonstrated, for the first time, significantly elevated 
risks of hospitalisation due to any renal disease specifically for survivors of 
neuroblastoma, Wilms’ tumour and soft tissue sarcoma. However, this risk 
significantly decreased with increasing attained age. Since the risk of hospitalisation 
due to renal disease is compared to the general population, the effect of decreasing 
risk with attained age may be due to the increasing risk of renal disease in the 
background population risk with older age – it may be possible to make potentially 
causal relationships for many, but not all, of these diseases. 
 
Renal failure, which is considered to be one of the most important, and possibly fatal, 
renal morbidities was measured and survivors had a 6-fold risk of being hospitalised 
for this compared to the general population. In particular, survivors of Wilms’ tumour 
had a 22-fold risk of being hospitalised due to renal failure with a corresponding 
excess of 18 cases compared to the general population per 10,000 survivors per 
year – previous studies demonstrated an elevated risk of renal failure in childhood 
cancer survivors but did not compare the risk to the general population and did not 
investigate the risk by childhood cancer diagnosis7,69,175. Previous studies have 
reported decreased glomerular filtration rate (GFR) due to anti-cancer therapy 
ultimately leading to chronic renal failure70,178,179,181,182– although we do not have 
information relating to treatment or GFR in this study, our survivors had a 6-fold risk 
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of being hospitalised for chronic renal failure compared to the general population. To 
our knowledge, no study has yet investigated acute renal failure as a long-term 
adverse effect following survival of childhood cancer in a large-scale population-
based cohort. This study reports a 5-fold increased risk of childhood cancer survivors 
being hospitalised due to acute renal failure compared to the general population. 
Survivors of Wilms’ tumour had a 15-fold increased risk of hospitalisation for acute 
renal failure with 1 excess case of hospitalisation per 2,000 survivors per year 
compared to the general population. 
 
There have been very few studies investigating the onset of urolithiasis, or kidney 
stones, in survivors of childhood cancer. One particular US study found that the 
prevalence of kidney stones was twice as high in survivors than the general 
population for younger ages and approximately no difference in risk for survivors and 
the general population for older age groups183. In comparison, survivors aged 5–19 in 
our study had a 6-fold risk of being hospitalised for a kidney stone compared to the 
general population. This risk decreased to 2-fold for survivors aged 20–29, and 
survivors older than 30 no longer had a significantly elevated risk of being 
hospitalised for kidney stones compared to the general population. Although the US 
study had treatment data, they did not report on all childhood cancer types. Our study 
found that survivors of neuroblastoma and soft tissue sarcoma were the only 
childhood cancer types that actually had a significantly elevated risk of being 
hospitalised for kidney stones compared to the general population (3-fold and 2-fold 
risk respectively) – possibly because the majority of neuroblastoma and 
rhabdomyosarcoma, in children, occur in the abdomen. 
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We found no previous studies reporting hospitalisations due to other renal morbidities 
such as glomerular disease, renal tubulo-interstitial disease (or tubulo-interstitial 
nephritis), urinary tract infection, other kidney disorders and other urinary diseases 
after five-year childhood cancer survival. Our study shows that survivors of childhood 
cancer are, in fact, at an increased risk of being hospitalised due to these five renal 
conditions with approximately 2-fold risk of being hospitalised for glomerular disease, 
renal tubulo-interstitial disease, urinary tract infections, other urinary diseases and 
with a 6-fold increased risk of being hospitalised for other kidney diseases. 
 
The increased risks of renal failure in survivors of childhood cancer indicate that 
survivors may need to be monitored for such diseases. The National Institute of Care 
and Excellence (NICE) guidelines for monitoring chronic renal failure184, states that 
the frequency of recommended monitoring of GFR increases up to 4 times per year 
dependent on GFR levels, our study shows that survivors of childhood cancer are at 
increased risk of being hospitalised due to severe chronic renal failure (where GFR is 
an indicator of renal failure) compared to the general population. This indicates that it 
is important for survivors of childhood cancer to have their GFR frequently monitored 
– especially those who had WT and may already have kidney function impairment 
from the treatment or the cancer itself. However, measuring the GFR in all survivors 
of childhood cancer will require a lot of resources and in some cases the benefit of 
measuring GFR will not necessarily outweigh the cost (i.e. stress caused by 
frequently returning to the hospital for tests). Therefore, monitoring of GFR should 
only be considered for particular survivors who have a significantly high risk. 
 
74 
 
Limitations 
A limitation of our study was that the HES database began from 1997 – this meant 
that no hospitalisation would have been recorded in the HES database prior to this 
time. As a result, survivors who were previously diagnosed with their initial cancer in 
1940–1960 may have been hospitalised due to a renal condition after 30 years and 
this would be missed from the HES database. Therefore is likely that the risk of being 
hospitalised for those diagnosed in the early years is underestimated. It is difficult to 
determine how well validated HES data is in terms of accuracy of ICD coding and 
thus there may be overlap in some classifications of renal disease (such as renal 
tubulo-interstitial disease and impaired renal tubular function). Our study measures 
the hospitalisations due to renal conditions, which we assume that the renal condition 
has been ongoing and has eventually reached a stage where it becomes serious 
enough to hospitalise the survivor. However, survivors could have been hospitalised 
for renal diseases prior to 1997 and would not appear in this study, potentially 
underestimating the true risk of renal morbidities. Since our study includes patients 
diagnosed with cancer up until the end of 2006, five-year survival would potentially 
start in 2011 for these survivors. This would mean that those diagnosed with their 
initial cancer towards the end of the study (2000 onwards) may not accrue enough 
person-years to develop a renal disease or even be severe enough to be hospitalised 
for a renal disease indicating that hospitalisations due to renal disease would be 
severely underestimated for these survivors. Finally, the use of first hospitalisation 
may not capture the full extent of the disease and the disease may continue to recur 
in survivors over a prolonged period. Ideally, for a future study, repeated 
hospitalisations should be measured, to gauge the burden of the disease, but these 
hospitalisations should be validated. By doing this, it will be possible to investigate 
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the routes to certain diagnoses (i.e. chronic renal failure leading to acute renal failure 
after 10 years). 
 
Conclusion 
Survivors of childhood cancer are at twice the risk of being hospitalised due to a 
renal disease compared to the general population. Specific risks were highest for 
survivors of Wilms’ tumour whom had a 30-fold risk of being hospitalised due to 
chronic renal failure compared to the general population. Monitoring of GFR levels in 
survivors of Wilms’ tumour is strongly advised, especially in those who are aged 5-
29, to help prevent severe cases of chronic renal failure from emerging. 
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3.5 Tables and Figures 
Table 3.5.1 Characteristics of all 1,183 Renal Hospitalisations in the British 
Childhood Cancer Survivor Study. 
  All Renal Hospitalisations 
(N = 1,183) 
Sex  Male 504 (43%) 
 Female 679 (57%) 
   
Sub-types of Renal Glomerular Disease 28 
Morbidities1 Renal Tubulo-Interstitial 206 
 Renal Failure 172 
 Acute Renal Failure 64 
 Chronic Renal Failure 82 
 Urolithiasis 183 
 Urinary Tract Infection 481 
 Other Disorders of Kidney 48 
 Other Urinary System 375 
   
Age at Mean 6.3 
Diagnosis of FPN Median 5.2 
(years) 0 – 4 576 (48.7%) 
 5 – 9 289 (24.4%) 
 10 – 14 318 (26.9%) 
   
Age at  Mean 27.9 
Renal Hospitalisation 5 – 14 221 (18.7%) 
(years)2 15 – 24 369 (31.2%) 
 25 – 34 242 (20.5%) 
 35 – 44 190 (16.0%) 
 45 – 54 103 (  8.7%) 
 55 – 64 48 (  4.1%) 
 65+ 10 (  0.8%) 
   
Decade of  Median 1986 
FPN diagnosis 1940-1949 8 (  0.7%) 
(years)2 1950-1959 52 (  4.4%) 
 1960-1969 127 (10.7%) 
 1970-1979 207 (17.5%) 
 1980-1989 302 (25.5%) 
 1990-1999 342 (28.9%) 
 2000-2006 145 (12.3%) 
   
 
1 Sub-type of renal morbidities does not sum to the total number of renal hospitalisations as they were analysed as sub-
groups and the outcome of interest changed for each time-to-event analysis. As a result, no percentages are shown as 
the numbers are not respective to the total. 
2 Skewed due to HES starting only in 1997 and renal events may have been missed prior to 1997 for some of the older 
survivors and hence lower numbers in the earlier years of childhood cancer diagnosis. 
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Table 3.5.2 Table of Standardised Hospitalisations Ratios due to renal disease compared to the general population. 
 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma).  
  
 All Renal Outcomes 
 O/E SHR RR AER RER 
Type of Childhood  
Cancer§ 
     
Overall 1183 / 627.31 1.9 (1.8-2.0) NA‡ 18.0 (15.8-20.2) NA‡ 
      
Leukaemia 252 / 158.87 1.6 (1.4-1.8) REF 10.3 (6.9-13.8) REF 
Hodgkin’s Lymphoma 52 / 46.35 1.1 (0.9-1.5) 1.1 (0.8-1.5) 2.8 (-4.2-9.7) 1.1 (0.8-1.6) 
NHL 38 / 30.92 1.2 (0.9-1.7) 1.1 (0.8-1.6) 4.7 (-3.3-12.8) 1.1 (0.8-1.6) 
CNS 296 / 147.52 2.0 (1.8-2.2) 1.6 (1.3-1.9) 21.9 (16.9-26.9) 1.6(1.3-1.9) 
Neuroblastoma 87 / 24.20 3.6 (2.9-4.4) 2.1 (1.7-2.7) 45.1 (32.0-58.3) 2.2 (1.7-2.8) 
N-Retinoblastoma 21 / 24.56 0.9 (0.6-1.3) 0.8 (0.5-1.2) -3.2 (-11.2-4.9) 0.7 (0.4-1.2) 
H-Retinoblastoma  14 / 16.59 0.8 (0.5-1.4) 0.7 (0.4-1.3) -3.4 (-13.0-6.2) 0.7 (0.4-1.4) 
Wilms’ tumour 136 / 47.40 2.9 (2.4-3.4) 2.2 (1.8-2.7) 36.9 (27.4-46.4) 2.3 (1.8-2.8) 
Bone 56 / 26.90 2.1 (1.6-2.7) 2.0 (1.5-2.8) 27.1 (13.4-40.8) 2.1 (1.5-2.9) 
STS 123 / 42.11 2.9 (2.4-3.5) 2.4 (2.0-3.0) 40.8 (29.9-51.8) 2.6 (2.1-3.2) 
Other 108 / 61.90 1.7 (1.4-2.1) 1.4 (1.1-1.8) 16.5 (9.2-23.8) 1.4 (1.1-1.8) 
P-Heterogeneity†   < 0.001  < 0.001 
Gender      
Male 504 / 259.31 1.9 (1.8-2.1) REF 14.5 (11.9-17.1) REF 
Female 679 / 368.00 1.8 (1.7-2.0) 0.7 (0.6-0.8) 22.2 (18.6-25.9) 1.6 (1.4-1.8) 
P-Heterogeneity†   < 0.001  < 0.001 
Attained Age      
5-19 400 / 105.78 3.8 (3.4-4.2) REF 28.6 (24.8-32.4) REF 
20-29 335 / 205.63 1.6 (1.5-1.8)  0.4 (0.3-0.4) 13.5 (9.7-17.2) 0.7 (0.6-0.8) 
30-39 203 / 141.46 1.4 (1.3-1.6) 0.4 (0.3-0.4) 10.3 (5.6-14.9) 0.7 (0.6-0.8) 
40-49 143 / 103.05 1.4 (1.2-1.6) 0.3 (0.2-0.3) 12.0 (5.0-19.0) 0.6 (0.5-0.8) 
50+ 102 / 71.40 1.4 (1.2-1.7) 0.2 (0.2-0.3) 18.4 (6.5-30.4) 0.7 (0.5-0.9) 
P-Trend†   < 0.001  < 0.001 
Age (Diagnosis)      
0 – 4 576 / 252.83 2.3 (2.1-2.5) REF 22.2 (19.0-25.4) REF 
5 – 9 289 / 166.88 1.7 (1.5-1.9) 0.9 (0.7-1.0) 14.9 (10.9-19.0) 0.9 (0.8-1.1) 
10 – 14 318 / 207.59 1.5 (1.4-1.7) 0.9 (0.8-1.1) 13.6 (9.3-17.9) 1.1 (0.9-1.3) 
P-Trend†   0.356  0.634 
Year (Diagnosis)      
1940 – 1969 187 / 124.99 1.9 (1.3-1.7) REF 17.5 (9.9-25.1) REF 
1970 – 1979 207 / 139.95 1.5 (1.3-1.7) 1.1 (0.9-1.3) 12.0 (7.0-17.1) 0.8 (0.6-1.0) 
1980 – 1989 302 / 170.24 1.8 (1.6-2.0) 1.3 (1.1-1.5) 15.5 (11.5-19.5) 0.8 (0.6-0.9) 
1990 – 1999 342 / 153.62 2.2 (2.0-2.5) 1.1 (0.9-1.3) 18.5 (15.0-22.1) 0.6 (0.5-0.7) 
2000 – 2006 145 / 38.50 3.8 (3.2-4.4) 1.0 (0.8-1.2) 34.5 (26.9-42.2) 0.3 (0.3-0.4) 
P-Trend†    0.852  < 0.001 
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Table 3.5.3 Table of Standardised Hospitalisations Ratios due to glomerular disease compared to the general population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
*External Poisson regression models did not converge due to low overall numbers (N=28). 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma).  
 Glomerular Disease 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 28 / 17.12 1.6 (1.1-2.3) NA‡ 0.4 (0.0-0.7) NA‡ 
      
Leukaemia 6 / 4.40 1.4 (0.6-3.0) NA* 0.2 (-0.3-0.7) NA* 
Hodgkin’s lymphoma 0 / 1.31 0.0 (NA) NA* -0.6 (NA) NA* 
NHL 3 / 0.92 3.3 (1.1-10.2) NA* 1.4 (-0.9-3.6) NA* 
CNS 4 / 4.02 1.0 (0.4-2.7) NA* -0.0 (-0.6-0.6) NA* 
Neuroblastoma 1 / 0.78 1.3 (0.2-9.1) NA* 0.2 (-1.2-1.5) NA* 
N-Retinoblastoma 2 / 0.70 2.9 (0.7-11.5) NA* 1.1 (-1.3-3.6) NA* 
H-Retinoblastoma  0 / 0.50 0 (NA) NA* -0.6 (NA) NA* 
Wilms’ tumour 6 / 1.35 4.5 (2.0-9.9) NA* 1.9 (-0.1-3.8) NA* 
Bone 2 / 0.68 3.0 (0.7-11.8) NA* 1.2 (-1.3-3.7) NA* 
STS 3 / 1.22 2.5 (0.8-7.6) NA* 0.9 (-0.8-2.5) NA* 
Other 1 / 1.62 0.6 (0.1-4.4) NA* -0.2 (-0.9-0.5) NA* 
P-Heterogeneity†      
Gender      
Male 14 / 10.92 1.3 (0.8-2.2) NA* 0.2 (-0.2-0.6) NA* 
Female 14 / 6.58 2.1 (1.3-3.6) NA* 0.5 (0.0-1.0) NA* 
P-Heterogeneity†      
Attained Age      
5-19 15 / 4.80 3.1 (1.9-5.2) NA* 1.0 (0.3-1.7) NA* 
20-29 5 / 4.27 1.1 (0.5-2.8) NA* 0.1 (-0.4-0.5) NA* 
30-39 3 / 3.54 0.8 (0.3-2.6) NA* -0.1 (-0.6-0.5) NA* 
40-49 3 / 2.72 1.1 (0.4-3.4) NA* 0.1 (-0.9-1.1) NA* 
50+ 2 / 2.17 0.9 (0.2-3.7) NA* -0.1 (-1.7-1.5) NA* 
P-Trend†      
Age (Diagnosis)      
0 – 4 14 / 7.87 1.8 (1.1-3.0) NA* 0.4 (-0.1-0.9) NA* 
5 – 9 8 / 4.49 1.8 (0.9-3.6) NA* 0.4 (-0.2-1.1) NA* 
10 – 14 6 / 5.15 1.2 (0.5-2.6) NA* 0.1 (-0.5-0.7) NA* 
P-Trend†      
Year (Diagnosis)      
1940 – 1969 5 / 3.70 1.4 (0.6-3.2) NA* 0.4 (-0.8-1.6) NA* 
1970 – 1979 4 / 3.67 1.1 (0.4-2.9) NA* 0.1 (-0.6-0.7) NA* 
1980 – 1989 2 / 4.34 0.5 (0.1-1.8) NA* -0.3 (-0.6-0.0) NA* 
1990 – 1999 12 / 4.42 2.7 (1.5-4.8) NA* 0.7 (0.1-1.4) NA* 
2000 – 2006 5 / 1.36 3.7 (1.5-8.8) NA* 1.2 (-0.2-2.6) NA* 
P-Trend†      
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Table 3.5.4 Table of Standardised Hospitalisations Ratios due to renal tubulo-interstitial disease compared to the general 
population. 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma). 
  
 Renal Tubulo-Interstitial Disease 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 206 / 107.4 1.9 (1.7-2.2) NA‡ 3.1 (2.2-4.0) NA‡ 
      
Leukaemia 36 / 32.00 1.1 (0.8-1.6) REF 0.4 (-0.8-1.7) REF 
Hodgkin’s lymphoma 12 / 6.35 1.9 (1.1-3.3) 2.0 (0.9-4.4) 2.8 (-0.6-6.1) 2.3 (1.0-5.4) 
NHL 6 / 4.50 1.3 (0.6-3.0) 1.6 (0.6-4.1) 1.0 (-2.2-4.2) 1.7 (0.6-4.9) 
CNS 29 / 24.37 1.2 (0.8-1.7) 1.0 (0.6-1.8) 0.7 (-0.9-2.2) 1.0 (0.5-1.9) 
Neuroblastoma 20 / 4.37 4.6 (3.0-7.1) 2.5 (1.2-5.1) 10.9 (4.8-17.0) 2.6 (1.2-5.5) 
N-Retinoblastoma 3 / 3.63 0.8 (0.3-2.6) 1.1 (0.3-3.5) -0.6 (-3.6-2.4) 1.1 (0.3-4.2) 
H-Retinoblastoma  2 / 2.27 0.9 (0.2-3.5) 1.2 (0.3-4.9) -0.3 (-3.9-3.2) 1.1 (0.2-6.3) 
Wilms’ tumour 31 / 8.30 3.7 (2.6-5.3) 3.6 (2.0-6.2) 9.2 (4.8-13.6) 3.9 (2.1-7.1) 
Bone 9 / 4.30 2.1 (1.1-4.0) 2.6 (1.1-6.1) 4.3 (-1.1-9.7) 2.8 (1.1-7.0) 
STS 36 / 6.72 5.4 (3.9-7.4) 5.2 (3.0-8.9) 14.3 (8.6-20.1) 5.9 (3.3-10.6) 
Other 22 / 10.58 2.1 (1.4-3.2) 2.0 (1.1-3.7) 4.0 (0.8-7.2) 2.1 (1.1-4.1) 
P-Heterogeneity†   < 0.001  < 0.001 
Gender      
Male 73 / 24.98 2.9 (2.3-3.7) REF 2.8 (1.8-3.8) REF 
Female 133 / 82.42 1.6 (1.4-1.9) 0.6 (0.4-0.8) 3.5 (2.0-5.1) 2.7 (1.9-3.9) 
P-Heterogeneity†   0.027  < 0.001 
Attained Age      
5-19 103 / 24.11 4.3 (3.5-5.2) REF 7.6 (5.7-9.5) REF 
20-29 54 / 48.32 1.1 (0.9-1.5) 0.5 (0.3-0.7) 0.6 (-0.9-2.1) 0.9 (0.6-1.4) 
30-39 31 / 19.31 1.6 (1.1-2.3) 0.3 (0.2-0.6) 1.9 (0.1-3.7) 0.5 (0.3-0.9) 
40-49 13 / 9.97 1.3 (0.8-2.2) 0.3 (0.1-0.5) 0.9 (-1.2-3.0) 0.4 (0.2-0.8) 
50+ 5 / 5.69 0.9 (0.4-2.1) 0.1 (0.1-0.3) -0.4 (-2.9-2.1) 0.2 (0.1-0.7) 
P-Trend†   < 0.001  < 0.001 
Age (Diagnosis)      
0 – 4 112 / 45.61 2.5 (2.0-3.0) REF 4.5 (3.1-5.9) REF 
5 – 9 39 / 29.23 1.3 (1.0-1.8) 0.6 (0.4-1.0) 1.2 (-0.3-2.6) 0.7 (0.4-1.2) 
10 – 14 55 / 32.56 1.7 (1.3-2.2) 0.9 (0.6-1.5) 2.7 (1.0-4.5) 1.1 (0.7-1.8) 
P-Trend†   0.640  0.883 
Year (Diagnosis)      
1940 – 1969 23 / 10.01 2.3 (1.5-3.5) REF 3.6 (1.0-6.2) REF 
1970 – 1979 29 / 17.30 1.7 (1.2-2.4) 1.3 (0.7-2.6) 2.1 (0.2-3.9) 1.3 (0.6-2.7) 
1980 – 1989 58 / 33.13 1.8 (1.4-2.3) 1.7 (0.9-3.3) 2.9 (1.1-4.6) 1.8 (0.9-3.6) 
1990 – 1999 70 / 37.39 1.9 (1.5-2.4) 1.2 (0.7-2.3) 3.2 (1.6-4.7) 1.4 (0.7-2.7) 
2000 – 2006 26 / 9.57 2.7 (1.9-4.0) 1.0 (0.5-2.1) 5.3 (2.1-8.5) 0.7 (0.3-1.5) 
P-Trend†   0.702  0.233 
80 
 
Table 3.5.5 Table of Standardised Hospitalisations Ratios due to renal failure compared to the general population. 
 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma). 
  
 Renal Failure 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 172 / 29.61 5.8 (5.0-6.7) NA‡ 4.6 (3.8-5.4) NA‡ 
      
Leukaemia 29 / 6.08 4.8 (3.3-6.9) REF 2.5 (1.3-3.7) REF 
Hodgkin’s lymphoma 7 / 2.60 2.7 (1.3-2.6) 1.4 (0.6-3.4) 2.1 (-0.4-4.7) 1.4 (0.6-3.4) 
NHL 4 / 1.75 2.3 (0.9-6.1) 0.8 (0.2-2.7) 1.5 (-1.1-4.1) 0.8 (0.2-2.8) 
CNS 28 / 7.32 3.8 (2.6-5.5) 1.3 (0.7-2.3) 3.0 (1.5-4.5) 1.3 (0.7-2.3) 
Neuroblastoma 10 / 1.06 9.4 (5.1-17.5) 2.0 (0.9-4.7) 6.2 (1.9-10.5) 1.9 (0.8-4.4) 
N-Retinoblastoma 0 / 1.28 0 (NA) 0 (NA) -1.1 (NA) 0 (NA) 
H-Retinoblastoma  3 / 0.88 3.4 (1.1-10.5) 1.2 (0.3-5.3) 2.7 (-1.6-7.1) 1.1 (0.2-5.6) 
Wilms’ tumour 46 / 2.11 21.8 (16.4-29.1) 6.7 (4.0-11.3) 17.8 (12.4-23.2) 7.0 (0.4-11.8) 
Bone 10 / 1.40 7.1 (3.8-13.2) 3.4 (1.5-7.5) 7.8 (2.2-13.5) 3.4 (1.5-7.7) 
STS 19 / 2.24 8.5 (5.4-13.3) 2.2 (1.1-4.5) 8.2 (4.0-12.3) 2.2 (1.0-4.5) 
Other 16 / 2.89 5.5 (3.4-9.0) 1.9 (0.9-3.7) 4.6 (1.8-7.4) 1.9 (1.0-3.8) 
P-Heterogeneity†   < 0.001  < 0.001 
Gender      
Male 99 / 18.85 5.3 (4.3-6.4) REF 4.7 (3.5-5.8) REF 
Female 73 / 10.76 6.8 (5.4-8.5) 1.3 (0.9-1.9) 4.3 (3.2-5.5) 0.7 (0.5-1.1) 
P-Heterogeneity†   0.389  0.095 
Attained Age      
5-19 76 / 3.59 21.1 (16.9-26.5) REF 7.0 (5.3-8.6) REF 
20-29 42 / 6.97 6.0 (4.5-8.2) 0.5 (0.3-0.7) 3.6 (2.3-4.9) 0.7 (0.4-1.0) 
30-39 31 / 6.73 4.6 (3.2-6.5) 0.2 (0.1-0.4) 4.0 (2.2-5.7) 0.5 (0.3-0.9) 
40-49 11 / 5.64 2.0 (1.1-3.5) 0.2 (0.1-0.3) 1.6 (-0.3-3.5) 0.6 (0.3-1.1) 
50+ 12 / 6.67 1.8 (1.0-3.2) 0.1 (0.0-0.2) 3.1 (-0.8-7.0) 0.7 (0.3-1.3) 
P-Trend†   < 0.001  0.037 
Age (Diagnosis)      
0 – 4 92 / 10.97 8.4 (6.8-10.3) REF 5.5 (4.2-6.7) REF 
5 – 9 45 / 7.83 5.7 (4.3-7.7) 1.2 (0.8-1.9) 4.5 (2.9-6.1) 1.3 (0.8-2.0) 
10 – 14 35 / 10.81 3.2 (2.3-4.5) 1.0 (0.6-1.7) 2.9 (1.5-4.3) 1.1 (0.6-1.9) 
P-Trend†   0.915  0.608 
Year (Diagnosis)      
1940 – 1969 26 / 9.61 2.7 (1.8-4.0) REF 4.5 (1.8-7.3) REF 
1970 – 1979 39 / 7.10 5.5 (4.0-7.5) 2.4 (1.3-4.2) 5.6 (3.5-7.8) 1.1 (0.6-2.0) 
1980 – 1989 34 / 6.86 5.0 (3.5-6.9) 2.3 (1.3-4.1) 3.1 (1.8-4.4) 0.7 (0.4-1.3) 
1990 – 1999 49 / 4.89 10.0 (7.6-13.3) 4.0 (2.3-6.9) 4.3 (2.9-5.6) 0.8 (0.5-1.4) 
2000 – 2006 24 / 1.15 21.0 (14.0-31.3) 3.6 (1.9-6.8) 7.3 (4.3-10.4) 0.5 (0.3-1.0) 
P-Trend†   < 0.001  0.016 
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Table 3.5.6 Table of Standardised Hospitalisations Ratios due to acute renal failure compared to the general population. 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma). 
  
 Acute Renal Failure 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 64 / 12.77 5.0 (3.9-6.4) NA‡ 1.7 (1.2-2.2) NA‡ 
      
Leukaemia 11 / 2.51 4.4 (2.4-7.9) REF 0.9 (0.2-1.6) REF 
Hodgkin’s lymphoma 4 / 1.14 3.5 (1.3-9.3) 1.3 (0.4-4.3) 1.4 (-0.5-3.3) 1.2 (0.4-4.4) 
NHL 1 / 0.78 1.3 (0.2-9.1) 0.4 (0.1-3.5) 0.1 (-1.1-1.4) 0.4 (0.1-3.8) 
CNS 14 / 3.20 4.4 (2.6-7.4) 1.4 (0.6-3.0) 1.6 (0.5-2.6) 1.2 (0.5-2.8) 
Neuroblastoma 2 / 0.44 4.5 (1.1-18.1) 1.3 (0.3-6.0) 1.1 (-0.8-3.0) 1.3 (0.3-6.0) 
N-Retinoblastoma 0 / 0.55 0 (NA) 0 (NA) -0.5 (NA) 0 (NA) 
H-Retinoblastoma  1 / 0.37 2.7 (0.4-19.2) 1.1 (0.1-9.0) 0.8 (-1.7-3.3) 1.1 (0.1-9.3) 
Wilms’ tumour 13 / 0.87 14.9 (8.7-25.7) 4.6 (2.0-10.5) 4.9 (2.0-7.7) 4.6 (2.0-10.7) 
Bone 3 / 0.64 4.7 (1.5-14.6) 1.8 (0.5-6.9) 2.1 (-0.9-5.2) 2.0 (0.5-7.5) 
STS 7 / 0.99 7.0 (3.4-14.8) 2.4 (0.9-6.4) 2.9 (0.4-5.4) 2.5 (0.9-6.7) 
Other 8 / 1.28 6.3 (3.1-12.5) 2.1 (0.8-5.4) 2.4 (0.4-4.3) 2.2 (0.9-5.7) 
P-Heterogeneity†   0.011  0.011 
Gender      
Male 40 / 8.40 4.8 (3.5-6.5) REF 1.8 (1.1-2.6) REF 
Female 24 / 4.37 5.5 (3.6-8.2) 1.0 (0.6-1.7) 1.4 (0.7-2.0) 0.6 (0.4-1.1) 
P-Heterogeneity†   0.842  0.084 
Attained Age      
5-19 20 / 1.20 16.7 (10.8-25.9) REF 1.8 (1.0-2.6) REF 
20-29 18 / 3.06 5.9 (3.7-9.3) 0.5 (0.3-1.1) 1.5 (0.7-2.4) 1.2 (0.6-2.5) 
30-39 11 / 2.47 4.5 (2.5-8.0) 0.4 (0.2-0.9) 1.4 (0.3-2.4) 1.1 (0.5-2.6) 
40-49 11 / 2.36 4.7 (2.6-8.4) 0.4 (0.2-0.8) 2.5 (0.6-4.4) 1.6 (0.7-3.8) 
50+ 4 / 3.68 1.1 (0.4-2.9) 0.2 (0.1-0.5) 0.2 (-2.1-2.5) 2.9 (1.2-6.8) 
P-Trend†   < 0.001  0.028 
Age (Diagnosis)      
0 – 4 25 / 4.52 5.5 (3.7-8.2) REF 1.4 (0.7-2.0) REF 
5 – 9 23 / 3.36 6.8 (4.5-10.3) 1.5 (0.8-2.8) 2.4 (1.2-3.5) 1.6 (0.9-3.1) 
10 – 14 16 / 4.89 3.3 (2.0-5.3) 0.9 (0.4-1.8) 1.3 (0.4-2.3) 1.0 (0.4-2.1) 
P-Trend†   0.699  0.945 
Year (Diagnosis)      
1940 – 1969 12 / 4.50 2.7 (1.5-4.7) REF 2.1 (0.2-3.9) REF 
1970 – 1979 20 / 2.75 7.3 (4.7-11.3) 2.9 (1.4-6.1) 3.0 (1.5-4.6) 1.1 (0.5-2.3) 
1980 – 1989 9 / 2.78 3.2 (1.7-6.2) 1.5 (0.6-3.6) 0.7 (0.0-1.4) 0.3 (0.1-0.9) 
1990 – 1999 17 / 2.21 7.7 (4.8-12.4) 2.5 (1.2-5.4) 1.4 (0.6-2.2) 0.4 (0.2-0.9) 
2000 – 2006 6 / 0.54 11.2 (5.0-24.9) 2.5 (0.9-6.9) 1.7 (0.2-3.3) 0.2 (0.1-0.6) 
P-Trend†   0.064  < 0.001 
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Table 3.5.7 Table of Standardised Hospitalisations Ratios due to chronic renal failure compared to the general population. 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma).  
 Chronic Renal Failure 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 82 / 12.83 6.4 (5.1-7.9) NA‡ 2.2 (1.6-2.8) NA‡ 
      
Leukaemia 8 / 2.66 3.0 (1.5-6.0) REF 0.6 (-0.0-1.2) REF 
Hodgkin’s lymphoma 2 / 1.13 1.8 (0.4-7.1) 1.8 (0.4-8.7) 0.4 (-0.9-1.8) 1.7 (0.3-8.9) 
NHL 3 / 0.74 4.1 (1.3-12.6) 3.3 (0.9-12.8) 1.5 (-0.7-3.7) 3.2 (0.8-13.0) 
CNS 10 / 3.16 3.2 (1.7-5.9) 1.9 (0.8-5.0) 1.0 (0.1-1.9) 1.9 (0.7-5.0) 
Neuroblastoma 6 / 0.47 12.9 (5.8-28.7) 4.5 (1.6-13.2) 3.8 (0.5-7.1) 4.2 (1.4-12.7) 
N-Retinoblastoma 0 / 0.56 0 (NA) 0 (NA) -0.5 (NA) 0 (NA) 
H-Retinoblastoma  1 / 0.39 2.5 (0.4-18.0) 1.8 (0.2-14.8) 0.8 (-1.7-3.3) 1.6 (0.1-17.2) 
Wilms’ tumour 28 / 0.95 29.6 (20.4-42.8) 13.9 (6.2-30.9) 10.9 (6.7-15.1) 14.5 (6.4-32.8) 
Bone 5 / 0.59 8.5 (3.5-20.4) 7.7 (2.4-24.9) 4.0 (0.0-8.0) 8.0 (2.4-26.7) 
STS 11 / 0.95 11.6 (6.4-20.9) 7.8 (3.1-19.4) 4.9 (1.7-8.1) 8.0 (3.1-20.3) 
Other 8 / 1.23 6.5 (3.2-13.0) 3.6 (1.3-9.6) 2.4 (0.4-4.3) 3.7 (1.3-10.3) 
P-Heterogeneity†   < 0.001  < 0.001 
Gender      
Male 45 / 8.01 5.6 (4.2-7.5) REF 2.2 (1.4-2.9) REF 
Female 37 / 4.81 7.7 (5.6-10.6) 2.1 (1.3-3.3) 2.2 (1.4-3.1) 0.9 (0.6-1.4) 
P-Heterogeneity†   0.002  0.690 
Attained Age      
5-19 45 / 1.70 26.4 (19.7-35.4) REF 4.2 (2.9-5.4) REF 
20-29 20 / 2.87 7.0 (4.5-10.8) 0.4 (0.3-0.8) 1.7 (0.9-2.6) 0.6 (0.3-1.0) 
30-39 9 / 3.28 2.7 (1.4-5.3) 0.2 (0.1-0.4) 0.9 (-0.0-1.9) 0.4 (0.2-0.9) 
40-49 4 / 2.60 1.5 (0.6-4.1) 0.1 (0.0-0.2) 0.4 (-0.7-1.6) 0.3 (0.1-0.8) 
50+ 4 / 2.37 1.7 (0.6-4.5) 0.1 (0.0-0.2) 0.9 (-1.3-3.2) 0.3 (0.1-1.0) 
P-Trend†   < 0.001  0.001 
Age (Diagnosis)      
0 – 4 52 / 4.87 10.7 (8.1-14.0) REF 3.2 (2.2-4.1) REF 
5 – 9 14 / 3.40 4.1 (2.4-6.9) 0.7 (0.4-1.3) 1.3 (0.4-2.2) 0.7 (0.3-1.2) 
10 – 14 16 / 4.56 3.5 (2.2-5.7) 1.0 (0.5-2.0) 1.4 (0.4-2.3) 0.9 (0.4-1.8) 
P-Trend†   0.728  0.481 
Year (Diagnosis)      
1940 – 1969 11 / 4.04 2.7 (1.5-4.9) REF 1.9 (0.1-3.7) REF 
1970 – 1979 14 / 3.41 4.1 (2.4-6.9) 1.4 (0.6-3.1) 1.9 (0.6-3.1) 1.0 (0.4-2.3) 
1980 – 1989 19 / 3.05 6.2 (4.0-9.8) 2.0 (0.9-4.2) 1.8 (0.9-2.8) 0.9 (0.4-2.0) 
1990 – 1999 26 / 1.89 13.7 (9.4-20.2) 3.4 (1.7-6.9) 2.3 (1.4-3.3) 0.9 (0.4-2.0) 
2000 – 2006 12 / 0.44 27.4 (15.6-48.2) 2.7 (1.2-6.5) 3.7 (1.5-5.9) 0.6 (0.3-1.4) 
P-Trend†   < 0.001  0.270 
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Table 3.5.8 Table of Standardised Hospitalisations Ratios due to urolithiasis compared to the general population. 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma).  
 Urolithiasis 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 183 / 142.50 1.3 (1.1-1.5) NA‡ 1.3 (0.5-2.2) NA‡ 
      
Leukaemia 36 / 32.72 1.1 (0.8-1.5) REF 0.4 (-0.9-1.6) REF 
Hodgkin’s lymphoma 19 / 13.76 1.4 (0.9-2.2) 1.9 (1.0-3.6) 2.6 (-1.6-6.7) 2.1 (1.1-4.1) 
NHL 13 / 8.82 1.5 (0.9-2.5) 1.8 (0.9-3.7) 2.8 (-1.9-7.4) 2.0 (0.9-4.2) 
CNS 39 / 33.71 1.2 (0.8-1.6) 1.1 (0.7-1.9) 0.8 (-1.0-2.5) 1.1 (0.6-2.0) 
Neuroblastoma 13 / 4.78 2.7 (1.6-4.7) 1.9 (0.9-4.3) 5.7 (0.8-10.6) 1.9 (0.8-4.5) 
N-Retinoblastoma 4 / 5.28 0.8 (0.3-2.0) 0.9 (0.3-3.2) -1.1 (-4.6-2.3) 0.8 (0.2-4.1) 
H-Retinoblastoma  0 / 3.93 0 (NA) 0 (NA) -5.1 (NA) 0 (NA) 
Wilms’ tumour 12 / 10.54 1.1 (0.6-2.0) 1.3 (0.6-2.7) 0.6 (-2.2-3.3) 1.4 (0.7-3.1) 
Bone 8 / 6.19 1.3 (0.6-2.6) 1.9 (0.8-4.2) 1.6 (-3.4-6.7) 2.0 (0.8-4.6) 
STS 23 / 10.12 2.3 (1.5-3.4) 2.2 (1.2-4.1) 6.3 (1.7-10.9) 2.5 (1.3-4.7) 
Other 16 / 12.65 1.3 (0.8-2.1) 1.2 (0.6-2.3) 1.2 (-1.6-3.9) 1.1 (0.5-2.4) 
P-Heterogeneity†   0.053  0.052 
Gender      
Male 118 / 102.17 1.2 (1.0-1.4) REF 0.9 (-0.3-2.2) REF 
Female 65 / 40.32 1.6 (1.3-2.1) 1.0 (0.7-1.5) 1.7 (0.6-2.8) 0.6 (0.4-0.9) 
P-Heterogeneity†   0.679  0.021 
Attained Age      
5-19 48 / 7.67 6.3 (4.7-8.3) REF 3.9 (2.6-5.2) REF 
20-29 74 / 45.75 1.6 (1.3-2.0) 0.3 (0.2-0.5) 2.9 (1.2-4.6) 1.4 (0.5-2.3) 
30-39 32 / 44.99 0.7 (0.5-1.0) 0.2 (0.1-0.4) -2.1 (-3.9—0.3) 1.6 (0.9-2.7) 
40-49 19 / 28.97 0.7 (0.4-1.0) 0.1 (0.1-0.3) -2.9 (-5.4—0.4) 1.1 (0.6-2.2) 
50+ 10 / 15.11 0.7 (0.4-1.2) 0.1 (0.1-0.2) -3.0 (-6.6-0.6) 1.0 (0.5-2.3) 
P-Trend†   < 0.001  0.801 
Age (Diagnosis)      
0 – 4 72 / 52.54 1.4 (1.1-1.7) REF 1.3 (0.2-2.4) REF 
5 – 9 46 / 39.19 1.2 (0.9-1.6) 0.9 (0.6-1.4) 0.8 (-0.8-2.4) 1.0 (0.6-1.7) 
10 – 14 65 / 50.77 1.3 (1.0-1.6) 1.1 (0.7-1.8) 1.7 (-0.2-3.6) 1.4 (0.8-2.2) 
P-Trend†   0.517  0.225 
Year (Diagnosis)      
1940 – 1969 32 / 30.83 1.0 (0.7-1.5) REF 0.3 (-2.7-3.4) REF 
1970 – 1979 43 / 41.24 1.0 (0.8-1.4) 0.9 (0.5-1.5) 0.0 (-0.2-0.3) 0.8 (0.4-1.4) 
1980 – 1989 55 / 42.74 1.3 (1.0-1.7) 0.9 (0.6-1.5) 1.4 (-0.3-3.1) 0.7 (0.4-1.2) 
1990 – 1999 44 / 23.90 1.8 (1.4-2.5) 0.8 (0.5-1.3) 1.9 (0.7-3.2) 0.3 (0.2-0.6) 
2000 – 2006 9 / 3.78 2.4 (1.2-4.6) 0.7 (0.3-1.5) 1.7 (-0.2-3.6) 0.1 (0.0-0.3) 
P-Trend†   0.260  < 0.001 
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Table 3.5.9 Table of Standardised Hospitalisations Ratios due to urinary tract infection compared to the general population. 
 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma). 
  
 Urinary Tract Infection 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 481 / 217.67 2.2 (2.0-2.4) NA‡ 8.4 (7.0-9.8) NA‡ 
      
Leukaemia 104 / 60.78 1.7 (1.4-2.1) REF 4.7 (2.5-6.9) REF 
Hodgkin’s lymphoma 15 / 12.80 1.2 (0.7-1.9) 0.8 (0.4-1.5) 1.1 (-2.6-4.8) 0.8  (0.4-1.6) 
NHL 8 / 8.97 0.9 (0.4-1.8) 0.4 (0.1-1.0) -0.6 (-4.3-3.0) 0.3 (0.1-1.1) 
CNS 157 / 50.04 3.1 (2.7-3.7) 1.9 (1.4-2.5) 15.6 (12.0-19.2) 2.0 (1.5-2.6) 
Neuroblastoma 34 / 9.47 3.6 (2.6-5.0) 1.1 (0.7-1.9) 17.2 (9.2-25.2) 1.2 (0.7-2.0) 
N-Retinoblastoma 5 / 8.33 0.6 (0.2-1.4) 0.5 (0.2-1.1) -2.9 (-6.8-0.9) 0.4 (0.1-1.2) 
H-Retinoblastoma  6 / 5.26 1.1 (0.5-2.5) 0.8 (0.4-1.9) 1.0 (-5.3-7.2) 0.9 (0.4-2.1) 
Wilms’ tumour 52 / 17.15 3.0 (2.3-4.0) 1.4 (1.0-2.1) 14.2 (8.4-19.9) 1.5 (1.0-2.2) 
Bone 23 / 8.90 2.6 (1.7-3.9) 1.9 (1.2-3.2) 12.9 (4.3-21.5) 2.0 (1.2-3.4) 
STS 32 / 14.05 2.3 (1.6-3.2) 1.1 (0.7-1.7) 8.8 (3.4-14.2) 1.1 (0.7-1.9) 
Other 45 / 21.91 2.1 (1.5-2.8) 1.0 (0.6-1.5) 8.1 (3.5-12.8) 1.0 (0.6-1.5) 
P-Heterogeneity†   < 0.001  < 0.001 
Gender      
Male 139 / 49.04 2.8 (2.4-3.3) REF -2.8 (-3.0—2.7) REF 
Female 342 / 168.63 2.0 (1.8-2.3) 0.7 (0.5-0.9) 12.4 (9.8-15.0) 3.3 (2.6-4.1) 
P-Heterogeneity†   0.002  < 0.001 
Attained Age      
5-19 240 / 54.26 4.4 (3.9-5.0) REF 17.9 (15.0-20.8) REF 
20-29 104 / 79.03 1.3 (1.1-1.6) 0.4 (0.3-0.5) 2.6 (0.5-4.6) 0.6 (0.5-0.8) 
30-39 65 / 39.05 1.7 (1.3-2.1) 0.4 (0.3-0.6) 4.2 (1.7-6.8) 0.5 (0.4-0.7) 
40-49 48 / 48.96 1.9 (1.4-2.6) 0.4 (0.3-0.6) 6.8 (2.8-10.8) 0.5 (0.4-0.8) 
50+ 24 / 20.36 1.2 (0.8-1.8) 0.3 (0.2-0.5) 2.1 (-3.5-7.8) 0.7 (0.5-1.0) 
P-Trend†   < 0.001  < 0.001 
Age (Diagnosis)      
0 – 4 245 / 94.68 2.6 (2.3-2.9) REF 10.2 (8.1-12.2) REF 
5 – 9 118 / 56.93 2.1 (1.7-2.5) 0.9 (0.7-1.2) 7.4 (4.8-10.0) 1.0 (0.7-1.3) 
10 – 14 118 / 66.06 1.8 (1.5-2.1) 0.9 (0.7-1.2) 6.3 (3.7-8.9) 1.0 (0.8-1.4) 
P-Trend†   0.567  0.889 
Year (Diagnosis)      
1940 – 1969 69 / 32.68 2.1 (1.7-2.7) REF 10.1 (5.5-14.6) REF 
1970 – 1979 74 / 38.01 1.9 (1.6-2.4) 1.2 (0.8-1.7) 6.4 (3.4-9.3) 0.7 (0.5-1.1) 
1980 – 1989 123 / 59.44 2.1 (1.7-2.5) 1.2 (0.9-1.8) 7.4 (4.8-9.9) 0.8 (0.6-1.1) 
1990 – 1999 158 / 68.87 2.3 (2.0-2.7) 0.9 (0.6-1.3) 8.7 (6.3-11.1) 0.7 (0.5-0.9) 
2000 – 2006 57 / 18.66 3.1 (2.4-4.0) 0.7 (0.4-1.0) 12.3 (7.6-17.1) 0.3 (0.2-0.5) 
P-Trend†   0.009  < 0.001 
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Table 3.5.10 Table of Standardised Hospitalisations Ratios due to other kidney diseases compared to the general 
population. 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma). 
  
 Other Kidney Diseases 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 48 / 7.37 6.5 (4.9-8.6) NA‡ 1.3 (0.9-1.8) NA‡ 
      
Leukaemia 6 / 1.73 3.5 (1.6-7.7) REF 0.5 (-0.1-1.0) REF 
Hodgkin’s lymphoma 2 / 0.57 3.5 (0.9-13.9) 1.2 (0.1-11.6) 0.7 (-0.7-2.0) 1.2 (0.1-14.6) 
NHL 1 / 0.39 2.6 (0.4-18.4) 1.8 (0.2-16.7) 0.4 (-0.9-1.7) 1.8 (0.2-19.4) 
CNS 8 / 1.76 4.6 (2.3-9.1) 1.3 (0.3-5.2) 0.9 (0.1-1.7) 1.3 (0.3-5.9) 
Neuroblastoma 6 / 0.30 20.1 (9.0-44.8) 1.5 (0.2-13.6) 3.9 (0.6-7.3) 1.6 (0.2-15.9) 
N-Retinoblastoma 2 / 0.30 6.6 (1.6-26.3) 2.3 (0.3-21.8) 15.0 (-9.5-39.5) 2.2 (0.2-28.5) 
H-Retinoblastoma  0 / 0.21 0 (NA) 0 (NA) -0.3 (NA) 0 (NA) 
Wilms’ tumour 8 / 0.56 14.3 (7.1-28.6) 3.0 (0.7-13.9) 3.0 (0.8-5.2) 3.2 (0.7-15.9) 
Bone 2 / 0.32 6.3 (1.6-25.3) 2.3 (0.2-21.7) 1.5 (-1.0-4.0) 2.5 (0.3-24.8) 
STS 7 / 0.53 13.3 (6.4-28.0) 6.2 (1.6-23.6) 3.1 (0.6-5.7) 6.8 (1.7-27.4) 
Other 6 / 0.71 8.4 (3.8-18.7) 4.0 (1.1-15.4) 1.9 (0.2-3.5) 4.4 (1.1-18.0) 
P-Heterogeneity†   0.294  0.280 
Gender      
Male 22 / 3.98 5.5 (3.6-8.4) REF 1.1 (0.5-1.6) REF 
Female 26 / 3.39 7.7 (5.2-11.3) 1.2 (0.5-2.6) 1.6 (0.9-2.3) 1.2 (0.5-2.6) 
P-Heterogeneity†   0.803  0.733 
Attained Age      
5-19 25 / 1.39 18.0 (12.2-26.6) REF 2.3 (1.3-3.2) REF 
20-29 8 / 1.82 4.4 (2.2-8.8) 0.2 (0.1-0.7) 0.6 (0.1-1.2) 0.3 (0.1-0.9) 
30-39 9 / 1.64 5.5 (2.9-10.6) 0.2 (0.1-0.7) 1.2 (0.2-2.2) 0.3 (0.1-1.3) 
40-49 5 / 1.36 3.7 (1.5-8.8) 0.4 (0.1-1.2) 1.1 (-0.2-2.3) 0.9 (0.3-2.7) 
50+ 1 / 1.16 0.9 (0.1-6.1) 0.1 (0.0-0.5) 1.0 (-1.2-1.0) 0.4 (0.1-2.2) 
P-Trend†   0.006  0.382 
Age (Diagnosis)      
0 – 4 28 / 3.03 9.2 (6.4-13.4) REF 1.7 (1.1-2.4) REF 
5 – 9 12 / 1.92 6.2 (3.5-11.0) 1.2 (0.5-3.4) 1.2 (0.4-2.0) 1.2 (0.4-3.4) 
10 – 14 8 / 2.42 3..3 (1.7-6.6) 1.2 (0.4-3.8) 0.7 (0.0-1.3) 1.2 (0.4-4.0) 
P-Trend†   0.659  0.695 
Year (Diagnosis)      
1940 – 1969 7 / 1.86 3.8 (1.8-7.9) REF 1.4 (-0.0-2.8) REF 
1970 – 1979 10 / 1.71 5.9 (3.2-10.9) 1.2 (0.3-4.9) 1.5 (0.4-2.5) 0.7 (0.2-3.2) 
1980 – 1989 10 / 1.78 5.6 (3.0-10.4) 1.1 (0.3-4.3) 0.9 (0.2-1.7) 0.5 (0.1-2.0) 
1990 – 1999 13 / 1.59 8.2 (4.7-14.0) 2.1 (0.6-7.1) 1.1 (0.4-1.8) 0.8 (0.2-2.7) 
2000 – 2006 8 / 0.44 18.4 (9.2-36.7) 1.7 (0.4-6.9) 2.4 (0.6-4.2) 0.5 (0.1-2.2) 
P-Trend†   0.233  0.535 
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Table 3.5.11 Table of Standardised Hospitalisations Ratios due to other urinary diseases compared to the general 
population. 
‡Not applicable for overall estimates. 
†Not applicable for SHR and AER as these estimates were not calculated using a model. 
§Abbreviations: non-Hodgkin’s lymphoma (NHL), Central Nervous System (CNS), non-heritable 
retinoblastoma (N-Retinoblastoma), heritable retinoblastoma (H-Retinoblastoma). 
  
 Other Urinary Diseases 
 O/E SHR RR AER RER 
Type of Childhood 
Cancer§ 
     
Overall 375 / 335.89 1.1 (1.0-1.2) NA‡ 1.3 (0.0-2.5) NA‡ 
      
Leukaemia 68 / 84.53 0.8 (0.6-1.0) REF -1.8 (-3.6-0.0) REF 
Hodgkin’s lymphoma 7 / 22..29 0.3 (0.1-0.7) 0.4 (0.2-1.0) -7.4 (-10.0—4.9) 0.3 (0.1-1.2) 
NHL 18 / 14.97 1.2 (0.8-1.9) 1.5 (0.8-2.7) 2.0 (-3.5-7.5) 1.5 (0.8-3.0) 
CNS 97 / 79.74 1.2 (1.0-1.5) 1.8 (1.3-2.5) 2.5 (-0.3-5.3) 1.9 (1.3-2.8) 
Neuroblastoma 46 / 13.67 3.4 (2.5-4.5) 3.8 (2.5-5.6) 22.8 (13.4-32.2) 4.2 (2.7-6.5) 
N-Retinoblastoma 9 / 13.72 0.7 0.3-1.3) 1.0 (0.5-2.2) -4.2 (-9.4-1.0) 1.0 (0.4-2.5) 
H-Retinoblastoma  5 / 9.00 0.6 (0.2-1.3) 0.7 (2.7-2.0) -5.2 (-10.9-0.5) 0.7 (0.2-2.5) 
Wilms’ tumour 25 / 26.19 1.0 (0.6-1.4) 1.3 (0.8-2.1) -0.5 (-4.4-3.5) 1.3 (0.7-2.3) 
Bone 14 / 14.60 1.0 (0.6-1.6) 1.5 (0.7-2.9) -0.5 (-7.3-6.2) 1.6 (0.8-3.3) 
STS 53 / 22.55 2.4 (1.8-3.1) 3.4 (2.3-5.0) 15.0 (8.0-22.1) 3.9 (2.5-5.9) 
Other 33 / 34.63 1.0 (0.7-1.3) 1.7 (1.1-2.6) -0.6 (-4.5-3.4) 1.8 (1.1-2.8) 
P-Heterogeneity†   < 0.001  < 0.001 
Gender      
Male 184 / 102.53 1.8 (1.6-2.1) REF 4.8 (3.3-6.4) REF 
Female 191 / 233.36 0.8 (0.7-0.9) 0.4 (0.3-0.5) -3.0 (-5.0—1.1) 1.2 (1.0-1.6) 
P-Heterogeneity†   < 0.001  0.067 
Attained Age      
5-19 150 / 65.67 2.3 (1.9-2.7) REF 8.1 (5.8-10.4) REF 
20-29 87 / 103.06 0.8 (0.7-1.0) 0.4 (0.3-0.6) -1.6 (-3.5-0.2) 0.6 (0.4-0.8) 
30-39 72 / 67.83 1.1 (0.8-1.3) 0.6 (0.4-0.8) 0.7 (-2.0-3.4) 0.9 (0.6-1.3) 
40-49 40 / 56.51 0.7 (0.5-1.0) 0.4 (0.3-0.5) -4.9 (-8.5—1.2) 0.8 (0.5-1.2) 
50+ 26 / 42.83 0.6 (0.4-0.9) 0.3 (0.2-0.4) -9.9 (-15.8—4.0) 0.9 (0.6-1.5) 
P-Trend†   < 0.001  0.636 
Age (Diagnosis)      
0 – 4 194 / 138.63 1.4 (1.2-1.6) REF 3.7 (1.9-5.6) REF 
5 – 9 78 / 87.49 0.9 (0.7-1.1) 0.8 (0.6-1.1) -1.1 (-3.2-0.9) 0.8 (0.6-1.1) 
10 – 14 103 / 109.78 0.9 (0.8-1.1) 0.9 (0.6-1.2) -0.8 (-3.2-1.6) 0.9 (0.6-1.3) 
P-Trend†   0.291  0.468 
Year (Diagnosis)      
1940 – 1969 78 / 71.84 1.1 (0.9-1.4) REF 1.7 (-3.1-6.5) REF 
1970 – 1979 67 / 71.56 0.9 (0.7-1.2) 1.1 (0.7-1.5) -0.8 (-3.6-2.0) 0.6 (0.4-0.9) 
1980 – 1989 96 / 85.13 1.1 (0.9-1.4) 1.3 (1.0-1.9) 1.3 (-1.0-3.5) 0.6 (0.4-0.8) 
1990 – 1999 93 / 84.64 1.1 (0.9-1.3) 0.9 (0.7-1.3) 8.1 (-1.0-2.6) 0.4 (0.3-0.5) 
2000 – 2006 41 / 22.72 1.8 (1.3-2.5) 0.8 (0.5-1.2) 5.9 (1.8-9.9) 0.2 (0.1-0.4) 
P-Trend†   0.244  < 0.001 
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Abstract 
Background: Five-year survival of childhood cancer has increased substantially over 
the past few decades. However, the risks of subsequent primary neoplasms (SPN), 
particularly digestive SPN, remain uncertain in the aging survivor cohort. We 
investigated risks of developing specific digestive SPNs, particularly by type of 
childhood cancer in a large-scale cohort. 
Methods: The PanCareSurFup (PCSF) cohort includes 80,483 five-year survivors of 
childhood cancer from 12 countries in Europe. We investigated the risk of developing 
digestive SPNs by standardised incidence ratios (SIRs) and absolute excess risks 
(AERs).  
Results: Survivors of Wilms’ tumour have 15-fold, 9-fold, 56-fold, 11-fold and 24-fold 
increased risk of digestive cancer overall, colorectal, liver, stomach, and pancreatic 
cancer, respectively. Survivors of Hodgkin’s lymphoma have a 9-fold, 8-fold, 7-fold, 
6-fold and 6-fold increased risk of digestive cancer overall, colorectal, liver, stomach 
and pancreatic cancer, respectively. Survivors of non-Hodgkin’s lymphoma have a 6-
fold, 7-fold, 6-fold and 6-fold increased risk of colorectal, liver, stomach and 
pancreatic cancer, respectively. Survivors of neuroblastoma have a 5-fold increased 
risk of digestive cancer overall and colorectal cancer. Finally, survivors of CNS 
tumours have 5-fold increased risk of liver cancer. 
Conclusion: Survivors of Wilms’ tumour experienced the highest excess risk of 
digestive cancer 15-fold expected, and Wilms’ survivors experienced 56-fold, 24-fold, 
11-fold and 9-fold excepted risk of liver, pancreatic, stomach and colorectal cancer, 
respectively. Survivors of Hodgkin’s lymphoma experienced the second highest 
excess risk of digestive cancers 9-fold expected, and Hodgkin’s survivors 
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experienced an 8-fold, 7-fold, 6-fold and 6-fold expected risk of colorectal, liver, 
stomach and pancreatic cancer, respectively. Such risk stratification information 
should be very helpful in the development of clinical follow-up guidelines for 
European survivors.  
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4.1 Introduction 
Over the last few decades five-year survival after childhood cancer has increased 
substantially to currently over 80%4. However, it is widely acknowledged that 
survivors are at risk of long-term adverse health conditions such as premature 
mortality and subsequent primary neoplasms (SPN). The risks and causes of SPNs 
are important to investigate, as it is one of the largest causes of premature mortality 
in survivors8,185,186. Some previous studies have investigated the risk of developing 
digestive SPNs38 among survivors of childhood cancer, but most studies lacked 
statistical power to satisfactorily address the risks of digestive SPNs, particularly 
beyond age 40 years. The risk of developing any type of digestive SPNs has been 
previously investigated in smaller scale studies in individual countries44,74,187-189, but 
not in a large-scale collaborative study with long follow-up.  
 
We used data from a large-scale Pan-European cohort on over 80,000 survivors of 
childhood cancer to investigate the risks of digestive SPNs. The main advantage with 
such a large cohort is that there is substantial amount of follow-up and person-years 
with over 50% of the cohort having survived at least 25 years. The principal objective 
of this study was to investigate the risks of developing SPNs in specific sites of the 
digestive system among 5-year survivors of childhood cancer including; colorectal, 
liver, stomach, pancreas, small intestine, gallbladder, anus and oesophagus; also to 
investigate how these risks vary by demographic and cancer related factors such as 
gender, country, first primary neoplasm (FPN) diagnosis, age at FPN diagnosis, era 
of FPN diagnosis and attained age. 
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4.2 Methods 
Pan Care Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies 
(PanCareSurFup) 
PanCareSurFup is a consortium of 16 European institutions in 12 countries 
established in February 2011 and funded by the 7th Framework Programme of the 
European Commission (www.pancaresurfup.eu)190. The global aim of PCSF 
consortium is to conduct studies into long-term complications of treatment for cancer, 
to establish guidelines for clinical follow-up of survivors, and to disseminate the 
results and provide training and workshops for stakeholders. PanCareSurFup is the 
largest ever collaborative study undertaken to investigate long-term adverse health 
outcomes among survivors of childhood and adolescent cancer. One of the principal 
objectives of PanCareSurFup was to estimate risks of developing subsequent 
primary neoplasms within a large-scale Pan-European cohort of 5-year survivors of a 
cancer diagnosed under age 20 years.  In total, 80,483 survivors of childhood cancer 
were included ascertained from 12 different cancer registries or major treatment 
centres across 12 different countries within Europe (Table 4.5.1), including United 
Kingdom, Norway, Sweden, Finland, Denmark, Iceland, France, Switzerland, 
Hungary, Slovenia, Italy and the Netherlands.  Data relating to each individual cohort 
was transferred securely to the co-ordinating centre at University of Mainz, Germany, 
for initial cleaning of data. The individual cohorts were subsequently transferred to 
the University of Birmingham, UK, for further consistency checks and statistical 
analyses.  Ethical approval for the study was obtained within the country of origin for 
each contributing cohort separately. 
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First Primary Neoplasm Ascertainment 
First primary neoplasms (FPNs) were classified into groups of childhood cancer type 
according to the International Classification of Childhood Cancers (ICCC) (3rd 
revision)10 by converting all FPN diagnosis codes into the third revision of the 
International Classification of Diseases for Oncology (ICD-O) using the IARC cancer 
registry tools software from IARC191. Individuals were excluded if their FPN was not 
convertible to ICD-O or did not have a malignant behaviour code (except for 
intracranial and bladder tumours for which all behaviour codes were included). 
 
Subsequent Primary Neoplasm Ascertainment  
Subsequent primary neoplasms (SPNs) were ascertained using several methods 
including linkage with population-based cancer registries (Nordic countries, Slovenia, 
Switzerland and UK), follow-up clinics (Switzerland, France and Hungry), 
questionnaires (Switzerland, France, Hungary and Netherlands), medical record 
databases (Hungary, Italy and Netherlands), national mortality records (Switzerland, 
France and Italy) and health insurance registries (France). For purposes of this study, 
SPNs were classified by digestive site using the International Classification of 
Diseases (ICD). The range of codes that identified all digestive SPNs in ICD-10 were 
C15.0 to C25.9; in ICD-9 were 150.9 to 155.2; in ICD-8 and ICD-7 were 150.0 to 
157.9 (Table 4.5.2). Potential SPNs were excluded if the site of development was 
metastatic or if there was other uncertainty concerning whether it was the primary 
tumour. All SPNs were validated principally using pathology reports and occasionally 
other definitive diagnostic reports. 
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General Population Rates 
General population rates were obtained from site-based neoplasm rates relating to 
as many collaborating countries as possible. The general population neoplasm rates 
for individual calendar years were downloaded from the European Cancer 
Observatory (ECO) provided by the International Agency for Research on Cancer 
(IARC)192 for Denmark (1978–2007), Finland (1989–2007), Norway (1953–2007), 
Sweden (1960–2009) and Iceland (1955–2007). Rates for incidence of neoplasms in 
Slovenia were available for the period 1961–2010 and were downloaded from the 
Slovenian Epidemiology and Cancer Registry website (SLORA: Slovenia and 
Cancer)193; UK rates were available for the period 1971–2007 from the Office for 
National Statistics (ONS); and Switzerland rates were available for the period 1985–
2010 from the National Institute of Cancer Epidemiology and Registration (NICER). 
For person-years occurring in calendar years that fell outside of the ranges provided 
above, rates relating to the nearest calendar year for which rates were available were 
used as a proxy.  
 
Statistical Analysis 
The period at risk of developing a SPN in the digestive system commenced five 
years from childhood cancer diagnosis and continued until the first occurrence of 
death, loss to follow-up or study end date. Multiple SPNs per survivor were permitted 
to avoid bias in comparisons of risks with the general population cancer incidence 
rates. Standardised incidence ratios (SIR) were calculated as the ratio of observed to 
expected number of digestive SPNs. Absolute excess risks (AERs) were calculated 
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from the observed minus expected number of specific digestive SPN, divided by the 
number of person-years at risk, multiplied by 10,000. Cumulative incidence for 
specific digestive SPNs was estimated by treating death as a competing risk155. 
Multivariable Poisson regression models were fitted to estimate the relative risk (RR) 
and the relative excess risk (RER) for SPNs in specific digestive organs taking into 
account factors attained age, sex, type of childhood cancer, country, age at diagnosis 
and era of diagnosis. Relative risks (RR) may be interpreted as the ratio of SIRs, 
adjusted for relevant co-factors fitted. Relative excess risks (RER) may be interpreted 
as the ratio of AERs, adjusted for relevant co-factors fitted. Statistical significance for 
all analyses was defined as a 2-sided P < 0.05. All analyses were carried out in Stata 
13 (StataCorp, College Station, Texas).   
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4.3 Results 
Cohort Characteristics 
From the total 80,483 survivors in the cohort, 323 digestive SPNs were observed in 
277 survivors. There were 1,276,233 person-years following 5-year survival with 
mean and median follow-up of 15.6 and 13.8 years, respectively (Table 4.5.3). The 
majority of SPNs developed in survivors of Hodgkin’s disease (N=62), Wilms’ tumour 
(N=53), other tumours (N=50) and tumours of the central nervous system (N=39). 
From the total number of digestive SPNs, 154 were colorectal, 52 were in the liver, 
39 were in the stomach, 33 were in the pancreas, 20 were in the small intestine, 16 
were in the oesophagus and 3 were in the anus (Table 4.5.4). In subsequent analysis 
we only focused on groups with over 20 observed SPNs. 
 
Risk of any digestive subsequent primary neoplasm 
Overall, survivors of childhood cancer were nearly 4 times more likely to develop a 
subsequent cancer in the digestive system compared to expected from the general 
population (SIR=3.8; 95%CI: 3.4-4.3) with 2 additional cases of subsequent digestive 
cancer per 10,000 person-years (AER=1.9; 95%CI: 1.6-2.1) (Table 4.5.5). As 
attained age increased, the number of excess cases of digestive cancers also 
increased to 8 excess cases observed per 10,000 person-years beyond 50 years of 
age. Hungary and France exhibited the highest risks of developing a digestive SPN; 
20-fold (SIR=20.0; 95%CI; 12.5-32.2) and 10-fold (SIR=10.1; 95%CI: 7.9-12.9) with 3 
and 7 excess cases per 10,000 person-years, respectively. Survivors of Wilms’ 
tumour and Hodgkin’s’ disease were most likely to develop a digestive SPN 
compared to expected; 15-fold (SIR=14.7; 95%CI: 11.3-19.3) and 9-fold (SIR=8.5; 
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95%CI: 6.6-10.9), respectively. After adjusting for potential confounding factors, 
females were 20% less likely to develop a digestive SPN compared to males 
(RR=0.8; 95%CI: 0.6-1.0). Cumulative incidence of digestive SPN was 1.2% (95%CI: 
1.0-1.3) at 50 years of age and 2.2% (95%CI: 1.8-2.6) at 60 years of age; the 
respective expected cumulative incidence for the general population was 0.4% and 
1.4% (Figure 4.5.1). 
 
Risk of subsequent primary colorectal cancer 
Survivors experienced 3 times the expected number of colorectal cancers compared 
to that expected from the general population (SIR=3.2; 95%CI: 2.7-3.7) with 0.8 
additional cases of colorectal cancer per 10,000 person-years (AER=0.8; 95%CI: 0.6-
1.0) (Table 4.5.6). The absolute excess risk increased significantly with attained age 
and the highest observed excess risk was 8 excess cases of colorectal SPN per 
10,000 person-years among those aged at least 50 years. When evaluating the risks 
by country, Hungary and France had the highest risks, with 13-fold (SIR=13.1; 
95%CI: 6.2-27.4) and 7-fold (SIR=6.5; 95%CI: 4.4-9.7) that expected from the 
general population, respectively. Survivors of Wilms’ tumour and Hodgkin’s disease 
had the highest risk of developing a colorectal SPN, with 9-times (SIR=9.0; 95%CI: 
5.8-14.1) and 8-times (SIR=7.9; 95%CI: 5.6-11.2) the risk expected respectively. The 
excess risk (both RR and RER) of developing a colorectal SPN increased with more 
recent decade of FPN diagnosis (p<0.01) and decreased with increased age at FPN 
diagnosis (p<0.01). At 50 years of age, the cumulative incidence of colorectal cancer 
for survivors was 0.3% (95%CI: 0.3-0.4) and 1.5% (95%CI: 1.2-1.9) at 60 years of 
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age; the respective expected cumulative incidence from rates in the general 
population were 0.2% and 0.8% (Figure 4.5.2).   
 
Risk of subsequent primary liver neoplasm 
Survivors were at 10 times (SIR=10.3; 95%CI: 7.9-13.5) the risk of developing 
primary liver cancer compared to that expected, with 0.4 excess cases of liver cancer 
per 10,000 person-years (Table 4.5.7). The absolute excess risk increased 
significantly with increasing attained age and the highest excess risk observed was 4 
excess cases of subsequent liver cancer per 10,000 person-years among those aged 
at least 50 years. Highest risk of developing liver SPNs compared to expected were 
found in France and Hungary with 45-fold (SIR=45.3; 95%CI: 28.1-72.8) and 38-fold 
(SIR=37.5; 95%CI: 12.1-116.4) the expected risk, respectively. Survivors of Wilms’ 
tumour, leukaemia and neuroblastoma had the highest risk of developing liver SPNs 
with 56-fold (SIR=56.0; 95%CI: 33.2-94.6), 15-fold (SIR=15.3; 95%CI: 7.6-30.6) and 
15-fold (SIR=15.1; 95%CI: 3.8-60.2) the risk compared to that expected, respectively. 
After adjusting for other risk factors in multivariable analyses, significant 
heterogeneity remained by country of residence (p<0.01). The cumulative incidence 
of liver SPN was 0.2% (95%CI: 0.1-0.2) at 50 years of age and 0.4% (95%CI: 0.2-
0.5) at 60 years of age, compared to 0.02% and 0.07% from the general population, 
respectively (Figure 4.5.3). 
 
Risk of subsequent primary stomach neoplasm 
Survivors experienced 3 times the number of stomach cancers than expected 
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(SIR=3.4; 95%CI: 2.5-4.6) with 0.2 excess cases per 10,000 person-years in excess 
of that expected (Table 4.5.8). Survivors of Wilms’ tumour (SIR=11.1; 95%CI: 4.6-
26.6) had the highest excess risk, followed by survivors of lymphoma (SIR=6.0; 
95%CI: 3.2-11.1). Survivors residing in Hungary (SIR=20.4; 95%CI: 5.1-81.5) and 
France (SIR=12.3; 95%CI: 6.4-23.7) had the highest risk of developing subsequent 
stomach cancers compared to the general population. Survivors experienced an 
excess risk of subsequent stomach cancer with 0.5 excess cases per 10,000 person-
years (AER=0.5; 95%CI: 0.2-0.8) at 30-39 years of age. The cumulative incidence of 
stomach was 0.12% (95%CI: 0.08-0.19) at 50 years of age and 0.27% at 60 years of 
age, which was twice that of the general population at 50 years of age (0.06%) and 
increased to 0.17% at 60 years of age (Figure 4.5.4). 
 
Risk of subsequent primary pancreatic neoplasm 
Overall, survivors experienced 4-fold the number of pancreatic SPNs (SIR=3.6; 
95%CI: 2.5-5.0) with 0.2 excess cases per 10,000 person-years compared to the 
general population (Table 4.5.9). The risk of developing pancreatic SPNs was 
greatest for survivors of Wilms’ tumour and lymphoma which were 24-fold (SIR=23.8; 
95%CI: 11.9-47.7) and 6-fold (SIR=5.5; 95%CI: 2.6-11.4) compared to that expected 
from the general population, respectively. Survivors residing in Hungary (SIR=35.1; 
95%CI: 8.8-140.2) and France (SIR=9.6; 95%CI: 4.3-21.4) experienced the highest 
risk compared to the general population. Cumulative incidence was 0.1% (95%CI: 
0.1-0.2) at 50 years of age and increased to 0.3% (95%CI: 0.2-0.5) at 60 years of 
age; respective figures for the general population were 0.04% and 0.17% (Figure 
4.5.5). 
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Childhood Cancer Diagnosis 
Survivors of Wilms’ tumour and Hodgkin’s lymphoma appeared to be at the highest 
risk of developing digestive SPNs; hence we conducted more comprehensive 
subgroup analyses by specific factors such as sex, age, country of residence, age of 
FPN diagnosis, decade of FPN diagnosis and attained age. After adjusting for 
potential confounding factors, the relative risk of developing digestive SPNs for 
Wilms tumour survivors decreased with increasing attained age compared to the 
general population (p=0.033). However, the absolute excess risk significantly 
increased with increasing attained age (p<0.01) (Table 4.5.10). Cumulative incidence 
for Wilms’ tumour survivors was 5.6% (95%CI: 3.8-7.9) at 50 years of age, which is 
14-fold that expected (0.4%) (Figure 4.5.6).  
 
For survivors of Hodgkin’s lymphoma, after adjustment for confounders, we found 
that the absolute excess risk increased substantially with increasing attained age 
(p<0.01). Significant heterogeneity remained between contributing countries (Table 
4.5.11). Cumulative incidence for Hodgkin’s lymphoma survivors was 3.0% (95%CI: 
2.1-4.3) at 50 years of age, which is 7.5-fold that of the expected cumulative 
incidence (0.4%) (Figure 4.5.7).   
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4.4 Discussion 
To our knowledge, this is the largest ever cohort to investigate the risks of developing 
SPNs in specific sites of the digestive system among survivors of childhood cancer. 
The key findings to emerge are summarised in Table 4.5.12. Survivors of Wilms’ 
tumour have 15-fold, 9-fold, 56-fold, 11-fold and 24-fold increased risk of digestive 
cancer overall, colorectal, liver, stomach, and pancreatic cancer, respectively. 
Survivors of Hodgkin’s lymphoma have a 9-fold, 8-fold, 7-fold, 6-fold and 6-fold 
increased risk of digestive cancer overall, colorectal, liver, stomach and pancreatic 
cancer, respectively. Survivors of non-Hodgkin’s lymphoma have a 6-fold, 7-fold, 6-
fold and 6-fold increased risk of colorectal, liver, stomach and pancreatic cancer, 
respectively. Survivors of neuroblastoma have a 5-fold increased risk of digestive 
cancer overall and colorectal cancer. Finally, survivors of CNS tumours have 5-fold 
increased risk of liver cancer (although there has been discussion regarding the link 
between CNS tumours and digestive cancers, there has been no large-scale study to 
show the association between CNS tumours and digestive cancers to date).  
 
Previous studies only had sufficient number of survivors to examine a single site 
within the digestive system79,194-199 or the digestive system overall38,74,187, but we had 
sufficient numbers of survivors—in our European cohort—to investigate all sites in 
one study. There was one previous study that also incorporated several countries in 
Europe which investigated the risk of digestive SPNs but the number of observed 
SPNs in specific digestive sites was not as high as our cohort78. Also, this is the first 
study to investigate the risks of specific types of digestive SPNs such as liver SPN, 
stomach SPN and pancreatic SPN by FPN diagnosis. 
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Our SIR for any digestive SPN was consistent with previous studies with SIRs 
ranging from 2.1 to 4.838,74,187. Our study also reported similar AERs when taking into 
account the risk time (person-years); we observed 2 excess cases of digestive SPN 
in 10,000 survivors per year whereas the previous smaller European study observed 
3 excess cases of digestive SPN per 10,000 survivors per year78. 
 
We anticipated that survivors of Wilms’ tumour to be the highest contributor to SPNs 
in the digestive system in addition to being the highest contributor for colorectal 
SPNs. However, it has been previously reported that survivors of Hodgkin’s 
lymphoma frequently develop digestive SPNs195,200-204.  
 
The SIR and excess risk of colorectal SPNs were comparable to previous studies 
ranging from a relative risk of 7-fold for survivors of Hodgkin’s lymphoma to a SIR of 
7-fold for overall childhood cancer survivors compared to the general population78,204 
and our cumulative incidence was also similar with 0.2% compared to 0.5% at 40 
years of age195. Our SIR for colorectal SPN for Hodgkin’s lymphoma survivors was 
substantially lower than CCSS (SIR=36.4; 95%CI: 15.7-71.8)200, however, only 8 
colorectal cancers were observed in the CCSS indicating that their findings may be 
inaccurate. Almost half of the colorectal SPNs (48%) developed in survivors of 
Hodgkin’s disease (21%), CNS tumours (15%) and Wilms’ tumour (12%).  
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The SIR was significantly elevated for liver, stomach and pancreatic SPNs and is 
similar to two smaller scale studies74,78. However, no previous study has had 
sufficient statistical power to satisfactorily investigate the risks of liver, stomach and 
pancreatic SPNs by type of childhood cancer. All categories of childhood cancer, 
except retinoblastoma, had a significantly higher risk of liver SPNs compared to the 
general population; survivors of lymphoma, Wilms’ tumour, sarcoma and other 
tumours had a significantly higher risk of stomach SPNs compared to the general 
population; survivors of lymphoma, Wilms’ tumour and other tumours had a 
significantly higher risk of pancreatic SPNs compared to the general population. 
Wilms’ tumour survivors, of whom a large proportion likely have had their 
abdominopelvic regions irradiated, are at highest risk of liver (56-fold), stomach (11-
fold) and pancreatic (24-fold) SPNs compared to the general population. 
 
Survivors from France had a significantly higher risk compared to survivors residing 
in other countries. This was most likely due to France, being a hospital-based centre, 
receiving referrals of complicated cancer cases from different countries and treating 
them with high dose radiotherapy. However, we cannot rule out that the effect may 
be due to differences in demographics between countries such as diet, alcohol, 
smoking, etc. 
 
A guideline from the Children’s Oncology Group (COG) recommends that survivors 
who have received radiotherapy in excess of 30 Gy should receive colonoscopy 
every 5 years starting at 35 years of age. However, performing colonoscopies in all 
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survivors of childhood cancer will require a lot of resources and in some cases the 
benefit of a colonoscopy may not necessarily outweigh the cost (i.e. stress caused by 
frequently returning to the hospital for tests or only being able to detect a small 
proportion of secondary digestive malignancies in a large cohort). Therefore, 
colonoscopies should only be considered for particular survivors who have a 
significantly high risk. 
 
Study Limitations 
Initially, the validation of FPNs in different countries was difficult due to a difference in 
coding procedures. We managed to convert all the different types of coding, using 
the IARC registry tool software, into one common class of definitions (ICD-O-3). 
However, the conversion of codes between different versions of ICD and ICD-O may 
have resulted in some FPNs being classified as “unknown” or “missing” as cancer 
classifications are updated over time – but over 90% of codes were successfully 
converted. Another potential limitation of this study was the lack of information on 
radiotherapy and chemotherapy exposures given for childhood cancer. Radiotherapy 
and chemotherapy have been implicated in causing SPNs, but we were not able to 
stratify the risks of SPN in the digestive system by levels of radiotherapy exposure or 
chemotherapeutic drug quantities. This study, being multi-national, makes it difficult 
to infer likely radiotherapy and chemotherapy exposures from FPN and era of FPN 
diagnosis. Detailed analyses of the risks of SPNs by radiotherapy and chemotherapy 
exposures would require a nested case-control study, which is currently in progress 
as part of the PanCareSurFup studies. Another potential limitation relates to the fact 
that general population cancer incidence rates were not available for France, 
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Hungary, Italy and the Netherlands. Instead, cancer incidence population rates from 
the UK were used to estimate the population rates in those countries, which may be 
under, or overestimating the expected number of digestive SPNs. 
 
Conclusion 
Survivors of Wilms’ tumour experienced the highest excess risk of digestive cancer 
15-fold expected, and Wilms’ survivors experienced 56-fold, 24-fold, 11-fold and 9-
fold excepted risk of liver, pancreatic, stomach and colorectal cancer, respectively. 
Survivors of Hodgkin’s lymphoma experienced the second highest excess risk of 
digestive cancers 9-fold expected, and Hodgkin’s survivors experienced an 8-fold, 7-
fold, 6-fold and 6-fold expected risk of colorectal, liver, stomach and pancreatic 
cancer, respectively. Such risk stratification information should be very helpful in the 
development of clinical follow-up guidelines for European survivors – these 
guidelines may highlight particular groups of survivors who have had abdominal 
radiation (i.e. Wilms’ tumour) for referral to colorectal cancer screening.  
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4.5 Tables and Figures 
 
Table 4.5.1 Individual cohort characteristics. 
Country of origin 
Number of 5-year 
Survivors 
Period of Childhood 
Cancer Diagnosis 
Childhood Cancer 
Ascertainment 
Age at Childhood 
Cancer Diagnosis 
(in years) 
Study Exit 
(calendar 
year) 
Number of 
Digestive SPNs 
SPN Ascertainment 
Methods 
France 3,138 1946 – 1986 Hospital—based < 19 2015 64 Various Methods 
Hungary 4,885 1971 – 2008 Population—based < 20 2014 17 Various Methods 
Italy (Population) 10,781 1964 – 2005 Population—based < 20 2014 14 Various Methods 
Italy (Hospital) 9,129 1960 – 2008 Hospital—based < 20 2014 15 Various Methods 
Netherlands 6,044 1963 – 2001 Population—based < 18 2012 17 Various Methods 
Denmark 4,832 1943 – 1998 Population—based < 20 2003 31 Population—based 
Sweden 7,709 1958 – 1998 Population—based < 20 2003 14 Population—based 
Norway 3,877 1953 – 1997 Population—based < 20 2002 12 Population—based 
Finland 6,229 1953 – 2006 Population—based < 20 2012 40 Population—based 
Iceland 274 1955 – 1998 Population—based < 20 2003 0 Population—based 
Slovenia 1,252 1960 – 2002 Population—based < 17 2014 9 Population—based 
Switzerland 4,373 1964 – 2005 Population—based < 20 2014 5 Various Methods 
UK 17,960 1940 – 1991 Population—based < 15 2006 85 Population—based 
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Table 4.5.2 Table of codes from different versions of the International Classification of Diseases corresponding to specific digestive sites. 
ICD-10 Code ICD-9 Code ICD-8 Code ICD-7 Code Description 
C15 150 150 150 Oesophagus 
C16 151 151 151 Stomach 
C17 152 152 152 Small Intestine 
C18 153 153 153 Colon 
C19 154.0 154.0 154 Rectosigmoid Junction 
C20 154.1 154.1 154 Rectum 
C21 154.2 – 154.3 154.2 154* Anus and Anal Canal 
C22 155 155 155.0 Liver and Bile Ducts 
C23 156.0 156.0 155.1 Gallbladder 
C24 156.1 – 156.9 156.1 – 156.9 155.1 Other Biliary Tract 
C25 157 157 157 Pancreas 
All codes include the suffix range .0 to .9 in the definitions with exception to codes that already have a specified suffix. *Does not include anus in the definition.  
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Table 4.5.3 Characteristics of all 80,483 five-year survivors in the European PCSF study and 277 
survivors who developed a subsequent cancer in the digestive system. 
  All Survivors 
(N = 80,483) 
Survivors who developed 
Digestive SPN (N = 277)
ɣ
 
Sex  Male 43,894 (54.5%) 181 (65.3%) 
 Female 36,589 (45.5%) 96 (34.7%) 
    
Age at FPN Diagnosis Mean 8.1 9.4 
(years) Median 7.0 9.5 
 0 – 4 31,892 (39.6%) 79 (28.5%) 
 5 – 9 18,565 (23.1%) 65 (23.5%) 
 10 – 14 17,712 (22.0%) 77 (27.8%) 
 15 – 19 12,314 (15.3%) 56 (20.2%) 
    
Attained Age (years)‡ Mean 31.3 37.3 
 Median 30.5 36.6 
 5 –   9 88 (2.3%) 0 (0.0%) 
 10 – 19 681 (18.0%) 22 (7.9%) 
 20 – 29 1,057 (27.9%) 62 (22.4%) 
 30 – 39 1,078 (28.4%) 86 (31.1%) 
 40 – 49 563 (14.8%) 64 (23.1%) 
 50 – 59 256 (6.7%) 36 (13.0%) 
 60 – 69 66 (1.7%) 7 (2.5%) 
 70+ 6 (0.2%) 0 (0.0%) 
    
Initial diagnosis Leukaemia 20,537 (25.5%) 21 (7.6%) 
 Hodgkin’s Lymphoma 6,595 (8.2%) 54 (19.5%) 
 Non-Hodgkin’s Lymphoma 3,920 (4.9%) 15 (5.4%) 
 CNS 14,469 (18.0%) 37 (13.4%) 
 Neuroblastoma 3,971 (4.9%) 8 (2.9%) 
 Retinoblastoma 2,500 (3.1%) 5 (1.8%) 
 Wilms’ Tumour 5,381 (6.7%) 46 (16.6%) 
 Bone 3,419 (4.3%) 7 (2.5%) 
 Soft Tissue Sarcoma 4,873 (6.1%) 25 (9.0%) 
 Other 10,578 (13.1%) 45 (16.3%) 
 Unclassified 4,240 (5.3%) 14 (5.1%) 
    
Follow up since  Mean 15.6 26.3 
5-year survival from Median 13.8 25.7 
FPT Diagnosis (years) 0 – 9 28,717 (35.7%) 21 (7.6%) 
 10 – 19 25,442 (31.6%) 57 (20.6%) 
 20 – 29 16,264 (20.2%) 102 (36.8%) 
 30 – 39  7,533 (9.4%) 62 (22.4%) 
 40 – 49  2,188 (2.7%) 33 (11.9%) 
 50+ 339 (0.4%) 2 (0.7%) 
    
 
‡
Age at which the survivor first exits the study alive, relating only to development of SPN (N=3,795). 
ɣ
A total of 323 digestive SPNs were observed from 277 survivors. 
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Table 4.5.4 Frequency of subsequent digestive SPNs stratified by FPN diagnosis for childhood cancer survivors.
First Primary Total Colorectal Liver  Stomach Pancreas Small Intestine Oesophagus Gallbladder Anus 
Leukaemia  23 
(7.1%) 
7 
(4.5%) 
8 
(15.4%) 
0 
(0.0%) 
1 
(3.0%) 
5 
(25.0%) 
1 
(6.3%) 
1 
(16.7%) 
0 
(0.0%) 
Hodgkin’s Lymphoma 62 
(19.2%) 
32 
(20.8%) 
4 
(7.7%) 
10 
(25.6%) 
6 
(18.2%) 
1 
(5.0%) 
6 
(37.5%) 
2 
(33.3%) 
1 
(33.3%) 
NHL  18 
(5.6%) 
14 
(9.1%) 
1 
(1.9%) 
0 
(0.0%) 
1 
(3.0%) 
0 
(0.0%) 
2 
(12.5%) 
0 
(0.0%) 
0 
(0.0%) 
CNS  39 
(12.1%) 
23 
(14.9%) 
5 
(9.6%) 
3 
(7.7%) 
3 
(9.1%) 
3 
(15.0%) 
1 
(6.3%) 
0 
(0.0%) 
1 
(33.3%) 
Neuroblastoma 9 
(2.8%) 
5 
(3.2%) 
2 
(3.8%) 
1 
(2.6%) 
0 
(0.0%) 
1 
(5.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
Retinoblastoma  8 
(2.5%) 
5 
(3.2%) 
1 
(1.9%) 
1 
(2.6%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(6.3%) 
0 
(0.0%) 
0 
(0.0%) 
Wilms’ Tumour  53 
(16.4%) 
19 
(12.3%) 
14 
(26.9%) 
5 
(12.8%) 
8 
(24.2%) 
4 
(20.0%) 
1 
(6.3%) 
2 
(33.3%) 
0 
(0.0%) 
Bone 10 
(3.1%) 
4 
(2.6%) 
0 
(0.0%) 
5 
(12.8%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(6.3%) 
0 
(0.0%) 
0 
(0.0%) 
STS  32 
(9.9%) 
14 
(9.1%) 
5 
(9.6%) 
3 
(7.7%) 
4 
(12.1%) 
3 
(15.0%) 
1 
(6.3%) 
1 
(16.7%) 
1 
(16.7%) 
Other  50 
(15.5%) 
21 
(13.6%) 
9 
(17.3%) 
7 
(17.9%) 
9 
(27.3%) 
2 
(10.0%) 
2 
(12.5%) 
0 
(0.0%) 
0 
(0.0%) 
Unclassified 19 
(5.9%) 
10 
(6.5%) 
3 
(5.8%) 
4 
(10.3%) 
1 
(3.0%) 
1 
(5.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
Total 323 
(100%) 
154 
(100%) 
52 
(100%) 
39 
(100%) 
33 
(100%) 
20 
(100%) 
16 
(100%) 
6 
(100%) 
3 
(100%) 
109 
 
Table 4.5.5 Standardised Incidence Ratios and Absolute Excess Risks for 
subsequent cancer in the digestive system. 
Factor Exposure O/E SIR (95% CI) RR (95% CI) AER (95% CI) RER (95% CI) 
Overall All combined 323 / 84.6 3.8 (3.4 – 4.3) NA1 1.9 (1.6 – 2.1) NA1 
       
Sex Male 202 / 47.9 4.2 (3.7 – 4.8) 1.0 (REF) 2.2 (1.8 – 2.7) 1.0 (REF) 
 Female 121 / 36.7 3.3 (2.8 – 3.9) 0.8 (0.6 – 1.0) 1.4 (1.1 – 1.8) 0.6 (0.4 – 0.8) 
 Pheterogeneity   0.032  0.001 
       
Cohort UK  85 / 21.92 3.9 (3.1 – 4.8) 1.0 (REF) 1.7 (1.2 – 2.0) 1.0 (REF) 
 France (Villejuif) 64 / 6.35 10.1 (7.9 – 12.9) 2.1 (1.5 – 3.0) 6.9 (5.1 – 8.8) 2.6 (1.7 – 3.9) 
 Hungary 17 / 0.85 20.0 (12.5 – 32.2) 2.8 (1.6 – 4.9) 3.2 (1.6 – 4.8) 3.2 (1.7 – 5.9) 
 Italy (pop.) 14 / 5.62 2.5 (1.5 – 4.2) 0.6 (0.3 – 1.0) 0.6 (0.1 – 1.2) 0.6 (0.3 – 1.2) 
 Italy (hospital) 15 / 1.84 8.1 (4.9 – 13.5) 1.0 (0.6 – 1.8) 1.2 (0.5 – 1.9) 1.0 (0.5 – 1.9) 
 Netherlands 17 / 3.54 4.8 (3.0 – 7.7) 0.9 (0.5 – 1.5) 1.3 (0.5 – 2.1) 0.8 (0.4 – 1.7) 
 Denmark 31 / 13.48 2.3 (1.6 – 3.3) 1.0 (0.6 – 1.5) 2.2 (0.8 – 3.6) 1.1 (0.6 – 2.1) 
 Sweden 14 / 8.03 1.7 (1.0 – 2.9) 0.5 (0.3 – 0.9) 0.5 (0.1 – 1.0) 0.4 (0.2 – 1.0) 
 Norway 12 / 4.54 2.6 (1.5 – 4.7) NA2 1.4 (0.1 – 2.6) NA2 
 Finland 40 / 14.09 2.8 (2.1 – 3.9) 0.9 (0.6 – 1.4) 2.5 (1.3 – 3.7) 1.1 (0.6 – 2.0) 
 Iceland 0 / 0.23 0 (NA) 0 (NA) -0.7 (NA) 0 (NA) 
 Slovenia 9 / 2.79 3.2 (1.7 – 6.2) NA2 2.5 (0.1 – 4.9) NA2 
 Switzerland 5 / 1.28 3.9 (1.6 – 9.4) 0.6 (0.2 – 1.6) 0.8 (-0.1 – 1.8) 0.7 (0.2 – 2.5) 
 Pheterogeneity   < 0.01  < 0.01 
       
Age at Diagnosis 0-4 yrs 94 / 14.70 6.4 (5.2 – 7.8) 1.0 (REF) 1.5 (1.1 – 1.9) 1.0 (REF) 
 5-9 yrs 75 / 14.17 5.3 (4.2 – 6.6) 1.1 (0.8 – 1.5) 2.0 (1.5 – 2.6) 1.2 (0.8 – 1.7) 
 10-14 yrs 89 / 28.23 3.2 (2.6 – 3.9) 0.8 (0.6 – 1.2) 2.1 (1.5 – 2.8) 0.8 (0.5 – 1.2) 
 15-19yrs 65 / 27.46 2.4 (1.9 – 3.0) 0.9 (0.6 – 1.4) 2.3 (1.3 – 3.3) 0.8 (0.4 – 1.5) 
 Ptrend   0.376  0.270 
       
FPN Diagnosis Leukaemia 23 / 6.17 3.7 (2.5 – 5.6) 1.0 (REF) 0.6 (0.3 – 0.9) 1.0 (REF) 
 Hodgkin’s Lymphoma 62 / 7.29 8.5 (6.6 – 10.9) 3.7 (2.2 – 6.2) 5.7 (4.1 – 7.3) 4.7 (2.5 – 8.8) 
 NHL 18 / 4.56 4.0 (2.5 – 6.3) 1.8 (0.9 – 3.3) 2.2 (0.8 – 3.5) 1.9 (0.8 – 4.3) 
 CNS 39 / 17.97 2.2 (1.6 – 3.0) 1.1 (0.6 – 1.9) 0.9 (0.4 – 1.4) 1.1 (0.5 – 2.2) 
 Neuroblastoma 9 / 1.76 5.1 (2.7 – 9.8) 1.3 (0.6 – 2.9) 1.1 (0.2 – 2.0) 1.4 (0.5 – 3.5) 
 Retinoblastoma 8 / 3.18 2.5 (1.3 – 5.0) 1.1 (0.5 – 2.5) 0.8 (-0.1 – 1.8) 0.7 (0.2 – 2.9) 
 Wilms Tumour 53 / 3.60 14.7 (11.3 – 19.3) 3.8 (2.3 – 6.5) 4.8 (3.4 – 6.2) 4.3 (2.3 – 8.3) 
 Bone Sarcoma 10 / 6.24 1.6 (0.9 – 3.0) 0.8 (0.4 – 1.8) 0.7 (-0.4 – 1.8) 0.4 (0.1 – 2.8) 
 STS 32 / 7.74 4.1 (2.9 – 5.8) 2.0 (1.2 – 3.6) 2.8 (1.5 – 4.1) 2.5 (1.2 – 5.0) 
 Other 50 / 19.06 2.6 (2.0 – 3.5) 1.6 (0.9 – 2.7) 1.8 (1.0 – 2.6) 1.7 (0.8 – 3.4) 
 Not classifiable 19 / 7.02 2.7 (1.7 – 4.2) NA2 1.8 (0.5 – 3.1) NA2 
 Pheterogeneity   < 0.01  < 0.01 
       
Era of Diagnosis <1970 136 / 57.27 2.4 (2.0 – 2.8) 1.0 (REF) 2.6 (1.8 – 3.3) 1.0 (REF) 
 1970-1979 111 / 16.70 6.6 (5.5 – 8.0) 1.5 (1.1 – 2.0) 2.6 (2.0 – 3.2) 1.3 (0.9 – 1.9) 
 1980-1989 59 / 8.14 7.2 (5.6 – 9.4) 1.1 (0.7 – 1.7) 1.3 (0.9 – 1.7) 1.1 (0.7 – 1.7) 
 1990-1999 14 / 2.23 6.3 (3.7 – 10.6) 0.8 (0.4 – 1.6) 0.6 (0.2 – 1.0) 0.8 (0.4 – 1.8) 
 >=2000 3 / 0.22 13.9 (4.5 – 43.2) 1.3 (0.4 – 4.6) 1.1 (-0.2 – 2.3) 1.3 (0.3 – 5.6) 
 Ptrend   0.255  0.610 
       
Attained Age 0-19 yrs 25 / 1.69 14.8 (10.0 – 21.8) 1.0 (REF) 0.5 (0.3 – 0.7) 1.0 (REF) 
 20-29 yrs 70 / 7.12 9.8 (7.8 – 12.4) 0.6 (0.4 – 1.0) 1.4 (1.1 – 1.8) 2.9 (1.7 – 5.0) 
 30-39 yrs 92 / 15.37 6.0 (4.9 – 7.3) 0.4 (0.2 – 0.6) 3.2 (2.4 – 4.0) 7.0 (4.1 – 12.0) 
 40-49 yrs 75 / 24.26 3.1 (2.5 – 3.9) 0.2 (0.1 – 0.4) 5.7 (3.8 – 7.5) 14.9 (8.1 – 27.4) 
 50+ yrs 61 / 36.11 1.7 (1.3 – 2.2) 0.1 (0.1 – 0.2) 7.8 (3.0 – 12.6) 19.1 (8.2 – 45.0) 
  Ptrend   < 0.01  < 0.01 
1 Not applicable for overall analysis. 
2 Comparison not available due to unsuccessful conversion of ICD-7 codes. 
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Table 4.5.6 Standardised Incidence Ratios and Absolute Excess Risks for 
subsequent colorectal cancer. 
Factor Exposure O/E SIR (95% CI) RR (95% CI) AER (95% CI) RER (95% CI) 
Overall All combined 154 / 48.46 3.2 (2.7 – 3.7) NA1 0.8 (0.6 – 1.0) NA1 
       
Sex Male 95 / 25.72 3.7 (3.0 – 4.5) 1.0 (REF) 1.0 (0.7 – 1.3) 1.0 (REF) 
 Female 59 / 22.74 2.6 (2.0 – 3.3) 0.8 (0.6 – 1.2) 0.6 (0.4 – 0.9) 0.7 (0.4 – 1.1) 
 Pheterogeneity   0.325  0.116 
 
Cohort UK  52 / 12.55 4.1 (3.2 – 5.4) 1.0 (REF) 2.4 (1.3 – 3.6) 1.0 (REF) 
 France Villejuif 24 / 3.68 6.5 (4.4 – 9.7) 1.1 (0.6 – 1.8) 1.3 (0.3 – 2.3) 1.1 (0.6 – 2.1) 
 Hungary 7 / 0.54 13.1 (6.2 – 27.4) 1.6 (0.7 – 3.8) 0.4 (-0.0 – 0.6) 1.5 (0.6 – 3.9) 
 Italy (pop.) 9 / 3.30 2.7 (1.4 – 5.2) 0.6 (0.3 – 1.3) 0.3 (-0.1 – 0.6) 0.6 (0.2 – 1.6) 
 Italy (hospital) 4 / 1.12 3.6 (1.3 – 9.6) 0.5 (0.2 – 1.3) 0.4 (-0.1 – 0.8) 0.4 (0.1 – 1.4) 
 Netherlands 6 / 2.14 2.8 (1.3 – 6.2) 0.4 (0.2 – 1.0) 0.6 (-0.3 – 1.5) 0.4 (0.1 – 1.1) 
 Denmark 13 / 7.97 1.6 (0.9 – 2.8) 0.7 (0.4 – 1.3) 0.0 (-0.2 – 0.3) 0.7 (0.2 – 2.3) 
 Sweden 5 / 4.54 1.1 (0.5 – 2.6) 0.4 (0.2 – 1.1) 0.6 (-0.3 – 1.5) 0.3 (0.0 – 2.8) 
 Norway 6 / 2.91 2.1 (0.9 – 4.6) NA2 1.2 (0.4 – 2.0) NA2 
 Finland 20 / 7.31 2.7 (1.8 – 4.2) 0.8 (0.4 – 1.4) -0.4 (NA) 0.6 (0.2 – 1.5) 
 Iceland 0 / 0.13 0 (NA) 0 (NA) 1.0 (-0.6 – 2.6) 0 (NA) 
 Slovenia 4 / 1.55 2.6 (1.0 – 6.9) NA2 0.7 (-0.1 – 1.6) NA2 
 Switzerland 4 / 0.72 5.5 (2.1 – 14.8) 0.9 (0.3 – 2.6) 1.1 (0.7 – 1.5) 1.2 (0.3 – 4.0) 
 Pheterogeneity   0.141  < 0.01 
       
Age at 0-4 yrs 41 / 8.56 4.8 (3.5 – 6.5) 1.0 (REF) 0.6 (0.3 – 0.9) 1.0 (REF) 
Diagnosis 5-9 yrs 43 / 8.16 5.3 (3.9 – 7.1) 1.0 (0.6 – 1.6) 1.2 (0.7 – 1.6) 0.9 (0.5 – 1.8) 
 10-14 yrs 42 / 16.13 2.6 (1.9 – 3.5) 0.4 (0.3 – 0.8) 0.9 (0.5 – 1.4) 0.3 (0.1 – 0.7) 
 15-19yrs 28 / 15.61 1.8 (1.2 – 2.6) 0.3 (0.2 – 0.7) 0.8 (0.1 – 1.4) 0.2 (0.0 – 0.5) 
 Ptrend   < 0.01  < 0.01 
       
FPN Diagnosis Leukaemia 7 / 3.70 1.9 (0.9 – 4.0) 1.0 (REF) 0.1 (-0.1 – 0.3) 1.0 (REF) 
 Hodgkin’s Lymphoma 32 / 4.05 7.9 (5.6 – 11.2) 6.8 (2.9 – 16.0) 2.9 (1.8 – 4.1) 15.5 (3.1 – 67.7) 
 NHL 14 / 2.53 5.5 (3.3 – 9.3) 4.5 (1.8 – 11.5) 1.9 (0.7 – 3.0) 9.6 (1.9 – 47.4) 
 CNS 23 / 10.17 2.3 (1.5 – 3.4) 2.0 (0.8 – 4.8) 0.5 (0.2 – 1.0) 3.7 (0.8 – 18.0) 
 Neuroblastoma 5 / 1.03 4.8 (2.0 – 11.6) 2.7 (0.8 – 8.9) 0.6 (-0.1 – 1.3) 5.3 (0.9 – 32.3) 
 Retinoblastoma 5 / 1.81 2.8 (1.1 – 6.6) 1.7 (0.5 – 5.8) 0.5 (-0.2 – 1.3) 2.7 (0.3 – 22.0) 
 Wilms Tumour 19 / 2.11 9.0 (5.8 – 14.1) 4.7 (1.9 – 11.6) 1.6 (0.8 – 2.5) 8.7 (1.8 – 42.2) 
 Bone Sarcoma 4 / 3.49 1.1 (0.4 – 3.1) 1.2 (0.3 – 4.1) 0.1 (-0.6 – 0.8) 0 (NA) 
 STS 14 / 4.36 3.2 (1.9 – 5.4) 2.9 (1.1 – 7.5) 1.1 (0.3 – 2.0) 6.5 (1.3 – 32.5) 
 Other 21 / 10.90 1.9 (1.3 – 3.0) 2.3 (0.9 – 5.7) 0.6 (0.1 – 1.1) 2.3 (0.4 – 14.1) 
 Not classifiable 10 / 4.29 2.3 (1.3 – 4.3) NA2 0.9 (-0.1 – 1.8) NA2 
 Pheterogeneity   < 0.01  < 0.01 
       
Era of <1970 68 / 32.26 2.1 (1.7 – 2.7) 1.0 (REF) 1.2 (0.6 – 1.7) 1.0 (REF) 
Diagnosis 1970-1979 52 / 9.64 5.4 (4.1 – 7.1) 3.2 (1.9 – 5.2) 1.2 (0.8 – 1.6) 5.3 (2.3 – 12.0) 
 1980-1989 24 / 4.94 4.9 (3.3 – 7.2) 3.1 (1.5 – 6.2) 0.5 (0.2 – 0.7) 7.0 (2.4 – 20.6) 
 1990-1999 7 / 1.46 4.8 (2.3 – 10.0) 4.1 (1.4 – 11.9) 0.3 (0.0 – 0.6) 14.0 (3.1 – 64.6) 
 >=2000 3 / 0.15 19.6 (6.3 – 60.7) 16.4 (3.8 – 70.5) 1.1 (-0.2 – 2.4) 84.1 (12.5 – 564.0) 
 Ptrend   < 0.01  < 0.01 
       
Attained Age 0-19 yrs 4 / 0.98 4.1 (1.5 – 10.8) 1.0 (REF) 0.1 (-0.0 – 0.2) 1.0 (REF) 
 20-29 yrs 27 / 4.47 6.0 (4.1 – 8.8) 1.6 (0.5 – 4.5) 0.5 (0.3 – 0.7) 7.6 (2.1 – 27.2) 
 30-39 yrs 37 / 8.95 4.1 (3.0 – 5.7) 1.1 (0.4 – 3.2) 1.2 (0.7 – 1.7) 19.4 (5.4 – 69.3) 
 40-49 yrs 39 / 13.65 2.9 (2.1 – 3.9) 0.9 (0.3 – 2.5) 2.8 (1.5 – 4.2) 64.7 (18.0 – 232.7) 
 50+ yrs 47 / 20.41 2.3 (1.7 – 3.1) 0.8 (0.3 – 2.4) 8.3 (4.1 – 12.5) 164.5 (42.4 – 638.8) 
  Ptrend   0.065  < 0.01 
1 Not applicable for overall analysis. 
2 Comparison not available due to unsuccessful conversion of ICD-7 codes. 
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Table 4.5.7 Standardised Incidence Ratios and Absolute Excess Risks for 
subsequent liver cancer. 
Factor Exposureα O/E SIR (95% CI) RR (95% CI) AER (95% CI) RER (95% CI) 
Overall All combined 52 / 5.04 10.3 (7.9 – 13.5) NA1 0.4 (0.3 – 0.5) NA1 
       
Sex Male 33 / 3.26 10.1 (7.2 – 14.2) 1.0 (REF) 0.4 (0.3 – 0.6) 1.0 (REF) 
 Female 19 / 1.78 10.7 (6.8 – 16.7) 0.8 (0.4 – 1.5) 0.3 (0.2 – 0.4) 0.4 (0.3 – 1.0) 
 Pheterogeneity   0.447  0.017 
       
Cohort UK  7 / 1.28 5.5 (2.6 – 11.5) 1.0 (REF) 0.2 (0.0 – 0.3) 1.0 (REF) 
 France Villejuif 17 / 0.38 45.3 (28.1 – 72.8) 6.1 (2.4 – 15.7) 2.0 (1.0 – 3.0) 7.5 (2.4 – 20.2) 
 Hungary 3 / 0.08 37.5 (12.1 – 116.4) 6.4 (1.5 – 26.4) 0.6 (-0.1 – 1.3) 8.0 (1.7 – 35.6) 
 Italy α 8 / 0.58 13.9 (6.9 – 27.8) 2.2 (0.8 – 6.3) 0.3 (0.1 – 0.5) 2.5 (0.7 – 8.2) 
 Netherlands 1 / 0.26 3.9 (0.5 – 27.7) 0.6 (0.1 – 5.0) 0.1 (-0.1 – 0.3) 0.1 (NA) 
 Nordic countriesα 14 / 2.22 6.3 (3.7 – 10.7) 1.8 (0.6 – 4.9) 0.3 (0.1 – 0.5) 2.0 (0.6 – 7.3) 
 Slovenia 2 / 0.13 15.0 (3.8 – 60.0) NA2 0.8 (-0.4 – 1.9) NA2 
 Switzerland 0 / 0.13 0 (NA) 0.0 (NA) -0.0 (NA) 0.0 (NA) 
 Pheterogeneity   < 0.01  < 0.01 
       
Age at  0-4 yrs 24 / 1.11 21.6 (14.5 – 32.2) 1.0 (REF) 0.4 (0.3 – 0.6) 1.0 (REF) 
Diagnosis 5-9 yrs 11 / 0.93 11.8 (6.5 – 21.2) 0.9 (0.4 – 1.9) 0.3 (0.1 – 0.6) 1.0 (0.4 – 2.2) 
 10-14 yrs 12 / 1.56 7.7 (4.4 – 13.5) 0.7 (0.3 – 1.7) 0.4 (0.1 – 0.6) 0.7 (0.2 – 2.0) 
 15-19yrs 5 / 1.44 3.5 (1.4 – 8.4) 0.4 (0.1 – 1.4) 0.2 (-0.1 – 0.5) 0.3 (0.0 – 2.0) 
 Ptrend   0.037  0.183 
       
FPN Diagnosis Leukaemia 8 / 0.52 15.3 (7.6 – 30.6) 1.0 (REF) 0.3 (0.1 – 0.5) 1.0 (REF) 
 Lymphomaα 5 / 0.73 6.8 (2.8 – 16.4) 0.5 (0.2 – 1.8) 0.3 (-0.0 – 0.6) 0.5 (0.1 – 2.2) 
 CNS 5 / 1.06 4.7 (2.0 – 11.3) 0.4 (0.1 – 1.3) 0.2 (-0.0 – 0.4) 0.2 (0.0 – 2.0) 
 Neuroblastoma 2 / 0.13 15.1 (3.8 – 60.2) 0.6 (0.1 – 3.0) 0.3 (-0.1 – 0.7) 0.4 (0.1 – 3.3) 
 Retinoblastoma 1 / 0.19 5.2 (0.7 – 36.7) 0.3 (0.0 – 3.0) 0.1 (-0.2 – 0.5) 0.2 (0.0 – 5.9) 
 Wilms Tumour 14 / 0.25 56.0 (33.2 – 94.6) 2.0 (0.7 – 5.7) 1.3 (0.6 – 2.0) 1.9 (0.6 – 5.9) 
 Sarcomaα 5 / 0.81 6.1 (2.6 – 14.8) 0.3 (0.1 – 1.3) 0.3 (-0.0 – 0.6) 0.3 (0.1 – 1.6) 
 Other 9 / 1.04 8.6 (4.5 – 16.6) 0.8 (0.3 – 2.4) 0.5 (0.1 – 0.8) 0.9 (0.2 – 3.1) 
 Not classifiable 3 / 0.30 10.1 (3.3 – 31.3) NA2 0.4 (-0.1 – 0.9) NA2 
 Pheterogeneity   0.037  0.017 
       
Era of <1970 22 / 2.95 7.5 (4.9 – 11.3) 1.0 (REF) 0.6 (0.3 – 0.9) 1.0 (REF) 
Diagnosis 1970-1979 20 / 1.10 18.1 (11.7 – 28.1) 1.7 (0.8 – 3.8) 0.5 (0.3 – 0.8) 1.8 (0.8 – 4.7) 
 ≥1980α 10 / 0.99 10.1 (5.5 – 18.9) 0.8 (0.3 – 2.4) 0.1 (0.1 – 0.3) 0.7 (0.2 – 2.7) 
 Ptrend   0.647  0.639 
       
Attained Age 0-29 yrsα 17 / 1.15 14.7 (9.2 – 23.7) 1.0 (REF) 0.2 (0.1 – 0.3) 1.0 (REF) 
 30-39 yrs 12 / 0.84 14.3 (8.1 – 25.3) 1.1 (0.5 – 2.5) 0.5 (0.2 – 0.8) 3.6 (1.5 – 8.6) 
 40-49 yrs 10 / 1.19 8.4 (4.5 – 15.6) 0.8 (0.3 – 1.8) 1.0 (0.3 – 1.7) 9.7 (3.9 – 24.6) 
 50+ yrs 13 / 1.86 7.0 (4.1 – 12.0) 0.8 (0.4 – 2.0) 3.5 (1.3 – 5.7) 32.6 (10.8 – 98.2) 
  Ptrend   0.635  < 0.01 
α 
Some exposures were grouped together for this analysis due to very small numbers. 
1 Not applicable for overall analysis. 
2 Comparison not available due to unsuccessful conversion of ICD-7 codes.  
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Table 4.5.8 Standardised Incidence Ratios and Absolute Excess Risks for 
subsequent stomach cancer. 
Factor Exposureα O/E SIR (95% CI) RR (95% CI) AER (95% CI) RER (95% CI) 
Overall All combined 39 / 11.57 3.4 (2.5 – 4.6) NA1 0.2 (0.1 – 0.3) NA1 
       
Sex Male 22 / 7.04 3.1 (2.1 – 4.7) NA2 0.2 (0.1 – 0.4) NA2 
 Female 17 / 4.53 3.8 (2.3 – 6.0) NA2 0.2 (0.1 – 0.4) NA2 
 Pheterogeneity      
       
Cohort UK  8 / 2.83 2.8 (1.4 – 5.7) NA2 0.1 (-0.0 – 0.3) NA2 
 France (Villejuif) 9 / 0.73 12.3 (6.4 – 23.7) NA2 1.0 (0.3 – 1.7) NA2 
 Hungary 2 / 0.10 20.4 (5.1 – 81.5) NA2 0.4 (-0.2 – 0.9) NA2 
 Italy α 3 / 0.91 3.3 (1.1 – 10.2) NA2 0.3 (0.1 – 0.5) NA2 
 Netherlands 3 / 0.41 7.3 (2.4 – 22.7) NA2 0.3 (-0.1 – 0.6) NA2 
 Nordic countriesα 13 / 5.81 2.2 (1.3 – 3.9) NA2 0.3 (0.1 – 0.5) NA2 
 Slovenia 1 / 0.56 1.8 (0.3 – 12.7) NA2 0.2 (-0.6 – 1.0) NA2 
 Switzerland 0 / 0.23 0.0 (NA) NA2 -0.0 (NA) NA2 
 Pheterogeneity      
       
Age at Diagnosis 0-9 yrsα 10 / 3.80 2.6 (1.4 – 4.9) NA2 0.1 (0.0 – 0.2) NA2 
 10-14 yrs 16 / 3.80 4.2 (2.6 – 6.9) NA2 0.4 (0.2 – 0.7) NA2 
 15-19yrs 13 / 3.97 3.3 (1.9 – 5.6) NA2 0.6 (0.1 – 1.0) NA2 
 Ptrend      
       
FPN Diagnosis Leukaemia 0 / 0.79 0.0 (NA) NA2 -0.0 (NA) NA2 
 Lymphomaα 10 / 1.67 6.0 (3.2 – 11.1) NA2 0.5 (0.1 – 0.9) NA2 
 CNS 3 / 2.44 1.2 (0.4 – 3.8) NA2 0.0 (-0.1 – 0.2) NA2 
 Neuroblastoma 1 / 0.22 4.5 (0.6 – 32.1) NA2 0.1 (-0.2 – 0.4) NA2 
 Retinoblastoma 1 / 0.42 2.4 (0.3 – 17.0) NA2 0.1 (-0.2 – 0.4) NA2 
 Wilms Tumour 5 / 0.45 11.1 (4.6 – 26.6) NA2 0.4 (0.0 – 0.9) NA2 
 Sarcomaα 8 / 1.88 4.3 (2.1 – 8.5) NA2 0.4 (0.0 – 0.8) NA2 
 Other 7 / 2.58 2.7 (1.3 – 5.7) NA2 0.3 (-0.0 – 0.6) NA2 
 Not classifiable 4 / 1.11 3.6 (1.4 – 9.6) NA2 0.4 (-0.2 – 1.0) NA2 
 Pheterogeneity      
       
Era of Diagnosis <1970 13 / 7.71 1.7 (1.0 – 2.9) NA2 0.2 (-0.1 – 0.4) NA2 
 1970-1979 13 / 2.43 5.3 (3.1 – 9.2) NA2 0.3 (0.1 – 0.5) NA2 
 ≥1980α 13 / 1.43 9.1 (5.3 – 15.7) NA2 0.2 (0.1 – 0.3) NA2 
 Ptrend      
       
Attained Age 0-29 yrsα 6 / 1.17 5.1 (2.3 – 11.4) NA2 0.1 (0.0 – 0.1) NA2 
 30-39 yrs 14 / 2.67 5.3 (3.1 – 8.9) NA2 0.5 (0.2 – 0.8) NA2 
 40-49 yrs 9 / 3.63 2.5 (1.3 – 4.8) NA2 0.6 (-0.1 – 1.3) NA2 
 50+ yrs 10 / 4.11 2.4 (1.3 – 4.5) NA2 1.8 (-0.1 – 3.8) NA2 
  Ptrend      
α 
Some exposures were grouped together for this analysis due to very small numbers. 
1 Not applicable for overall analysis. 
2 Comparison not available due to low numbers. 
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Table 4.5.9 Standardised Incidence Ratios and Absolute Excess Risks for 
subsequent pancreatic cancer. 
Factor Exposureα O/E SIR (95% CI) RR (95% CI) AER (95% CI) RER (95% CI) 
Overall All combined 33 / 9.23 3.6 (2.5 – 5.0) NA1 0.2 (0.1 – 0.3) NA1 
       
Sex Male 21 / 5.12 4.1 (2.7 – 6.3) NA2 0.2 (0.1 – 0.4) NA2 
 Female 12 / 4.11 2.9 (1.7 – 5.1) NA2 0.1 (0.0 – 0.3) NA2 
 Pheterogeneity      
       
Cohort UK  8 / 2.14 3.7 (1.9 – 7.5) NA2 0.2 (0.0 – 0.3) NA2 
 France (Villejuif) 6 / 0.62 9.6 (4.3 – 21.4) NA2 0.6 (0.1 – 1.2) NA2 
 Hungary 2 / 0.06 35.1 (8.8 – 140.2) NA2 0.4 (-0.1 – 0.9) NA2 
 Italyα 3 / 0.91 3.3 (1.1 – 10.2) NA2 0.1 (-0.1 – 0.2) NA2 
 Netherlands 2 / 0.29 6.8 (1.7 – 27.2) NA2 0.2 (-0.1 – 0.4) NA2 
 Nordic countriesα 11 / 5.81 1.9 (1.0 – 3.4) NA2 0.1 (-0.0 – 0.3) NA2 
 Slovenia 1 / 0.28 3.6 (0.5 – 25.5) NA2 0.3 (-0.5 – 1.1) NA2 
 Switzerland 0 / 0.10 0.0 (NA) NA2 -0.0 (NA) NA2 
 Pheterogeneity      
       
Age at Diagnosis 0-4 yrs 8 / 1.37 5.9 (2.9 – 11.7) NA2 0.1 (0.0 – 0.2) NA2 
 5-9 yrs 9 / 1.40 6.4 (3.4 – 12.4) NA2 0.3 (0.1 – 0.5) NA2 
 10-14 yrs 8 / 3.05 2.6 (1.3 – 5.2) NA2 0.2 (-0.0 – 0.4) NA2 
 15-19yrs 8 / 3.42 2.3 (1.2 – 4.7) NA2 0.3 (-0.1 – 0.6) NA2 
 Ptrend 
    
 
 
FPN Diagnosis Leukaemia 1 / 0.50 2.0 (0.3 – 14.2) NA2 0.0 (-0.1 – 0.1) NA2 
 Lymphomaα 7 / 1.28 5.5 (2.6 – 11.4) NA2 0.4 (0.0 – 0.7) NA2 
 CNS 3 / 2.01 1.5 (0.5 – 4.6) NA2 0.0 (-0.1 – 0.2) NA2 
 Neuroblastoma 0 / 0.16 0.0 (NA) NA2 -0.0 (NA) NA2 
 Retinoblastoma 0 / 0.33 0.0 (NA) NA2 -0.1 (NA) NA2 
 Wilms Tumour 8 / 0.34 23.8 (11.9 – 47.7) NA2 0.7 (0.2 – 1.3) NA2 
 Sarcomaα 4 / 1.62 2.5 (0.9 – 6.6) NA2 0.2 (-0.1 – 0.5) NA2 
 Other 9 / 2.32 3.9 (2.0 – 7.5) NA2 0.4 (0.1 – 0.7) NA2 
 Not classifiable 1 / 0.67 1.5 (0.2 – 10.5) NA2 0.1 (-0.3 – 0.4) NA2 
 Pheterogeneity 
    
 
 
Era of Diagnosis <1970 16 / 6.96 2.3 (1.4 – 3.8) NA2 0.3 (0.0 – 0.6) NA2 
 1970-1979 13 / 1.55 8.4 (4.9 – 14.5) NA2 0.3 (0.1 – 0.5) NA2 
 ≥1980α 4 / 0.73 5.5 (2.1 – 14.6) NA2 0.1 (-0.0 – 0.1) NA2 
 Ptrend 
    
 
 
Attained Age 0-29 yrsα 5 / 0.46 10.9 (4.5 – 26.2) NA2 0.0 (0.0 – 0.1) NA2 
 30-39 yrs 9 / 1.35 6.7 (3.5 – 12.8) NA2 0.3 (0.1 – 0.6) NA2 
 40-49 yrs 9 / 2.58 3.5 (1.8 – 6.7) NA2 0.7 (0.1 – 1.4) NA2 
 50+ yrs 10 / 4.84 2.1 (1.1 – 3.8) NA2 1.6 (-0.3 – 3.6) NA2 
  Ptrend      
α 
Some exposures were grouped together for this analysis due to very small numbers. 
1 Not applicable for overall analysis. 
2 Comparison not available due to low numbers. 
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Table 4.5.10 Standardised Incidence Ratios and Absolute Excess Risks of 
subsequent digestive cancer in Wilms’ tumour survivors. 
Factor Exposure O/E SIR (95% CI) RR (95% CI) AER (95% CI) RER (95% CI) 
Overall All combined 53 / 3.60 14.7 (11.3 – 19.3) NA1 4.8 (3.4 – 6.2) NA1 
       
Sex Male 33 / 1.98 16.7 (11.8 – 23.4) 1.0 (REF) 6.0 (3.8 – 8.1) 1.0 (REF) 
 Female 20 / 1.62 12.4 (8.0 – 19.2) 0.7 (0.4 – 1.3) 3.6 (1.9 – 5.3) 0.6 (0.3 – 1.1) 
 Pheterogeneity   0.245  0.073 
       
Cohort UK  13 / 1.26 10.3 (6.0 – 17.8) 1.0 (REF) 3.4 (1.4 – 5.5) 1.0 (REF) 
 France 24 / 1.16 20.6 (13.8 – 30.7) 2.2 (1.1 – 4.4) 12.1 (7.0 – 17.2) 2.6 (1.2 – 5.3) 
 Hungary 2 / 0.04 51.4 (12.9 – 205.6) 4.3 (0.9 – 20.60) 5.2 (-2.2 – 12.5) 4.5 (0.9 – 22.9) 
 Italy 3 / 0.26 11.5 (3.7 – 35.6) 1.0 (0.3 – 3.5) 1.8 (-0.4 – 4.0) 0.9 (0.2 – 3.6) 
 Netherlands 4 / 0.25 16.1 (6.1 – 42.9) 1.4 (0.4 – 4.5) 3.2 (-0.2 – 6.6) 1.5 (0.4 – 5.0) 
 Nordic countries 7 / 0.59 11.9 (5.7 – 24.9) 1.2 (0.5 – 3.0) 4.0 (0.8 – 7.3) 1.3 (0.5 – 3.6) 
 Slovenia 0 / 0.01 0.0 (NA) NA2 -0.1 (NA) NA2 
 Switzerland 0 / 0.03 0.0 (NA) 0.0 (NA) -0.1 (NA) 0.0 (NA) 
 Pheterogeneity   0.257  0.183 
       
Age at Diagnosis 0-4 yrs 37 / 2.67 13.9 (10.1 – 19.2) 1.0 (REF) 4.2 (2.7 – 5.6) 1.0 (REF) 
 5-9 yrs 11 / 0.74 14.8 (8.2 – 26.7) 1.1 (0.6 – 2.2) 5.5 (2.0 – 9.0) 1.2 (0.6 – 2.5) 
 10-19 yrs 5 / 0.19 26.6 (11.1 – 64.0) 2.7 (1.0 – 7.0) 20.2 (1.8 – 38.6) 3.5 (1.3 – 9.5) 
 Ptrend   0.134  0.079 
       
Era of Diagnosis <1970 27 / 2.37 11.4 (7.8 – 16.60 1.0 (REF) 9.2 (5.4 – 13.1) 1.0 (REF) 
 1970-1979 22 / 0.84 26.2 (17.3 – 37.8) 1.4 (0.7 – 2.7) 6.1 (3.5 – 8.7) 1.1 (0.6 – 2.2) 
 1980-2009 4 / 0.39 10.2 (3.8 – 27.2) 0.4 (0.1 – 1.4) 0.9 (-0.1 – 1.8) 0.3 (0.1 – 1.2) 
 Ptrend   0.959  0.533 
       
Attained Age 0-29 yrs 13 / 0.63 20.5 (11.9 – 35.4) 1.0 (REF) 1.5 (0.6 – 2.3) 1.0 (REF) 
 30-39 yrs 19 / 0.94 20.3 (13.0 – 31.8) 0.7 (0.3 – 1.4) 12.2 (6.4 – 18.0) 5.3 (2.5 – 11.50 
 40+ yrs 21 / 2.03 10.4 (6.7 – 15.9) 0.3 (0.1 – 0.8) 33.9 (17.9 – 50.0) 13.0 (5.5 – 30.6) 
  Ptrend   0.033  < 0.01 
1 Not applicable for overall analysis. 
2 Comparison not available due to unsuccessful conversion of ICD-7 codes. 
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Table 4.5.11 Standardised Incidence Ratios and Absolute Excess Risks of 
subsequent digestive cancer in Hodgkin’s lymphoma survivors. 
Factor Exposure O/E SIR (95% CI) RR (95% CI) AER (95% CI) RER (95% CI) 
Overall All combined 62 / 7.29 8.5 (6.6 – 10.9) NA1 5.7 (4.1 – 7.3) NA1 
       
Sex Male 44 / 4.98 8.8 (6.6 – 11.9) 1.0 (REF) 6.3 (4.2 – 8.4) 1.0 (REF) 
 Female 18 / 2.31 7.8 (4.9 – 12.4) 0.9 (0.5 – 1.5) 4.6 (2.1 – 7.0) 0.7 (0.4 – 1.3) 
 Pheterogeneity   0.570  0.272 
       
Cohort UK  13 / 2.30 5.6 (3.3 – 9.7) 1.0 (REF) 3.9 (1.3 – 6.5) 1.0 (REF) 
 France 11 / 0.47 23.2 (12.8 – 41.9) 4.1 (1.8 – 9.3) 19.6 (7.5 – 31.7) 4.8 (1.9 – 11.9) 
 Hungary 4 / 0.12 34.6 (13.0 – 92.1) 5.8 (1.7 – 19.4) 8.6 (-0.1 – 17.2) 6.9 (1.9 – 25.2) 
 Italy 8 / 0.98 8.2 (4.1 – 16.3) 1.4 (0.6 – 3.4) 3.0 (0.6 – 5.4) 1.4 (0.5 – 3.9) 
 Netherlands 4 / 0.31 12.8 (4.8 – 34.0) 2.2 (0.7 – 7.3) 5.4 (-0.3 – 11.1) 2.5 (0.7 – 9.8) 
 Nordic countries 21 / 2.87 7.3 (4.8 – 11.2) 1.6 (0.8 – 3.2) 7.8 (3.9 – 11.7) 1.9 (0.8 – 4.2) 
 Slovenia 0 / 0.06 0.0 (NA) NA2 -0.4 (NA) NA2 
 Switzerland 1 / 0.17 5.8 (0.8 – 41.4) 1.1 (0.1 – 8.8) 2.1 (-2.9 – 7.1) 1.4 (0.2 – 12.9) 
 Pheterogeneity   0.026  0.023 
       
Age at Diagnosis 0-4 yrs 2 / 0.20 9.8 (2.4 – 39.1) 1.0 (REF) 2.6 (-1.4 – 6.5) 1.0 (REF) 
 5-9 yrs 17 / 1.15 14.8 (9.2 – 23.8) 1.6 (0.4 – 7.0) 6.6 (3.3 – 10.0) 1.9 (0.4 – 9.9) 
 10-19 yrs 43 / 5.93 7.2 (5.4 – 9.8) 1.1 (0.3 – 4.5) 5.7 (3.7 – 7.7) 1.5 (0.3 – 7.4) 
 Ptrend   0.418  0.847 
       
Era of Diagnosis <1970 26 / 3.99 6.5 (4.4 – 9.6) 1.0 (REF) 12.3 (6.7 – 17.9) 1.0 (REF) 
 1970-1979 25 / 1.97 12.7 (8.6 – 18.8) 1.2 (0.6 – 2.2) 7.9 (4.5 – 11.2) 0.8 (0.4 – 1.6) 
 1980-2009 11 / 1.33 8.3 (4.6 – 14.9) 0.5 (0.2 – 1.3) 2.0 (0.7 – 3.3) 0.3 (0.1 – 0.9) 
 Ptrend   0.654  0.096 
       
Attained Age 0-29 yrs 9 / 0.77 11.7 (6.1 – 22.5) 1.0 (REF) 1.4 (0.4 – 2.3) 1.0 (REF) 
 30-39 yrs 23 / 1.59 14.5 (9.6 – 21.8) 1.1 (0.5 – 2.4) 8.7 (4.9 – 12.5) 5.8 (2.4 – 13.6) 
 40+ yrs 30 / 4.93 6.1 (4.3 – 8.7) 0.4 (0.2 – 1.0) 13.3 (33.2) 11.8 (4.7 – 29.4) 
  Ptrend   0.094  < 0.01 
1 Not applicable for overall analysis. 
2 Comparison not available due to unsuccessful conversion of ICD-7 codes. 
 
  
116 
 
1 Hodgkin’s lymphoma and NHL combined due to insufficient numbers. 
2 Bone sarcoma and STS combined due to insufficient numbers.  
Table 4.5.12 SIRs and 95% confidence intervals for FPNs of at least 5-fold expected 
and based on at least 5 observed SPN cancers of specified site. 
 
FPN Digestive Colorectal Liver Stomach Pancreatic 
Leukaemia - - 15.3 (7.6 – 30.6) - - 
Hodgkin’s lymphoma 8.5 (6.6 – 10.9) 7.9 (5.6 – 11.2) 
6.8 (2.8 – 16.4)1 6.0 (3.2 – 11.1)1 5.5 (2.6 – 11.4)1 
NHL - 5.5 (3.3 – 9.3) 
CNS - - 4.7 (2.0 – 11.3) - - 
Neuroblastoma 5.1 (2.7 – 9.8) 4.8 (2.0 – 11.6) - - - 
Retinoblastoma - - - - - 
Wilms’ tumour 14.7 (11.3 – 19.3) 9.0 (5.8 – 14.1) 56.0 (33.2 – 94.6) 11.1 (4.6 – 26.6) 23.8 (11.9 – 47.7) 
Bone - - 
6.1 (2.6 – 14.8)2 - - 
STS - - 
Other - - 8.6 (4.5 – 16.6) - - 
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Figure 4.5.1 Cumulative incidence of developing a digestive SPN among survivors of childhood cancer with 95% confidence 
intervals and the corresponding cumulative incidence expected from the general population. 
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Figure 4.5.2 Cumulative incidence of developing a colorectal cancer among survivors with 95% confidence intervals and the 
corresponding cumulative incidence expected from the general population. 
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Figure 4.5.3 Cumulative incidence of developing a liver cancer among survivors with 95% confidence intervals and the 
corresponding cumulative incidence expected from the general population. 
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Figure 4.5.4 Cumulative incidence of developing a stomach cancer among survivors with 95% confidence intervals and the 
corresponding cumulative incidence expected from the general population. 
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Figure 4.5.5 Cumulative incidence of developing a pancreatic cancer among survivors with 95% confidence intervals and the 
corresponding cumulative incidence expected from the general population. 
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Figure 4.5.6 Cumulative incidence of developing a digestive SPN among Wilms’ tumour survivors with 95% confidence intervals 
and the corresponding cumulative incidence expected from the general population. 
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Figure 4.5.7 Cumulative incidence of developing a digestive SPN among Hodgkin’s Lymphoma survivors with 95% confidence 
intervals and the corresponding cumulative incidence expected from the general population. 
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5 RISK OF ADVERSE HEALTH AND SOCIAL OUTCOMES 
BEYOND 50 YEARS AFTER HERITABLE RETINOBLASTOMA: THE 
BRITISH CHILDHOOD CANCER SURVIVOR STUDY. 
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Abstract 
Background: Survivors of heritable retinoblastoma (HRb) are at long-term risk of 
adverse health and social outcomes; however, the risks of developing second 
primary neoplasms (SPN) due to radiotherapy remain uncertain. We investigated the 
risk of developing adverse health outcomes, including risk of developing SPNs, in 
relation to previous treatment with radiotherapy. 
Patients and Methods: The British Childhood Cancer Survivor Study includes 552 
five-year survivors of HRb. We investigated risks of SPNs, cause-specific mortality—
and for those who completed a questionnaire—smoking status, educational 
achievement, health-status, adverse pregnancy outcomes and eye-related medical 
conditions. Risks were stratified by treatment with radiotherapy (none/beam/plaque) 
where possible. 
Results: Overall, mortality was 8-times that expected (SMR=7.8; 95%CI: 6.6, 9.3). 
Cumulative mortality from all causes of death, excluding recurrence, was 26% at 50 
years from diagnosis with 84% of excess deaths due to SPNs between 25–50 years 
from diagnosis. After 50 years from diagnosis, 59% of all excess deaths were 
attributable to SPNs. The risk of developing a bone SPN was over 300 times that 
expected (SIR=304.8; 95%CI: 214.6,420.1). Survivors who received external beam 
radiotherapy had a significantly higher risk of developing SPNs above the shoulder 
compared to no radiotherapy (SIR=4.0; 95%CI: 1.4,11.8).  
Conclusion: HRb survivors, remain at an elevated risk of mortality beyond 25 years 
of follow up with SPN accounting for 84% of all excess deaths between 25-50 years 
of follow-up. Although the risk of developing an SPN was high, there was evidence of 
external beam radiotherapy increasing the risk of SPN above the shoulder. Current 
guidelines recommend long-term follow-up and screening for secondary 
126 
 
malignancies for all HRb survivors, but evidence from this study shows specific 
attention should be given to those who received external beam radiotherapy as part 
of their initial treatment. 
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5.1 Introduction 
Retinoblastoma (Rb) is a rare type of childhood cancer developing in the eye in two 
forms: one heritable and one non-heritable. Heritable retinoblastoma is inherited as 
autosomal dominant with nearly complete penetrance and results from mutations in 
the RB1 tumour suppressor gene situated on chromosome 1320. Five-year survival 
after heritable retinoblastoma has improved substantially over recent decades from 
less than 70% in the 1970s to currently over 90%23,24. Although the vast majority of 
heritable retinoblastoma patients can expect to survive 5-years, survivors of heritable 
retinoblastoma are at a substantially increased risk of premature mortality and 
developing second primary neoplasms (SPNs)205-207 compared to the general 
population. 
 
Although a number of previous epidemiological studies investigated the risks of 
cause-specific mortality and risk of SPN8,199,206-215 in heritable retinoblastoma 
survivors, few studies investigated other adverse health and social outcomes such as 
health-related quality of life, smoking behaviour, marriage and educational 
achievement.  In addition, few studies investigated cause-specific mortality and risk 
of SPN by type of radiotherapy treatment received (i.e. by whether survivors received 
external beam radiotherapy, brachytherapy or no radiotherapy). 
 
The principal objective of this population-based study was to investigate long-term 
risks of cause-specific mortality and subsequent primary neoplasms by specific type 
of radiotherapy treatment; and to investigate risks of adverse pregnancy outcomes; 
eye-related medical conditions; smoking status, alcohol consumption, educational 
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attainment, marriage; and health status among 5-year survivors of heritable 
retinoblastoma. 
 
5.2 Methods 
British Childhood Cancer Survivor Study (BCCSS) 
The British Childhood Cancer Survivor Study (BCCSS) is a large-scale population-
based cohort study investigating the long-term adverse health and social outcomes 
of childhood cancer and its treatment. The BCCSS consists of 17,980 survivors of 
childhood cancer—including 552 survivors of heritable retinoblastoma—who were 
diagnosed before 15 years of age, between 1940 and 1991 in Great Britain and 
survived for at least five years154. Patients with bilateral retinoblastoma or a family 
history of the disease were classified as heritable. The BCCSS cohort was 
ascertained through the National Registry of Childhood Tumours (NRCT). 
 
Ascertainment of deaths and subsequent primary neoplasms 
Ascertainment of deaths (including underlying cause of death) and SPNs in the 
BCCSS was achieved by individual patient electronic record linkage via the NHS 
Information Centre216. Confirmation of all SPNs was undertaken by writing to relevant 
clinician(s) to obtain all diagnostic reports to confirm site, type, and date of diagnosis, 
with particular reference to pathology reports38. 
 
BCCSS Questionnaire  
All survivors who were alive and aged over 16 years were sent a 40-page 
questionnaire by their primary care physician on behalf of the BCCSS. In total, 298 
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(74%) of all eligible heritable retinoblastoma survivors (N=402) completed and 
returned the questionnaire154. The BCCSS questionnaire inquired about potential 
adverse health and social outcomes of childhood cancer and its treatment including 
questions regarding health-status (SF-36), health-care use, medical conditions, 
medical procedures, marriage, adverse pregnancy outcomes (e.g. miscarriage, 
stillbirth, preterm birth, abortion), smoking habits, alcohol consumption and 
educational achievements.  
 
Ethical approval for the BCCSS was obtained from the relevant Multi-Centre 
Research Ethics Committee and every Local Research Ethics Committee in Britain 
(212 in total). 
 
Statistical Analysis 
Cause-Specific Mortality 
To investigate cause-specific mortality, mortality rates of heritable retinoblastoma 
survivors in the BCCSS cohort were compared to mortality rates that would be 
expected based on the population of England & Wales. The period at risk of mortality 
began 5 years following initial diagnosis of childhood heritable retinoblastoma until 
the first occurrence of loss to death, follow up or exit date on 31st December 2014. 
Standardised mortality ratios (SMR) for specific causes of death were calculated by 
taking the ratio of observed over expected number of deaths for each cause. 
Absolute excess risks (AERs) were calculated by taking the observed minus 
expected number of deaths divided by the number of person-years at risk multiplied 
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by 10,000. Cumulative mortality for specific causes of death was estimated by 
treating other causes of death as competing risks155. 
 
Subsequent Primary Neoplasms 
The period at risk of developing a SPN was initiated 5 years following initial diagnosis 
of childhood heritable retinoblastoma until the first occurrence of loss to follow up, 
death or exit date on 31st December 2006. Multiple SPNs per survivor were permitted 
for comparisons with the general population to avoid bias, but only the first SPN was 
considered in measures of cumulative risk. Standardised incidence ratios (SIRs), 
AERs and cumulative incidence of developing an SPN were calculated using the 
same methods as described above in relation to death. Risks of SPN were calculated 
by mode of radiotherapy treatment given and whether the SPN occurred above or 
below the shoulder. 
 
Adverse Pregnancy Outcomes 
To investigate the risks of adverse pregnancy outcomes, logistic regression models 
were used to calculate odds ratios (OR) for low birth weight, preterm births, abortion 
and miscarriage. Models were adjusted for maternal age and pregnancy order. 
Adverse pregnancy outcomes were investigated by comparing heritable 
retinoblastoma survivors to all other survivors in the BCCSS cohort who had had at 
least one completed pregnancy (N=6,593) (comparison with UK population 
pregnancy rates was not achievable as there is currently no database which holds 
information relating to the rates of adverse pregnancy outcomes). 
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Medical Conditions 
To determine whether heritable retinoblastoma survivors were more prone to specific 
eye-related medical conditions after five-year survival, relative risks (RR) were 
calculated to compare heritable retinoblastoma survivors who did not receive surgery 
to survivors of all other cancers (N=10,190).  
 
Health-status – “Short Form 36” 
As part of the BCCSS questionnaire, functional health and well-being were measured 
by the SF-36 health-status questionnaire54. The SF-36 consists of eight 
measurement scales; physical function, role-physical, bodily pain, general health 
perception, mental health, role-emotional, social function and vitality. All eight SF-36 
scores are measured on a scale from 0 to 100; with higher scores indicating more 
favourable outcomes. To compare SF-36 scale scores observed for heritable 
retinoblastoma survivors with a reference population, normative data from the Oxford 
Healthy Life Survey (OHLS) were used. The OHLS is a general population survey 
conducted between 1991 and 1992 that included 13,042 individuals aged 18-64 
years randomly sampled from the Family Health Service Authority registers in 
Oxfordshire, Berkshire, Buckinghamshire and Northamptonshire. For each SF-36 
scale, difference in mean scores between survivors of heritable retinoblastoma and 
OHLS was calculated using linear regression which adjusted for age and sex.  
 
Smoking status, alcohol consumption and education level 
Among those heritable retinoblastoma survivors who completed the BCCSS 
questionnaire, smoking and alcohol consumption and educational attainment were 
compared to the general population by using data from the nationwide General 
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Household Survey (GHS)157. Adjustment for confounders and classification of current 
regular smokers, alcohol consumption and educational attainment has been defined 
in previous BCCSS studies51,61,64. For each outcome, ORs comparing heritable 
retinoblastoma survivors to the GHS were calculated using multivariable logistic 
regression with a generalized estimating equation modification that took into account 
clustering within the GHS; these ORs were adjusted for attained age and sex. 
 
Marital status 
To investigate marital status among heritable retinoblastoma survivors, ORs of ever 
being married—stratified by sex and attained age—were calculated using data from 
the National Marriage Registry as the reference population57. Age-specific ORs were 
then pooled into one overall OR by using the Mantel-Haenszel method for combining 
ORs158. 
 
Statistical significance for all analyses was defined as a 2-sided P<0.05. All analyses 
were carried out in Stata 13 (StataCorp, College Station, Texas). 
 
5.3 Results 
Cohort Characteristics 
From the total of 552 heritable retinoblastoma survivors in the cohort, 24.8% (N=137) 
had died, 1.1% (N=6) was lost to follow up and 74.1% (N=409) were alive at the exit 
date of the investigation (31st December 2014). Type of radiotherapy was split into 
survivors who received external beam radiotherapy (N=246)—defined as survivors 
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who only received external beam radiotherapy (N=164) and survivors who received 
mixed therapy (N=82)—and survivors who only received brachytherapy (N=129). 
Characteristics of heritable retinoblastoma survivors who completed the 
questionnaire were similar to all heritable retinoblastoma survivors in the BCCSS 
cohort (Table 5.5.1). But more males did not return the questionnaire compared to 
females and there was less follow-up in those who did not return the questionnaire, 
however, these factors were adjusted for in the analyses. Total follow-up of heritable 
retinoblastoma survivors in relation to mortality was 16,956 person-years following 5-
year survival with mean and median follow-up of 30.7 and 31.1 years from heritable 
retinoblastoma diagnosis respectively with over 90% of the cohort still alive and 
under follow-up at 25 years after diagnosis. 
 
Cause-Specific Mortality 
Heritable retinoblastoma survivors experienced 8 times the number of deaths 
expected (SMR=7.8; 95%CI: 6.6, 9.3) with 64 additional deaths (95%CI: 51.9, 76.5) 
per 10,000 person-years in excess of that expected (Table 5.5.2). We focused on 
causes of death with at least 10 observations. Ignoring causes of death relating to 
recurrence, cause-specific mortality was highest for SPNs (SMR=18.2; 95%CI: 14.7, 
22.4). In terms of the AER, the highest excess—with 72% of all excess deaths—was 
attributable to SPNs. Survivors who received external beam radiotherapy for their 
heritable retinoblastoma were more likely to die from an SPN (SMR=33.0; 95%CI: 
24.2, 44.0) compared to those who received only brachytherapy (SMR=12.2; 95%CI: 
7.9, 18.1) and those who did not receive any radiotherapy (SMR=12.6; 95%CI: 6.3, 
22.6). The AER due to all causes of death other than recurrence was 33.0 excess 
deaths (per 10,000 person-years) between 0–25 years after heritable retinoblastoma 
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diagnosis, but increased 2-fold to 66.4 excess deaths in 25–50 years. During 25–50 
years from heritable retinoblastoma diagnosis, causes of death other than recurrence 
or SPN only accounted for 15.7% of the excess number of deaths, whilst deaths due 
to SPNs alone accounted for 84.3% of the total number of excess deaths. 
Throughout the first 50 years of follow-up, no excess due to circulatory diseases was 
observed – however, post-50 years from diagnosis there were 65 excess deaths due 
to circulatory diseases per 10,000 survivors per year compared to the general 
population; although the observed number of deaths due to circulatory disease was 
only 3. 
 
Cumulative mortality due to SPN and all other causes of death increased to 21.3% 
and 4.9% by 50 years after heritable retinoblastoma diagnosis respectively; 
cumulative mortality due to SPN and all other causes of death increased to 32.7% 
and 11.1% by 60 years after heritable retinoblastoma respectively (Figure 5.5.1).  
 
Subsequent Primary Neoplasms 
Heritable retinoblastoma survivors experienced over 13 times the number of SPNs 
expected (SMR=13.6; 95%CI: 11.2, 16.3) with 70 additional SPNs (95%CI: 56.3, 
83.9) per 10,000 person-years in excess of that expected (Table 5.5.3). Survivors 
who received external beam radiotherapy had a significantly higher cumulative 
incidence of SPNs compared to those who received brachytherapy and those who 
did not receive radiotherapy (P=0.03) (Figure 5.5.2). The cumulative incidence of 
developing an SPN was 12.5%, 8.0% and 7.0% by 25 years for survivors who 
received external beam radiotherapy, brachytherapy and no radiotherapy 
respectively. These percentages increased to 43.0%, 34.0% and 39.5% by 50 years 
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respectively. The most common SPN was of bone sites, which occurred in 35 
heritable retinoblastoma survivors. The overall number of excess bone SPNs was 24 
(95%CI: 16.4, 32.1) per 10,000 person-years. However, the excess risk of bone 
SPNs was mainly between 5–20 years of follow-up; after 30 years from diagnosis, 
the number of excess cases of bone SPNs dropped to zero (Figure 5.5.3). The 
excess risk of SPNs of sites other than bone increases rapidly after 25 years from 
diagnosis and reached 134.5 excess cases of SPNs per 10,000 person-years 
compared to the general population – this is equivalent to 1.3% excess cases of SPN 
observed in survivors compared to the general population per year. Overall, heritable 
retinoblastoma survivors who received external beam radiotherapy had a marginal 
significantly increased risk of SPN compared to survivors who had no radiotherapy 
(RR=1.6; 95%CI: 1.0, 2.5). When stratifying by location of the SPN (above shoulder 
and below shoulder), survivors who received external beam radiotherapy had a 4-fold 
risk (RR=4.0; 95%CI: 1.4, 11.8) of SPN developing above the shoulder compared to 
those who did not receive any radiotherapy (Table 5.5.4). 
 
Medical Conditions 
Of those who returned the questionnaire and did not have surgery (which would likely 
be enucleation of the eye, N=23), over a quarter ended up blind (27.3%), over half 
developed cataracts (60.9%) and over half developed detached retinas (60.9%). The 
respective percentage of survivors who received radiotherapy prior to developing 
these conditions was 100%, 100% and 86%. Overall, heritable retinoblastoma 
survivors were 6-times more likely to be blind (RR=6.4; 95%CI: 5.7, 7.1), 17-times 
more likely to develop cataracts (RR=17.0; 95%CI: 16.7, 17.3) and 28-times more 
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likely to have a detached retina (RR=28.4; 95%CI: 28.0, 28.8) compared to survivors 
of all other cancers (Table 5.5.5).  
 
Pregnancy Outcomes 
Of the 298 heritable retinoblastoma survivors who completed the BCCSS 
questionnaire, 91 reported that themselves, or their partners, had been pregnant at 
least once and they produced 191 completed pregnancies. From 191 pregnancies, 
13.6% were aborted and 12.2% resulted in a miscarriage. Pregnancies of survivors 
of heritable retinoblastoma were no more likely to result in low birth weight (OR=0.6; 
95%CI: 0.3, 1.4), premature birth (OR=0.6; 95%CI: 0.3, 1.2), abortion (OR=1.2; 
95%CI: 0.8, 2.0) and no different in miscarriage (OR=0.8; 95%CI: 0.5, 1.3) compared 
to pregnancies from childhood cancer survivors which were not diagnosed with 
heritable retinoblastoma. 
 
Educational Attainment, Smoking and Marriage 
Heritable retinoblastoma survivors were more likely to obtain a degree (OR=1.8; 
95%CI: 1.4, 2.4), teaching qualification (OR=1.4; 95%CI: 1.1, 1.9), A-Level (OR=1.4; 
95%CI: 1.0, 1.8) and O-Level (OR=1.5; 95%CI: 1.1, 2.1) compared to the general 
population. Survivors were also less likely to be a regular smoker (OR = 0.5; 95%CI: 
0.4, 0.7) than the general population. Both male (OR = 0.5; 95%CI: 0.3, 0.7) and 
female (OR = 0.4; 95%CI: 0.3, 0.6) heritable retinoblastoma survivors were 
substantially less likely to be married compared to the general population. 
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Health Status (SF-36) 
Heritable retinoblastoma survivors scored significantly lower than the general 
population on two of the eight SF-36 scales; role-physical (difference in means, D=–
4.6; 95%CI: –8.2, –1.1) and social functioning (D=–2.5; 95%CI: –4.8, –0.1). However, 
heritable retinoblastoma survivors reported significantly better vitality (D=4.0; 95%CI: 
1.7, 6.3) than the general population.  
 
5.4 Discussion 
This is the first population-based study to assess the risk of SPNs by external beam 
radiotherapy and brachytherapy for heritable retinoblastoma survivors. Survivors of 
heritable retinoblastoma had a significantly higher risk of developing SPNs, 
specifically bone tumours in the first 25 years of follow-up and soft tissue sarcomas, 
digestive, genitourinary and breast carcinomas after 25 years of follow up, and an 
overall annual risk of 1.3% between 25-50 years of follow-up. Most survivors, with 
known treatment received radiotherapy (84%). Survivors were significantly more 
likely to develop a SPN and, specifically, over 300 times more likely to develop a 
bone SPN which is consistent with previous studies38,205,208,213,214,217,218. Similar to a 
previous study, we found significant evidence of radiotherapy, specifically external 
beam radiotherapy, increasing the risk of developing SPN199. When examining 
specific types of radiotherapy, the risk of SPNs developing above the shoulder due to 
external beam radiotherapy was 4-fold that compared to those who did not receive 
any radiotherapy; the risk was not increased for SPNs occurring below the shoulder 
(p=0.58). The risk of developing SPNs for those who received brachytherapy was 
comparable to those who did not receive any radiotherapy (p=0.62). We conclude 
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that external beam radiotherapy is a cause of SPNs, specifically above the shoulder, 
with the possibility of influence of other genetic factors – a previous study found 
significantly increased risks of specific types of RB1 gene mutation on the 
development of SPNs219. 
 
Similar to previous studies, survivors were at risk of premature mortality, particularly 
due to SPNs and recurrences; these causes of death account for 72% and 13% of 
the total excess risk respectively8,209,215,220. Excess deaths due to SPNs within 25 
years of follow up accounted for 68% of the total excess death but this increased to 
84% for 25–50 years of follow up indicating a large majority of excess deaths were 
attributable to second cancers after 25 years of follow up. When examining deaths 
due to SPNs by different radiotherapy types, a significantly higher SMR was 
observed for those who received external beam radiotherapy compared to those who 
received brachytherapy for their initial heritable retinoblastoma. In fact, mortality due 
to SPN for those who received brachytherapy for their initial heritable retinoblastoma 
was comparable to those who did not receive any radiotherapy.  
 
Heritable retinoblastoma survivors who did not undergo surgery, and hence unlikely 
to have their eyes enucleated, were significantly more likely to be blind, develop 
cataracts and develop a detached retina compared to other cancer survivors. 
Previous studies also reported significantly higher radiation induced cataracts in 
retinoblastoma survivors compared to no irradiation, however external beam 
radiotherapy was given much more commonly in previous studies (87% of patients in 
US compared to 45% in our UK study)221-223. 
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Pregnancies from heritable retinoblastoma survivors were no more likely to be 
underweight, premature, aborted or miscarried compared to other cancer survivors. A 
previous study detailed that those with heritable retinoblastoma reproduce at age 
similar to the general population and with a 50% chance of passing on the mutated 
RB1 allele with each pregnancy20. Although it is not known how many survivors were 
fully aware of their condition and its heritability aspect, it is vital that survivors are 
made aware of their hereditary condition or receive genetic counselling. 
 
With respect to social outcomes, and consistent with previous studies, heritable 
retinoblastoma survivors appear to lead a healthier lifestyle being less likely a regular 
smoker than the general population61,224. Survivors were significantly more likely to 
attain educational qualifications compared to the general population but were less 
likely to be married compared to the general population with only 38% of survivors 
who completed the questionnaire being married51,57. 
 
A previous study has shown that survivors of heritable retinoblastoma reported 
adverse health-status outcomes similar to our study, that is, lower role-physical and 
heightened vitality. However, social function is comparable to the general population 
and heritable retinoblastoma survivors had a significantly lower perception of their 
general health225.           
 
An existing guideline recommends survivors of heritable retinoblastoma to be actively 
screened for eye-related medical conditions and after five years, screening for 
secondary cancers every one to two years and eye-related medical conditions every 
two to three years226. This study provides evidence that survivors should remain on 
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long-term follow-up, as the risk of developing a SPN is significantly higher than the 
general population. Further investigation into the specific type of radiotherapy 
treatment revealed that survivors who have received external beam radiotherapy had 
a significantly higher risk of SPNs, compared to those who didn’t receive 
radiotherapy, developing above the shoulder. As nearly half (N=246/552) of our 
heritable retinoblastoma survivors received external beam radiotherapy, it should be 
considered that, during long-term follow-up, special attention should be given to 
those who have received external beam radiotherapy than those who received 
brachytherapy or did not receive any radiotherapy. 
 
Study Limitations 
A potential limitation of our study included the lack of detailed doses on radiotherapy 
and chemotherapy exposures given for heritable retinoblastoma. It is important to 
acknowledge that survivors included in the cohort were treated between 1940 and 
1991 and hence findings may not be generalisable to survivors treated in more 
recent years due to changes in exposure to different treatments – currently, 
radiotherapy is given less frequently as part of the initial treatment plan for 
retinoblastoma214.  Despite the lack of treatment information, long-term risks can be 
estimated in ageing survivors of heritable retinoblastoma. 
 
Conclusion 
In conclusion, survivors of heritable retinoblastoma lead a healthier lifestyle by being 
less likely a smoker and more likely to achieve educational qualifications but feel 
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significantly more limited than the general population in certain tasks, most likely, due 
to their impaired sight. This may also be the reason for their significantly reduced 
social functioning. Survivors of heritable retinoblastoma are at increased risk of 
premature mortality especially due to second malignancies – after 25 years of follow 
up, almost all excess deaths were due to second malignancies. The risk of second 
malignancies are high, especially bone in the first 25 years from initial diagnosis, 
which seems to be driven by external beam radiotherapy, but the risk of other 
cancers such as soft tissue sarcoma, digestive, genitourinary, breast carcinoma are 
especially high after 25 years from initial diagnosis. Current guidelines recommend 
long-term follow-up and screening for secondary malignancies for all heritable 
retinoblastoma survivors, but evidence from this study shows that specific attention 
should be given to those who received external beam radiotherapy as part of their 
initial treatment.
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5.5 Tables and Figures 
Table 5.5.1. Characteristics of all 552 Heritable Retinoblastoma (HRb) survivors in the 
British Childhood Cancer Survivor Study and of all those who completed a questionnaire. 
 
  All HRb 
Survivors 
Completed  
Questionnaire Returned 
No Completed 
Questionnaire Returned 
  (N = 552) (N = 298) (N = 254) 
Sex  Male 300 (54.4%) 149 (50.0%) 151 (59.5%) 
 Female 252 (45.6%) 149 (50.0%) 103 (41.5%) 
     
Age at Mean 1.1 1.2 0.9 
Diagnosis  < 1 332 (60.1%) 169 (56.7%) 163 (64.2%) 
(years) 1 – 14 220 (39.9%) 129 (43.3%) 91 (35.8%) 
     
Age at Mean n/a 40.5 n/a 
Questionnaire 5 – 14 n/a 0 (0.0%) n/a 
Completion1 15 – 24 n/a 34 (11.4%) n/a 
(Years) 25 – 34 n/a 68 (22.8%) n/a 
 35 – 44 n/a 87 (29.2%) n/a 
 45 – 54 n/a 70 (23.5%) n/a 
 55 – 64 n/a 35 (11.7%) n/a 
 65+ n/a 4 (1.3%) n/a 
     
Follow up since  5-14 23 (4.2%) 0 (0.0%) 23 (9.1%) 
HRb diagnosis2 15-24 29 (5.3%) 1 (0.3%) 28 (11.0%) 
(years) 25-34 101 (18.3%) 49 (16.4%) 52 (20.5%) 
 35-44 133 (24.1%) 76 (25.5%) 57 (22.4%) 
 45+ 266 (48.2%) 172 (57.7%) 94 (37.0%) 
     
Treated with  Yes 419 (75.9%) 216 (72.5%) 203 (79.9%) 
Radiotherapy No 81 (14.7%) 50 (16.8%) 31 (12.2%) 
 Missing 52 (9.4%) 32 (10.7%) 20 (7.9%) 
     
Treated with  External Beam 164 (29.7%) 78 (26.2%) 86 (33.9%) 
Specific Brachytherapy 129 (23.4%) 73 (24.5%) 56 (22.0%) 
Radiotherapy3 Mixed Therapy 82 (14.9%) 42 (14.1%) 40 (15.7%) 
 No Radiotherapy 81 (14.7%) 50 (16.8%) 31 (12.2%) 
 Missing 96 (17.4%) 55 (18.5%) 41 (16.1%) 
     
Treated with  Yes 74 (13.4%) 37 (12.4%) 37 (14.6%) 
Chemotherapy No 351 (63.6%) 185 (62.1%) 166 (65.4%) 
 Missing 127 (23.0%) 76 (25.5%) 51 (20.0%) 
     
Surgery Yes 337 (61.1%) 186 (62.4%) 151 (59.5%) 
 No 51 (9.2%) 23 (7.7%) 28 (11.0%) 
 Missing 164 (29.7%) 89 (29.9%) 75 (29.5%) 
 
1 The BCCSS questionnaire was sent out to survivors aged 16 or over. 
2 Years of follow-up after initial diagnosis; percentages correspond to the total number in cohort or completed questionnaire. 
3 Proportion of those who received radiotherapy and missing treatment information. External Beam denotes survivors who only received External 
Beam Radiotherapy. Brachytherapy denotes survivors who only received a plaque. Mixed Therapy denotes survivors who received both External 
Beam Radiotherapy and Brachytherapy. 
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Table 5.5.2. Cause-specific standardised mortality ratios (SMRs) and absolute excess risks (AERs) for survivors of Heritable Retinoblastoma. 
Cause† Obs/Exp SMR (95% CI) AER (95% CI) % of Total AER 0–25 Years‡ 
Observed               AER (%) 
25–50 Years‡ 
Observed               AER (%) 
50+ Years‡ 
Observed               AER (%) 
All Causes 137/17.5 7.8 (6.6 , 9.3) 64.2 (51.9 , 76.5) 100% 62 44.5 (100%) 54 66.4 (100%) 21 465.4 (100%) 
Neoplasm 117/5.0 23.4 (19.4 , 28.1) 60.2 (48.8 , 71.6) 94% 56 42.3 (95.0%) 45 65.6 (98.7%) 16 368.3 (79%) 
Recurrence 15/– – 8.1 (3.5, 12.6) 13% 15 11.5 (25.8%) 0 0 (0%) 0 0 (0%) 
SPN 91/5.0 18.2 (14.7 , 22.4) 46.2 (36.2 , 56.2) 72% 40 30.1 (67.6%) 39 56.0 (84.3%) 12 273.4 (58.7%) 
Any Radiotherapy 76/3.9 19.3 (15.2 , 24.1) 50.6 (38.6 , 62.6) NA¥ 34 36.7 (NA) 33 74.3 (NA) 9 508.4 (NA) 
Plaque Only 25/2.0 12.2 (7.9 , 18.1) 43.0 (24.6 , 61.3) NA¥ 14 28.1 (NA) 11 32.3 (NA) 0 0 (NA) 
External Beam 46/1.4 33.0 (24.2 , 44.0) 59.5(41.7 , 77.2) NA¥ 25 47.1 (NA) 17 95.4 (NA) 4 996.8 (NA) 
No Radiotherapy 11/0.9 12.6 (6.3, 22.6) 34.4 (12.3 , 56.5) NA¥ 4 20.5 (NA) 4 41.0 (NA) 3 663.2 (NA) 
Nervous 2/0.8 2.6 (0.3 , 9.5) 0.7 (–0.8 , 2.2) 1% 2 1.4 (3.1%) 0 –0.8 (–1.2%) 0 –1.2 (–0.3%) 
Circulatory 5/2.9 1.7 ( 0.6, 4.0) 1.1 (–1.2 , 3.5) 2% 0 –0.3 (–0.6%) 2 –0.5 (–0.8%) 3 64.6 (13.9%) 
Respiratory 4/0.9 4.3 (1.2 , 10.9) 1.6 (–0.5 , 3.8) 2% 2 1.4 (3.2%) 1 0.4 (0.7%) 1 21.9 (4.7%) 
Digestive 3/1.2 2.5 (0.5 , 7.4) 1.0 (–0.9, 2.8) 2% 1 0.6 (1.4%) 1 0.1 (0.2%) 1 21.5 (4.6%) 
Genitourinary 1/0.1 7.6 (0.2 , 42.5) 0.5 (–0.6, 1.5) 1% 0 –0.0 (–0.0%) 1 1.4 (2.2%) 0 –0.3 (–0.1%) 
Other 1/0.2 5.9 (0.1, 32.8) 0.4 (–0.6, 1.5) 1% 0 –0.4 (–1.0%) 1 –0.2 (–0.2%) 0 –2.5 (–0.5%) 
External 2/4.8 0.4 (0.1 , 1.5) –1.5 (–3.0 , 0.0) –2% 1 –0.5 (–1.1%) 1 –2.9 (–4.4%) 0 –6.7 (–1.4%) 
Calculation of SMR for deaths due to recurrence of HRb would not be appropriate since the expected mortality rate in the general population would be 0.  AER for recurrence was calculated as the incidence rate per 10,000 person-years. Confidence  
intervals were calculated using the approximate method where the  number of deaths≥100 and the Poisson exact method where number of deaths<10. † All causes of death presented as overall SMR, AER and also by years of follow up. Eleven causes  
of death classified as neoplastic but is unknown with regards to recurrence or SPN. Neoplasm comprises recurrence and SPNs and circulatory comprises cardiac and stroke. 2 causes of death were unknown. ‡ Numbers at risk: (0–25 Years: 552),  
(25–50 Years: 461) and (50+ Years: 127). ¥ Mortality due to SPN by modes of treatment was analysed as subgroups and not respective to total. 
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Table 5.5.3. SIRs and AERs for developing specific SPNs after Heritable Retinoblastoma. 
Second Primary Cancer  Overall 0–24 years from diagnosis 25–50 years from diagnosis 
 Obs/Exp SIR (95%CI) AER (95%CI)
1
 SIR (95%CI) (N) AER (95%CI)
1
 SIR (95%CI) (N) AER (95%CI)
1
 
All 115/8.4 13.6 (11.2-16.3) 70.1 (56.3-83.9) 24.4 (18.5-31.6) (57) 47.9 (34.9-60.9) 9.5 (7.2-12.3) (58) 137.1 (97.6-176.5) 
        
Bone 37/0.1 304.8 (214.6-420.1) 24.3 (16.4-32.1) 356.2 (249.5-493.2) (36) 31.5 (21.2-41.8) 49.1 (1.2-273.7) (1) 2.6 (-2.6-7.8) 
        
Soft Tissue  16/0.1 117.1 (66.9-190.1) 10.4 (5.3-15.6) 38.4 (7.9-112.1) (3) 2.6 (-0.4-5.5) 222.3 (118.4-380.2) (13) 34.2 (15.5-52.8) 
        
Genitourinary 15/1.9 7.9 (4.4-13.0) 8.6 (3.6-13.6) 1.9 (0.0-10.5) (1) 0.4 (-1.3-2.1) 10.3 (5.6-17.2) (14) 33.4 (14.0-52.7) 
        
Digestive 11/0.9 12.5 (6.2-22.4) 6.7 (2.4-10.9) 31.2 (6.4-91.3) (3) 2.5 (-0.4-5.5) 10.2 (4.4-20.1) (8) 19.1 (4.4-33.7) 
        
Breast 9/1.9 4.7 (2.1-8.9) 4.7 (0.8-8.5) 24.1 (5.0-70.4) (3) 24.1 (5.0-70.4) 3.3 (1.2-7.3) (6) 11.1 (-1.6-23.8) 
1
AER per 10,000 person–years. 
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Table 5.5.5. Risk of developing eye-related medical conditions after five-year survival compared to 
survivors of other cancers. 
†Comparisons for Heritable Retinoblastoma who did not received surgery compared with all other cancer 
survivors. Numbers relate to survivors of heritable retinoblastoma who did not receive surgery and to survivors 
of all other cancers, of who did not previously have the event and answered the relevant questions on the 
questionnaire. 
  
Table 5.5.4. Effect of radiotherapy on risk of developing 
an SPN presented as Risk Ratios (RR). 
  RR (95%CI) P-value 
All sites No RT 1.0 (ref.)  
 Plaque 0.9 (0.5,1.5) 0.62 
 Beam 1.6 (1.0,2.5) 0.05 
Bone No RT 1.0 (ref.)  
 Plaque 1.1 (0.4,2.8) 0.91 
 Beam 1.6 (0.7,3.5) 0.28 
Soft-tissue No RT 1.0 (ref.)  
 Plaque 0.8 (0.2,3.2) 0.80 
 Beam 1.5 (0.4,5.3) 0.51 
Above Shoulder No RT 1.0 (ref.)  
 Plaque 2.6 (0.8,8.2) 0.09 
 Beam 4.0 (1.4,11.8) 0.01 
Below Shoulder No RT 1.0 (ref.)  
 Plaque 0.6 (0.3,1.1) 0.1 
 Beam 1.2 (0.7,2.0) 0.58 
H-Retinoblastoma, N (%) Other Cancer Survivors, N (%) Relative Risk 95% Confidence Interval 
     
Blindness† 6 / 22 (27.3%) 429 / 10,013 (4.3%) 6.4 (5.7 – 7.1) 
     
Cataracts† 14 / 23 (60.9%) 360 / 10,031 (3.6%) 17.0 (16.7 – 17.3) 
     
Detached Retina† 14 / 23 (60.9%) 214 / 9,978 (2.1%) 28.4 (28.0 – 28.8) 
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†Odds ratios were pooled using Mantel-Haenszel method.  
1 adjusted for, sex and attained age. 
2 adjusted for sex, attained age, marital status, socioeconomic classification, educational attainment. 
3 controlled for attained age, sex, legal marital status, socioeconomic classifications, educational attainment, and region, and took into account the GHS 
weighting factor, for the likelihood of consuming over the recommendations for weekly alcohol units or consuming harmful weekly amounts of alcohol.  
4 HRb survivors compared against non-Rb survivors. (F) denotes pregnancies from female survivors and (M) denotes pregnancies from partners of male 
survivors. 
5 compared to British population marriage statistics from ONS 2002. 
Table 5.5.6. Odds Ratios (Ors) of pregnancy outcomes, smoking 
status, educational level and marital status. 
 N (%) OR (95%CI) 
Education (Achievement)1 
  
Degree 73 / 229 1.8 (1.4 – 2.4) 
Teaching Qualification 91 / 229 1.4 (1.1 – 1.9) 
A-Level 135 / 243 1.4 (1.0 – 1.8) 
O-Level 230 / 289 1.5 (1.1 – 2.1) 
   
Smoking2   
Current Regular Smokers 47 / 294 (16.0%) 0.5 (0.4 – 0.7) 
   
Alcohol Consumption3   
Current Drinker 230 / 297 (77.4%) 0.5 (0.3 – 0.6) 
Over Recommendation 45 / 228 (19.7%) 0.6 (0.4 – 0.8) 
Harmful Doses 3 / 228   (1.3%) 0.2 (0.1 – 0.6) 
   
Pregnancy Outcome4   
Low Birth Weight 9 / 124 (7.3%) 0.6 (0.3 – 1.4) 
Preterm Birth 15 / 136 (11.0%) 0.6 (0.3 – 1.2) 
Abortion 26 / 191 (13.6%) 1.2 (0.8 – 2.0) 
Miscarriage 23 / 189 (12.2%) 0.8 (0.5 – 1.3) 
   
Pregnancy Outcome (F)4   
Low Birth Weight 5 / 77 (6.5%) 0.5 (0.2 – 1.5) 
Preterm Birth 8 / 81 (9.9%) 0.5 (0.2 – 1.2) 
Abortion 16 / 113 (14.2%) 1.2 (0.7 – 2.1) 
Miscarriage 13 / 112 (11.6%) 0.7 (0.4 – 1.2) 
   
Pregnancy Outcome (M)4   
Low Birth Weight 4 / 47 (8.5%) 0.8 (0.2 – 3.1) 
Preterm Birth 7 / 55 (12.7%) 0.7 (0.2 – 2.1) 
Abortion 10 / 78 (12.8%) 1.4 (0.6 – 3.3) 
Miscarriage 10 / 77 (13.0%) 1.1 (0.5 – 2.4) 
Marital Status5   
Males 50 / 147 (34.0%) 0.5 (0.3 – 0.7) 
Females 62 / 149 (41.6%) 0.4 (0.3 – 0.6) 
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Table 5.5.7. Differences in mean SF–36 scores between Heritable Retinoblastoma survivors and OHLS reference population. 
SF-36 Scale Difference in mean (95%CI)1 
Reported Health Change –1.2 (–3.1, 0.6) 
Physical Function –0.7 (– 2.8, 1.3) 
Role–Physical –4.6 (–8.2, –1.1) 
Role–Emotional –0.2 (–4.0, 3.5) 
Social Functioning –2.5 (–4.8, –0.1) 
Mental Health 1.1 (–0.9, 3.1) 
Vitality 4.0 (1.7, 6.3) 
Bodily Pain 1.6 (–0.9, 4.2) 
General Health Perception 1.1 (–1.2, 3.4) 
1 Calculated scores were adjusted for age and sex. 
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Figure 5.5.1. Cumulative mortality stratified by causes of death; SPN, Recurrence, Other Causes and All Cause 
Expected. 
 
Figure 5.5.2. Cumulative incidence of developing an SPN among heritable retinoblastoma survivors according 
to whether treatment involved external beam radiotherapy (beam), brachytherapy (plaque) or no 
radiotherapy (nort). 
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Figure 5.5.3. Absolute excess risk (AER) for all second primary cancers and bone second primary cancers by 
years from retinoblastoma diagnosis 
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6 DISCUSSION 
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This chapter will provide a summary of the key findings from each of the four studies 
presented in Chapters 2–5, discuss the recommendations for future research, 
discuss the implications of how our findings may add to current guidelines for clinical 
follow-up and a final conclusion. 
 
6.1 Summary of Key Findings 
In Chapter 2 we studied the risk of various adverse health and social outcomes 
among survivors of Wilms’ tumour. This was the first ever study to investigate 
adverse health and social outcomes up to 50 years after diagnosis of Wilms’ tumour. 
Over 65% of survivors survived at least 30 years from childhood cancer diagnosis. 
Our findings indicated, for the first time, that survivors experienced a substantial 
increase in premature mortality after 30 years from childhood cancer diagnosis—75% 
of the excess deaths during this period were attributable to SPNs (50%) and cardiac 
diseases (25%). The number of excess cases of SPN occurring after 30 years from 
childhood cancer diagnosis was mainly attributable to digestive (41%) and breast 
(7%) cancer. Although their perception of their general health was significantly lower 
than expected from the general population, Wilms’ tumour survivors appear to have a 
healthier lifestyle (being less likely than expected to be a smoker and consuming 
lower than expected amounts of alcohol) than expected from the general population. 
They experienced limited physical functioning in everyday tasks, female Wilms’ 
tumour survivors were more likely to give birth prematurely and more underweight 
offspring and male Wilms’ tumour survivors were significantly less likely to be married 
than expected from the general population. 
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In Chapter 3 we investigated the risks of hospitalisation due to specific renal 
diseases subsequent to five-year survival after childhood cancer diagnosis. Overall, 
survivors of childhood cancer were twice as likely of being hospitalised due to renal 
disease than expected from the general population. Survivors of neuroblastoma, 
Wilms’ tumour and soft tissue sarcoma were at highest multiplicative excess risk of 
being hospitalized for renal disease with 4-fold, 3-fold and 3-fold the risk expected 
from the general population, respectively. After adjusting for confounders, survivors 
aged up to 29 had a significantly elevated risk of hospitalisation for renal disease—
the risk decreased after 30 years of age. Childhood cancer survivors had a 
significantly elevated risk of being hospitalised for each specific renal disease which 
we investigated (glomerular disease, renal tubulo-interstitial disease, renal failure, 
urolithiasis, urinary tract infection, other kidney disease and other urinary system 
disease). The excess risk of chronic renal failure was greatest among survivors of 
Wilms’ tumour who had 30-times the expected risk of being hospitalised compared to 
the general population. Wilms’ tumour survivors had a 15-fold expected risk of 
hospitalisation due to acute renal failure, which has not been reported previously. 
The multiplicative excess risk of hospitalistion significantly decreased, all specific 
renal diseases, with increasing attained age. 
 
In Chapter 4 we describe the risks of developing SPNs in specific digestive sites 
using a large pan-European cohort of childhood cancer survivors. Overall, childhood 
cancer survivors in Europe were four times more likely to develop a SPN in the 
digestive system than expected from the general population. After adjusting for other 
risk factors, the risk significantly decreased with attained age and females were less 
likely to develop a digestive SPN compared to males. Heterogeneity was observed 
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between countries but this was not unexpected as survivors residing in different 
countries were likely to be subject to different treatment regimens and some cohorts 
were hospital-based. This was the first ever study to investigate the development of 
SPNs in specific sites of the digestive system by specific types of childhood cancer 
diagnosis as no previous study had sufficient numbers to do so. Survivors of Wilms’ 
tumour experienced the highest excess risk of digestive cancer 15-fold expected, and 
Wilms’ survivors experienced 56-fold, 24-fold, 11-fold and 9-fold the expected risk of 
liver, pancreatic, stomach and colorectal cancer, respectively. Survivors of Hodgkin’s 
lymphoma experienced the second highest excess risk of digestive cancers 9-fold 
expected, and Hodgkin’s survivors experienced an 8-fold, 7-fold, 6-fold and 6-fold 
expected risk of colorectal, liver, stomach and pancreatic cancer, respectively. 
 
In Chapter 5 we studied the risk of various adverse health and social outcomes 
among survivors of heritable retinoblastoma. This study investigated adverse health 
and social outcomes beyond 50 years of follow up in heritable retinoblastoma 
survivors, as over 90% of these survivors survived at least 25 years from childhood 
cancer diagnosis. This was the first ever population-based study to investigate 
premature mortality and risk of SPNs by specific modes of radiotherapy treatment. 
Overall, survivors were 18-times more likely to die from a SPN compared to the 
general population. This risk significantly increased to 33-fold for survivors who 
received external beam radiotherapy; the risk among survivors who had received 
either brachytherapy and or no radiotherapy were not significantly different. The 
excess risk of premature death due to SPNs remained substantially elevated 
throughout the entire period of follow-up. In the first 25-year period following 
childhood cancer diagnosis, survivors were 356-times more likely than expected to 
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develop a bone SPN and in the period 25-50 years after childhood cancer diagnosis, 
survivors were significantly more likely to develop a soft tissue, digestive, 
genitourinary and breast SPN. The risk of SPN developing above the shoulder was 
4-fold higher among those who received external beam radiotherapy than among 
those not irradiated. Survivors of heritable retinoblastoma had a 6-fold risk of 
becoming blind, 17-fold risk of developing cataracts and 28-fold risk of detached 
retina compared to survivors of all other cancers. Despite these adverse outcomes, 
heritable retinoblastoma survivors lead a healthier lifestyle by smoking less and 
drinking less alcohol than expected from the general population and achieve better 
educational qualifications than expected from the general population. These findings 
are important in informing not only clinicians and health providers, but also survivors 
themselves. 
 
6.2 Recommendations for Future Research and Evidence Based Clinical 
Follow-up Guidelines 
The four studies that we have presented in this thesis relate to survivors who were 
treated with radiotherapy and chemotherapy many decades ago of which a large 
proportion had received radiotherapy and chemotherapy as part of their initial 
treatment. The treatment regimens have changed over recent decades but the 
majority of current survivors, at least 30 years from diagnosis, received radiotherapy 
and chemotherapy and the risks presented in this thesis relates directly to them. The 
major strength of this thesis was that the four studies used population-based data 
and was not subject to selection-bias. Because the BCCSS is the largest population-
based study of childhood cancer survivors in the world, a large proportion of 
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survivors were also on long-term follow-up that allowed us to investigate the risks of 
late effects up to 50 years after diagnosis (which previous studies were not able to 
do). However, the lack of detailed treatment information limited us from investigating 
the risks of such late effects by doses of radiotherapy or specific types of 
chemotherapeutic drugs. The establishment of a national clinical cohort – which is 
currently being set up, will hopefully address the issue of the lack of detailed 
treatment information. 
 
The studies in Chapter 3 and Chapter 4 will be discussed first as there is little 
research currently available in the public domain. The studies in Chapter 2 and 
Chapter 5 will be discussed afterwards relating to current clinical follow-up 
guidelines. 
 
The study in Chapter 3 was the first to investigate risks of hospitalisations due to 
specific renal diseases after five-year survival by type of childhood cancer diagnosis. 
Thus it was not possible to make comparisons of our findings to other studies. 
Therefore the risk estimates produced should be useful to those producing and 
updating evidence based clinical follow-up guidelines relating to renal outcomes. The 
establishment of a clinical cohort would allow absolute risks to be related to more 
detailed stratification in terms of treatment. 
 
The study in Chapter 4 was the first to investigate risks of specific digestive SPNs 
after five-year survival of childhood cancer by type of childhood cancer diagnosis. 
The large-scale pan-European cohort of childhood cancer survivors allowed us to 
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observe digestive SPNs and specific digestive SPNs (such as colorectal, liver, 
stomach, pancreas). We could only make comparisons to one other study, which 
investigated the risk of specific digestive SPN similar to our study. However, no 
studies had sufficient numbers to investigate specific digestive SPN by type of 
childhood cancer diagnosis. Therefore the risk estimates produced should again be 
useful to those producing and updating evidence based clinical follow-up guidelines. 
 
The study in Chapter 2 demonstrated that survivors of Wilms’ tumour are at 
increased risk of adverse health and social outcomes. In particular, this study 
describes the causes of premature mortality and the risks of SPNs after 30 years 
from Wilms’ tumour diagnosis for the first time. Although there are recommendations, 
there is currently no formal guideline relating to long-term clinical follow-up for 
survivors of Wilms’ tumour. Two sources recommend frequent follow-up visits and 
screening for recurrence of the tumour and also heart function tests if survivors were 
treated with anthracyclines227,228.  
 
This thesis reports the substantial increase in mortality after 30 years from Wilms’ 
tumour diagnosis—75% of the excess risk after 30 years from diagnosis was 
attributable to SPN (50%) and cardiac disease (25%). Wilms’ tumour survivors 
experienced a 5-fold risk of developing SPNs compared to the general population. 
Digestive SPN was most prevalent after 30 years from Wilms’ tumour diagnosis and 
had the highest risk during this period (18-fold) compared to the general population. 
All Wilms’ tumour survivors who developed a digestive SPN had received abdominal 
radiotherapy and those who developed breast SPN had received abdominal or chest 
radiotherapy. Survivors were leading a healthier lifestyle by being 30% less likely to 
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smoke and consume alcohol. Female survivors of Wilms’ tumour had a 3-fold risk of 
giving birth prematurely and low birth weight compared to the general population.  
 
(1) After 30 years from initial diagnosis, follow-up should focus on surveillance 
relating to SPNs and cardiac diseases, as 75% of excess deaths during this period 
were attributable to these causes of death in survivors of Wilms’ tumour. 
 
(2) Among those receiving direct abdominopelvic radiotherapy, the absolute risk of 
bowel cancer exceeds that of individuals with two first degree relatives with bowel 
cancer and the option of colonoscopy needs to be considered. 
 
(3) The increased risk of low birth weight and premature births among female 
survivors of Wilms’ tumour who received direct abdominopelvic irradiation, which is 
well established, means that such pregnancies should receive closer monitoring than 
normal pregnancies. 
 
The study in Chapter 5 demonstrated that survivors of heritable retinoblastoma are 
at increased risk of adverse health and social outcomes. In particular, this study 
describes the risks of premature mortality and the risks of SPNs by treatment 
modality up beyond 50 years of from initial childhood cancer diagnosis. A current 
guideline recommends frequent active monitoring after 5-year survival (up to 9 years 
of age) for survivors of retinoblastoma, particularly those who test positive for the 
RB1 gene or has a family history of retinoblastoma229. This guideline, along with the 
COG guideline, recommends evaluation of the eyes for radiation-related medical 
conditions such as cataracts, detached retina and other vision problems during 
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follow-up visits229,230. Currently, follow-up examinations focus on screening for SPNs, 
genetic counselling and evaluation of eye-related medical conditions229,231. 
 
This thesis reports the excess risks of premature mortality extending beyond 50 
years of follow-up, a 4-fold increased risk of SPNs developing above the shoulder if 
survivors received external beam radiotherapy, significantly increased risk of specific 
eye-related medical conditions (such as blindness, cataracts and detached retina).  
 
(1) Monitoring of SPNs above the shoulder is recommended for survivors who 
received external beam radiotherapy.  
 
(2) Surveillance and survivor self-awareness in relation to bone tumours is 
recommended for survivors who have not yet accrued 25 years of follow-up from 
diagnosis and similarly for soft tissue sarcoma, digestive, genitourinary and breast 
carcinoma in those who have been on follow-up for more than 25 years of follow-up 
since diagnosis. 
 
6.3 Conclusion 
This thesis aimed to contribute knowledge relating to the risks of adverse outcomes 
following survival after childhood cancer. The four studies included in this thesis 
describe a variety of adverse health and social outcomes and found that (i) survivors 
of Wilms’ tumour are at substantially increased excess risk of premature mortality 
after 30 years from first diagnosis, compared to that expected from the general 
population, which were mainly due to SPNs and cardiac disease; (ii) childhood 
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cancer survivors had a significantly increased risk of being hospitalised for each 
specific renal disease which we investigated (glomerular disease, renal tubulo-
interstitial disease, renal failure, urolithiasis, urinary tract infection, other kidney 
disease and other urinary system disease); (iii) childhood cancer survivors in Europe 
were four times as likely to develop a SPN in the digestive system compared to the 
general population; and (iv) survivors of heritable retinoblastoma who received 
external beam radiotherapy was four times more likely to develop a SPN above the 
shoulder compared to those who did not receive any radiotherapy.  
 
The new findings from the studies presented in this thesis contribute to the existing 
literature relating to the risks of adverse health and social outcomes among 
childhood cancer survivors and provide unbiased and reliable evidence to help risk 
stratification of survivors, help updating evidence based clinical follow-up guidelines 
and the evaluation of proposed future treatment protocols from and risk and benefit 
perspective.  
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8 APPENDIX 
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8.1 Table of childhood cancer types with corresponding ICD-0 codes 
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Tables were extracted from Steliarova-Foucher et al. to describe the type of 
childhood cancers with the corresponding ICD-O codes10. 
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8.2 Female Study Questionnaire from the BCCSS 
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8.4 Glossary of Abbreviations in Alphabetical Order 
Abbreviation 
 
Definition 
 
95% CI 
 
95% Confidence Interval 
AER Absolute Excess Risk 
BCCSS British Childhood Cancer Survivor Study 
CCRG Childhood Cancer Registry Group 
CHF Congestive Heart Failure 
CKD Chronic Kidney Disease 
CNS Central Nervous System 
CT Chemotherapy 
ECO European Cancer Observatory 
FPN First Primary Neoplasm 
GFR Glomerular Filtration Rate 
GHP General Health Perception 
GHS General Household Survey 
GP General Practitioner 
HES Hospital Episode Statistics 
HRb Heritable Retinoblastoma 
HRQL Health Related Quality of Life 
HSCIC Health and Social Care Information Centre 
IARC International Agency for Research on Cancer 
ICD International Classification of Diseases 
ICD-O International Classification of Diseases (Oncology) 
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NHL Non-Hodgkin’s Lymphoma 
NICE National Institute of Care and Excellence 
NRCT National Registry of Childhood Tumours 
O/E Observed divided by Expected 
OHLS Oxford Healthy Life Survey 
ONS Office for National Statistics 
OR Odds Ratio 
PCP Primary Care Physician/Provider 
PCSF 
Pan Care Childhood and Adolescent Cancer Survivor Care and 
Follow-Up Studies (PanCareSurFup) 
 
Rb Retinoblastoma 
RER Relative Excess Risk 
RR Risk Ratio 
RT Radiotherapy 
SF-36 Short Form 36 
SHR Standardised Hospitalisation Ratio 
SIOP 
Société Internationale d’Oncologie Pédiatrique  (International 
Society of Paediatric Oncology) 
 
SIR Standardised Incidence Ratio 
SMR Standardised Mortality Ratio 
SPN Subsequent Primary Neoplasm 
STS Soft Tissue Sarcoma 
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8.5 Statement of Contributions of the Research 
 
The British Childhood Cancer Survivor Study was set up by Professor Mike Hawkins 
in 1998. David Winter built electronic databases to store the data and also performed 
the linkage between the British Childhood Cancer Survivor Study and the Hospital 
Episode Statistics. 
 
Julie Kelly, Joyeeta Guha, Miranda Fidler, Chloe Bright and myself contributed to the 
extraction of treatment information (radiotherapy and chemotherapy) for the UK 
component of the PCSF study. 
 
I examined all medical files related to the 552 heritable retinoblastoma survivors in 
the British Childhood Cancer Survivor Study and extracted information relating to the 
type of radiotherapy (external beam or plaque) for the analysis presented in Chapter 
5. 
 
My supervisors Mike Hawkins, Raoul Reulen and Clare Frobisher provided guidance 
with regards to the study design, analysis and interpretation of the results. In 
particular, Mike gave me the opportunity to present my research at various 
international conferences. 
